Cambridge Isotope Laboratories, Inc. isotope.com

## Stable Isotope-Labeled Products For Metabolic Research




# Stable Isotopes in Metabolomics and Metabolism 

## Gary J. Patti

Department of Chemistry, Washington University, St. Louis, Missouri 63130 United States

Recent advances in mass spectrometry (MS) and nuclear magnetic resonance (NMR) technologies have greatly enhanced metabolite analysis. Hundreds to thousands of metabolites can now be measured simultaneously with unprecedented accuracy from exceedingly small amounts of biological material. These technical developments have given rise to the field of metabolomics, which generally aims to assess metabolic regulation as a function of health and disease. During the last decade, it has become relatively routine to perform metabolomic analysis on most biological samples. Interpretation of the acquired data, however, remains a considerable challenge. Stable isotopes are providing experimental strategies that overcome some of these barriers. One obstacle in performing metabolomics, for example, is that many of the signals detected by MS do not correspond to unique metabolites of biological origin. Rather, it has been demonstrated that hundreds to thousands of MS peaks arise from contaminants. Given that only real metabolites are derived from a nutrient precursor, isotopic labeling is being used to distinguish biologically derived metabolites from experimental noise. Additionally, because the incorporation of stable isotopes generally does not affect the retention time or ionization efficiency of metabolites, isotopically labeled compounds are the gold standard for quantifying the concentration of endogenous metabolites within a complex biological matrix.

Beyond their role in improving the analytical accuracy of metabolomics, isotopes can also be used as tracers in metabolic analyses. When metabolomics is performed without stable isotopic tracers, only metabolite concentrations can be determined. When metabolomics is performed with stable isotopic tracers, in contrast, both metabolite concentrations and pathway activities (i.e., metabolic fluxes) can be assessed. The latter provides a much richer understanding of metabolism.

While measuring metabolite concentrations without isotopes can certainly be insightful, such measurements reveal only part of the story. They provide a mere snapshot of metabolism that cannot be translated into a dynamic map of metabolite traffic on biochemical routes. When
comparing two sample groups, for example, an elevated metabolite level may indicate increased or decreased pathway flux. This is because metabolites can accumulate not only due to increased production, but also due to decreased consumption. Yet, the difference between increased production and decreased consumption may yield entirely different experimental interpretations. In a biomedical context, for instance, increased production of a metabolite may suggest pharmacological inhibition of the pathway as a therapeutic strategy. Thus, to understand pathway regulation and metabolic mechanisms of disease, the application of isotopic tracers is required.

In addition to enabling assessment of metabolic fluxes, isotopic tracers also add biochemical resolution to metabolomic analyses. Most metabolites lie at the intersection of multiple metabolic pathways. Without isotopic labeling, only a single metabolite pool is measured. It is not possible to distinguish the amount of this pool that is associated with one metabolic pathway relative to another. By using isotopic tracers, on the other hand, the fraction of the metabolic pool associated with a specific pathway can be delineated with labeling. As an example, palmitate can be synthesized from numerous metabolic substrates such as glucose, glutamine, acetate, etc. Stable isotopic tracers enable the fraction of palmitate produced from each precursor to be quantified.

Importantly, most modern MS and NMR instrumentation is well suited for the analysis of stable isotopes. Although processing of the data can be complicated, there are an increasing number of user-friendly software platforms (some commercial and some freely available). Moreover, when the appropriate isotopic tracer is selected, simple qualitative analyses of the data is often sufficient to yield important insight into metabolic pathway activities. Finally, it is worth noting that isotopic tracing experiments are not limited to micro-organisms that can be grown in defined media. To the contrary, some of the most widely used applications of isotope labeling have been in mammalian cell culture, plant and animal models, and in human patients.

## Table of Contents

Compounds ..... 3-27
Amino Acids and Their Derivatives ..... 3
Bile Acids ..... 8
Caffeine and Its Metabolites ..... 9
Carbohydrates ..... 9
Carnitine/Acylcarnitines ..... 11
Drugs and Their Metabolites ..... 12
Fatty Acids and Lipids ..... 13
Flavonoids ..... 15
MRI/MRS Tracers ..... 16
MS/MS Standards ..... 17
Neurotransmitters ..... 17
Nucleic Acids ..... 18
Organic Acids, Their Derivatives, and Conjugate Salts ..... 20
Other Compounds ..... 22
Steroids and Hormones ..... 23
Vitamins and Their Metabolites ..... 25
Urea and Water ..... 27
Sets, Mixtures, and Kits ..... 28-34
Sets ..... 28
Mixtures ..... 29
Kits ..... 30
Additional Information ..... 35-37
Research Use Statement ..... 35
Enhanced Data Package (EDP) ..... 36
cGMP Production Capabilities ..... 37
Application Note Examples ..... 38

## Compounds

## Amino Acids and Their Derivatives

| Catalog No. | Description |
| :---: | :---: |
| DLM-7476 | ADMA $\cdot \mathrm{HCl} \cdot \mathrm{XH}_{2} \mathrm{O}$ (asymmetric dimethylarginine) (2,3,3,4,4,5,5-D ${ }_{7}, 98 \%$ ) may be hydrate |
| CLM-1655 | D-Alanine ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-2495 | D-Alanine ( $3-{ }^{13} \mathrm{C}, 99 \%$ ) |
| DLM-7326 | D-Alanine ( $\mathrm{D}_{7}, 98 \%$ ) < $5 \% \mathrm{~L}$ |
| NLM-6762 | D-Alanine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| NLM-3289 | D-Alanine, N -acetyl ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CLM-705 | DL-Alanine ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-115 | DL-Alanine ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-707 | DL-Alanine ( $3-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-4514 | DL-Alanine ( $\left.{ }^{13} \mathrm{C}_{3}, 98 \%\right)$ |
| DLM-2760 | DL-Alanine (2-D, 98\%) |
| DLM-176 | DL-Alanine (3,3,3-D ${ }_{3}$, 98\%) |
| DLM-1276 | DL-Alanine (2,3,3,3-D ${ }_{4}$, 97-98\%) |
| NLM-706 | DL-Alanine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CLM-116 | L-Alanine ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-2016 | L-Alanine ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-117 | L-Alanine ( $3-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-117-MPT | L-Alanine (3-13 ${ }^{13}$, 99\%) |
| CLM-2734 | L-Alanine ( $2,3-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-2184-H | L-Alanine ( ${ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| DLM-3101 | L-Alanine (2-D, 96-98\%) |
| DLM-248 | L-Alanine (3,3,3-D ${ }_{3}$, 99\%) |
| DLM-250 | L-Alanine ( $2,3,3,3-\mathrm{D}_{4}, 98 \%$ ) |
| DLM-251 | L-Alanine ( $\mathrm{D}_{7}, 98 \%$ ) |
| NLM-454 | L-Alanine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| NLM-454-MPT | L-Alanine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| OLM-7460 | L-Alanine ( ${ }^{18} \mathrm{O}_{2}, 90 \%$ ) |
| CDLM-8649 | L-Alanine (3-13C, 99\%; 2-D, 96\%) |


| Catalog No. | Description |
| :---: | :---: |
| CDLM-3439 | L-Alanine ( $3-{ }^{13} \mathrm{C}, 99 \% ; 3,3,3-\mathrm{D}_{3}, 98 \%$ ) |
| CNLM-6993 | L-Alanine ( $1-{ }^{-13} \mathrm{C}, 99 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-3594 | L-Alanine ( $2-{ }^{13} \mathrm{C}, 99 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-534-H | L-Alanine ( ${ }^{33} \mathrm{C}_{3}, 99 \%$; ${ }^{15} \mathrm{~N}, 99 \%$ ) |
| DNLM-7178 | L-Alanine ( $2,3,3,3-\mathrm{D}_{4}, 98 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CDNLM-6800 | L-Alanine ( ${ }^{13} \mathrm{C}_{3}, 97-99 \%$; $\mathrm{D}_{4}, 97-99 \%$; ${ }^{15} \mathrm{~N}, 97-99 \%$ ) |
| DLM-9799 | DL-2-Aminoadipic acid (2,5,5-D ${ }_{3}, 98 \%$ ) |
| CLM-535 | 5-Aminolevulinic acid• $\mathrm{HCl}\left(4-{ }^{13} \mathrm{C}, 99 \%\right)$ |
| CLM-1371 | 5-Aminolevulinic acid• $\mathrm{HCl}\left(5-{ }^{-13} \mathrm{C}, 99 \%\right) \mathrm{CP} 96 \%$ |
| CLM-1268 | L-Arginine• $\mathrm{HCl}\left(1-{ }^{13} \mathrm{C}, 99 \%\right)$ |
| CLM-2070 | L-Arginine- HCl (guanido- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-2051 | L-Arginine. $\mathrm{HCl}\left(1,2-{ }^{13} \mathrm{C}_{2}, 99 \%\right)$ |
| CLM-2265-H | L-Arginine. $\mathrm{HCl}\left({ }^{13} \mathrm{C}_{6}, 99 \%\right)$ |
| DLM-6038 | L-Arginine- $\mathrm{HCl}\left(4,4,5,5-\mathrm{D}_{4}, 94 \%\right)<5 \% \mathrm{D}$ |
| DLM-541 | L-Arginine $\cdot \mathrm{HCl}\left(\mathrm{D}_{7}, 98 \%\right)$ |
| NLM-1267 | L-Arginine $\cdot \mathrm{HCl}\left(\alpha^{-15} \mathrm{~N}, 98 \%\right)$ |
| NLM-395 | L-Arginine•HCl (guanido- ${ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| NLM-395-MPT | L-Arginine. HCl (guanido- ${ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| NLM-396 | L-Arginine. $\mathrm{HCl}\left({ }^{15} \mathrm{~N}_{4}, 98 \%\right)$ |
| CNLM-7819 | L-Arginine $\mathrm{HCl}\left(1-{ }^{13} \mathrm{C}, 99 \% ; \alpha-{ }^{15} \mathrm{~N}, 98 \%\right)$ |
| CNLM-539-H | L-Arginine $\cdot \mathrm{HCl}\left({ }^{13} \mathrm{C}_{6}, 99 \% ;{ }^{15} \mathrm{~N}_{4}, 99 \%\right)$ |
| DNLM-7543 | L-Arginine•Cl ( $\mathrm{D}_{7}, 98 \%$; ${ }^{15} \mathrm{~N}_{4}, 98 \%$ ) |
| CDNLM-6801 | L-Arginine $\cdot \mathrm{HCl}$ <br> ( ${ }^{33} \mathrm{C}_{6}, 97-99 \% ; \mathrm{D}_{7}, 97-99 \% ;{ }^{15} \mathrm{~N}_{4}, 97-99 \%$ ) |
| ULM-8347 | L-Arginine HCl (unlabeled) |
| CNLM-9007-CA | L-Argininosuccinic acid, barium salt- $2 \mathrm{H}_{2} \mathrm{O}$ (arginine- ${ }^{13} \mathrm{C}_{6}, 99 \%$; ${ }^{15} \mathrm{~N}_{4}, 99 \%$ ) CP 90\% |
| ULM-9008-CA | L-Argininosuccinic acid, barium salt- $3 \mathrm{H}_{2} \mathrm{O}$ (unlabeled) CP 90\% |

[^0]
## Amino Acids and Their Derivatives (continued)

| Catalog No. | Description |
| :---: | :---: |
| CLM-8699-H | L-Asparagine. $\mathrm{H}_{2} \mathrm{O}\left({ }^{13} \mathrm{C}_{4}, 99 \%\right)$ |
| DLM-6844 | L-Asparagine. $\mathrm{H}_{2} \mathrm{O}\left(2,3,3-\mathrm{D}_{3}, 94 \%\right)$ |
| NLM-120 | L-Asparagine. $\mathrm{H}_{2} \mathrm{O}$ (amide- ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| NLM-3286 | L-Asparagine. $\mathrm{H}_{2} \mathrm{O}\left({ }^{15} \mathrm{~N}_{2}, 98 \%\right)$ |
| CNLM-7818 | L-Asparagine. $\mathrm{H}_{2} \mathrm{O}\left(1,4-{ }^{13} \mathrm{C}_{2}, 99 \% ; \alpha-{ }^{15} \mathrm{~N}, 98 \%\right)$ |
| CNLM-3819-H | L-Asparagine. $\mathrm{H}_{2} \mathrm{O}\left({ }^{13} \mathrm{C}_{4}, 99 \%\right.$; $\left.{ }^{15} \mathrm{~N}_{2}, 99 \%\right)$ |
| DNLM-6932 | L-Asparagine $\cdot \mathrm{H}_{2} \mathrm{O}\left(2,3,3-\mathrm{D}_{3}, 98 \% ;{ }^{15} \mathrm{~N}_{2}, 98 \%\right)$ |
| CDNLM-6802 | $\begin{aligned} & \text { L-Asparagine } \cdot \mathrm{H}_{2} \mathrm{O} \\ & \left({ }^{13} \mathrm{C}_{4}, 97-99 \% ; \mathrm{D}_{3}, 97-99 \% ;{ }^{15} \mathrm{~N}_{2}, 97-99 \%\right) \end{aligned}$ |
| CLM-865 | DL-Aspartic acid (3-13 $\mathrm{C}, 99 \%)$ |
| CLM-518 | DL-Aspartic acid (4-13C, 99\%) |
| DLM-832 | DL-Aspartic acid (2,3,3-2, ${ }_{3}, 98 \%$ ) |
| DLM-8599 | DL-Aspartic acid, N -acetyl (aspartate-2,3,3-D ${ }_{3}, 98 \%$ ) CP 97\% |
| CLM-3616 | L-Aspartic acid ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-3617 | L-Aspartic acid ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-627 | L-Aspartic acid ( $3-{ }^{-13} \mathrm{C}, 98-99 \%$ ) |
| CLM-519 | L-Aspartic acid (4-13C, 99\%) |
| CLM-4455 | L-Aspartic acid (1,4-13 $\mathrm{C}_{2}, 99 \%$ ) |
| CLM-1801-H | L-Aspartic acid ( ${ }^{13} \mathrm{C}_{4}, 99 \%$ ) |
| DLM-546 | L-Aspartic acid ( $2,3,3-\mathrm{D}_{3}, 98 \%$ ) |
| NLM-718 | L-Aspartic acid ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-7817 | L-Aspartic acid ( $1,4-{ }^{13} \mathrm{C}_{2}, 99 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-544-H | L-Aspartic acid ( ${ }^{13} \mathrm{C}_{4}, 99 \%$; ${ }^{15} \mathrm{~N}, 99 \%$ ) |
| DNLM-6931 | L-Aspartic acid (2,3,3-D ${ }_{3}, 98 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CDNLM-6803 | L-Aspartic acid <br> ( $\left.{ }^{13} \mathrm{C}_{4}, 97-99 \% ; \mathrm{D}_{3}, 97-99 \% ;{ }^{15} \mathrm{~N}, 97-99 \%\right)$ |
| ULM-8676 | L-Aspartic acid (unlabeled) |
| CLM-4899 | L-Citrulline (ureido- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| DLM-3860 | L-Citrulline (5,5-D ${ }_{2}, 98 \%$ ) |
| DLM-3860-MPT | L-Citrulline (5,5-D ${ }_{2}, 98 \%$ ) |
| DLM-6039 | L-Citrulline (4,4,5,5-D. ${ }^{\text {, }}$, $95 \%$ ) |
| NLM-6850 | L-Citrulline (ureido- ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CDLM-7879 | L-Citrulline (ureido- ${ }^{13} \mathrm{C}, 99 \% ; 5,5-\mathrm{D}_{2}, 98 \%$ ) |
| CDLM-7139 | L-Citrulline ( $5-{ }^{-13} \mathrm{C}, 99 \% ; 4,4,5,5-\mathrm{D}_{4}, 95 \%$ ) |
| CDLM-7139-MPT | L-Citrulline ( $5-{ }^{-13} \mathrm{C}, 99 \% ; 4,4,5,5-\mathrm{D}_{4}, 95 \%$ ) |
| DLM-3653 | Creatinine ( N -methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| CDLM-4211 | Cycloleucine (carboxyl ${ }^{13} \mathrm{C}, 99 \% ; 2,2,5,5-\mathrm{D}_{4}, 96 \%$ ) |
| DLM-6108 | DL-Cystathionine (3,3,4,4-D ${ }^{4}, 98 \%$ ) |
| CLM-3790 | DL-Cysteine (1-13 ${ }^{13}$, 99\%) |
| CLM-898 | DL-Cysteine (3-13C, 99\%) |
| DLM-899 | DL-Cysteine (3,3-D ${ }_{2}, 98 \%$ ) |
| CLM-3852 | L-Cysteine (1-13C, 99\%) |
| CLM-1868 | L-Cysteine (3-13 $\mathrm{C}, 99 \%)$ |
| CLM-4320-H | L-Cysteine ( ${ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| DLM-769 | L-Cysteine ( $3,3-\mathrm{D}_{2}, 98 \%$ ) |
| DLM-6901 | L-Cysteine (2,3,3-D ${ }^{\text {, }}$, 98\%) |
| NLM-2295 | L-Cysteine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| DLM-2942 | L-Cysteine, S-methyl (S-methyl-D ${ }_{3}$, 98\%) CP 97\% |
| CNLM-7815 | L-Cysteine ( $1-{ }^{13} \mathrm{C}, 99 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-3871-H | L-Cysteine ( ${ }^{13} \mathrm{C}_{3}, 99 \%$; ${ }^{15} \mathrm{~N}, 99 \%$ ) |
| DNLM-6902 | L-Cysteine (2,3,3-D ${ }_{3}, 98 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CDNLM-6809 | L-Cysteine ( $\left.{ }^{13} \mathrm{C}_{3}, 97-99 \% ; \mathrm{D}_{3}, 97-99 \% ;{ }^{15} \mathrm{~N}, 97-99 \%\right)$ |

MPT: microbiologically and pyrogen tested.

| Catalog No. | Description |
| :---: | :---: |
| DLM-8738 | S-Sulfo-DL-cysteine (2,3,3-D ${ }_{3}, 99 \%$ ) |
| DLM-1000 | DL-Cystine ( $\left.3,3,3^{\prime}, 3^{\prime}-\mathrm{D}_{4}, 98 \%\right)$ |
| NLM-1668 | DL-Cystine ( ${ }^{15} \mathrm{~N}_{2}, 95 \%$ ) |
| CLM-520 | L-Cystine ( $3,3^{\prime}{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| DLM-9812 | L-Cystine ( $3,3,33^{\prime}, 3^{\prime}-\mathrm{D}_{4}, 98 \%$ ) |
| NLM-3818 | L-Cystine ( ${ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| CNLM-4244-H | L-Cystine ( ${ }^{13} \mathrm{C}_{6}, 99 \%$; ${ }^{15} \mathrm{~N}_{2}, 99 \%$ ) |
| CDNLM-8659 | L-Cystine ( ${ }^{13} \mathrm{C}_{6}, 98 \%$; $\mathrm{D}_{6}, 98 \%$; ${ }^{15} \mathrm{~N}_{2}, 98 \%$ ) CP 95\% |
| DLM-8516 | N, N-Dimethylglycine• $\mathrm{HCl}\left(\mathrm{D}_{6}, 99 \%\right)$ |
| CLM-3632 | DL-Glutamic acid ( $3-{ }^{13} \mathrm{C}, 99 \%$ ) |
| DLM-335 | DL-Glutamic acid ( $2,4,4-\mathrm{D}_{3}, 98 \%$ ) |
| DLM-357 | DL-Glutamic acid (2,3,3,4,4-D $\left.{ }_{5}, 97 \%\right)$ |
| CLM-674 | L-Glutamic acid (1-13C, 99\%) |
| CLM-674-MPT | L-Glutamic acid (1-13C, 99\%) |
| CLM-2474 | L-Glutamic acid ( $2-1{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-4742 | L-Glutamic acid (3-13C, 99\%) |
| CLM-2431 | L-Glutamic acid (4-1 ${ }^{13} \mathrm{C}, 98-99 \%$ ) |
| CLM-613 | L-Glutamic acid ( $5-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-2024 | L-Glutamic acid (1,2-13 $\left.\mathrm{C}_{2}, 99 \%\right)$ |
| CLM-3646 | L-Glutamic acid (3,4-13 $\mathrm{C}_{2}, 99 \%$ ) |
| CLM-1800-H | L-Glutamic acid ( ${ }^{13} \mathrm{C}_{5}, 99 \%$ ) |
| DLM-3725 | L-Glutamic acid ( $2,4,4-\mathrm{D}_{3}, 97-98 \%$ ) |
| DLM-556 | L-Glutamic acid (2,3,3,4,4-D ${ }_{5}, 97-98 \%$ ) |
| NLM-135 | L-Glutamic acid ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-7812 | L-Glutamic acid (1-13 ${ }^{13} \mathrm{C}, 99 \%$; ${ }^{5} \mathrm{~N}, 98 \%$ ) |
| CNLM-554-H | L-Glutamic acid ( ${ }^{13} \mathrm{C}_{5}, 99 \%$; ${ }^{15} \mathrm{~N}, 99 \%$ ) |
| DNLM-6996 | L-Glutamic acid (2,3,3,4,4-D ${ }_{5}, 98 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CDNLM-6804 | L-Glutamic acid $\left({ }^{13} \mathrm{C}_{5}, 97-99 \% ; \mathrm{D}_{5}, 97-99 \% ;{ }^{15} \mathrm{~N}, 97-99 \%\right)$ |
| CLM-3721 | DL-Glutamic acid• $\mathrm{H}_{2} \mathrm{O}\left(1-{ }^{13} \mathrm{C}, 99 \%\right)$ |
| OLM-8028 | L-Glutamic acid. $\mathrm{HCl}\left({ }^{17} \mathrm{O}_{4}, \sim 30 \%\right)$ |
| CLM-3612 | L-Glutamine ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-3612-MPT | L-Glutamine ( $1-1{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-3613 | L-Glutamine ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-770 | L-Glutamine (4-13 ${ }^{13}$, 99\%) |
| CLM-1166 | L-Glutamine ( $5-1{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-2001 | L-Glutamine (1,2-13 $\left.\mathrm{C}_{2}, 99 \%\right)$ |
| CLM-3641 | L-Glutamine ( $3,4-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-1822-H | L-Glutamine ( ${ }^{13} \mathrm{C}_{5}, 99 \%$ ) |
| CLM-1822-H-MPT | L-Glutamine ( ${ }^{13} \mathrm{C}_{5}, 99 \%$ ) |
| DLM-1826 | L-Glutamine ( $2,3,3,4,4-\mathrm{D}_{5}, 97 \%$ ) |
| NLM-1016 | L-Glutamine ( $\alpha$ - ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| NLM-1016-MPT | L-Glutamine ( $\alpha$ - ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| NLM-557 | L-Glutamine (amide- ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| NLM-1328 | L-Glutamine ( ${ }^{15}{ }^{2}$, $98 \%$ ) |
| NLM-1328-MPT | L-Glutamine ( ${ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| CNLM-7813 | L-Glutamine ( $1-{ }^{13} \mathrm{C}, 99 \%$; $\alpha$ - ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-1275-H | L-Glutamine ( ${ }^{13} \mathrm{C}_{5}, 99 \%$; ${ }^{15} \mathrm{~N}_{2}, 99 \%$ ) |
| DNLM-6997 | L-Glutamine ( $2,3,3,4,4-\mathrm{D}_{5}, 97-98 \%$; ${ }^{15} \mathrm{~N}_{2}, 97-98 \%$ ) |
| CDNLM-6805 | L-Glutamine $\left({ }^{13} C_{5}, 97-99 \% ; D_{5}, 97-99 \% ;{ }^{15} \mathrm{~N}_{2}, 97-99 \%\right)$ |
| CLM-422 | Glycine ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-422-MPT | Glycine ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-136 | Glycine ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |

Chemical purity (CP) is $98 \%$ or greater, unless otherwise indicated.
For research use only. Not for use in diagnostic procedures.

| Catalog No. | Description |
| :---: | :---: |
| CLM-136-MPT | Glycine ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-1017 | Glycine (1,2-13 $\left.\mathrm{C}_{2}, 97-99 \%\right)$ |
| CLM-1017-MPT | Glycine (1,2-13 $\left.\mathrm{C}_{2}, 97-99 \%\right)$ |
| DLM-1674 | Glycine (2,2-D $\left.{ }_{2}, 98 \%\right)$ |
| DLM-280 | Glycine ( $\mathrm{S}_{5}, 98 \%$ ) |
| NLM-202 | Glycine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| NLM-202-MPT | Glycine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-507 | Glycine ( $1-{ }^{13} \mathrm{C}, 99 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-508 | Glycine ( $2-^{13} \mathrm{C}, 99 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-1673-H | Glycine ( ${ }^{13} \mathrm{C}_{2}, 99 \%$; ${ }^{15} \mathrm{~N}, 99 \%$ ) |
| CNLM-1673-H-MPT | Glycine ( ${ }^{13} \mathrm{C}_{2}, 99 \%$; ${ }^{15} \mathrm{~N}, 99 \%$ ) |
| DNLM-6862 | Glycine (2,2-D ${ }_{2}, 98 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CDNLM-6799 | Glycine ( ${ }^{13} \mathrm{C}_{2}, 97-99 \% ; 2,2-\mathrm{D}_{2}, 97-99 \%$; ${ }^{15} \mathrm{~N}, 97-99 \%$ ) |
| CNLM-7175 | Glycine• HCl , ethyl ester ( ${ }^{13} \mathrm{C}_{2}, 98 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| DLM-10822 | Glycine, N -octanoyl ( $2,2-\mathrm{D}_{2}, 98 \%$ ) |
| CLM-2636 | DL-Histidine (ring-2-13C, 99\%) |
| NLM-138 | DL-Histidine• $2 \mathrm{HCl}\left(\alpha-{ }^{15} \mathrm{~N}, 98 \%\right)$ |
| NLM-4649 | L-Histidine (ring- - $^{15} \mathrm{~N}, 98 \%$ ) (<5\% D) |
| NLM-4457 | L-Histidine (ring- $\pi-{ }^{15} \mathrm{~N}, 98 \%$ ) (<5\% D) |
| NLM-9585 | L-Histidine (ring- ${ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| DLM-8691 | $\pi$-Methyl-L-histidine (methyl-D ${ }_{3}, 98 \%$ ) |
| DLM-2949 | $\tau$-Methyl-L-histidine (methyl-D ${ }_{3}, 98 \%$ ) |
| DLM-2949-MPT | $\tau$-Methyl-L-histidine (methyl-D ${ }_{3}, 98 \%$ ) |
| CLM-1512 | L-Histidine $\cdot \mathrm{HCl} \cdot \mathrm{H}_{2} \mathrm{O}\left(\right.$ ring $-2-{ }^{-13} \mathrm{C}, 99 \%$ ) <5\% D |
| DLM-7855 | L-Histidine $\cdot \mathrm{HCl} \cdot \mathrm{H}_{2} \mathrm{O}$ (ring-2,4-D $\mathrm{D}_{2} ; \alpha, \beta, \beta-\mathrm{D}_{3}, 98 \%$ ) |
| NLM-2245 | L-Histidine. $\mathrm{HCl} \cdot \mathrm{H}_{2} \mathrm{O}\left(\alpha-{ }^{-15} \mathrm{~N}, 98 \%\right)$ |
| NLM-846 | L-Histidine $\cdot \mathrm{HCl} \cdot \mathrm{H}_{2} \mathrm{O}$ (ring- $\pi$ - ${ }^{-5} \mathrm{~N}, 98 \%$ ) <5\% D |
| DNLM-7366 | L-Histidine. $\mathrm{HCl} \cdot \mathrm{H}_{2} \mathrm{O}\left(\mathrm{D}_{5}, 98 \%\right.$; $\left.{ }^{15} \mathrm{~N}_{3}, 98 \%\right)$ |
| CDNLM-6806 | L-Histidine• $\mathrm{HCl} \cdot \mathrm{H}_{2} \mathrm{O}$ $\left({ }^{13} C_{6}, 97-99 \% ; D_{5}, ~ 97-99 \% ;{ }^{15} N_{3}, 97-99 \%\right) \text { CP 95\% }$ |
| CNLM-4645 | L-Homoarginine $\cdot \mathrm{HCl}\left({ }^{13} \mathrm{C}_{7}, 98 \%\right.$; $\left.{ }^{15} \mathrm{~N}_{4}, 98 \%\right)$ |
| DLM-8259 | DL-Homocysteine (3,3,4,4-D ${ }_{4}, 98 \%$ ) |
| DLM-3619 | DL-Homocystine (3,3, $\left.{ }^{\prime}, 3{ }^{\prime}, 4,4,4^{\prime}, 4^{\prime}-\mathrm{D}_{8}, 98 \%\right)$ |
| NLM-2466 | L-Homoserine ( ${ }^{15} \mathrm{~N}, 95-99 \%$ ) CP 97\% |
| CLM-10745 | Indole 3-carboxaldehyde (indole- ${ }^{13} \mathrm{C}_{8}, 99 \%$ ) |
| CLM-8742 | L-Allo-isoleucine ( ${ }^{13} \mathrm{C}_{6}, 97-99 \%$ ) |
| DLM-1505 | L-Allo-isoleucine ( $\mathrm{D}_{10}, 98 \%$ ) |
| CNLM-8670 | L-Allo-isoleucine ( ${ }^{13} \mathrm{C}_{6}, 97-99 \%$; ${ }^{15} \mathrm{~N}, 97-99 \%$ ) |
| CLM-1026 | L-Isoleucine ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-1026-MPT | L-Isoleucine ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-2248-H | L-Isoleucine ( ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| DLM-141 | L-Isoleucine ( $\mathrm{D}_{10}, 98 \%$ ) |
| NLM-292 | L-Isoleucine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-7810 | L-Isoleucine (1-13C, 99\%; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-561-H | L-Isoleucine ( ${ }^{13} \mathrm{C}_{6}, 99 \%$; ${ }^{15} \mathrm{~N}, 99 \%$ ) |
| DNLM-7325 | L-Isoleucine ( $\mathrm{D}_{10}, 98 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CDNLM-6807 | L-Isoleucine ( ${ }^{13} \mathrm{C}_{6}, 97-99 \%$; $\mathrm{D}_{10}, 97-99 \%$; ${ }^{15} \mathrm{~N}, 97-99 \%$ ) |
| DLM-7374 | Kynurenic acid (ring- $\mathrm{D}_{5}$, 98\%) |
| CLM-204 | DL-Leucine ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-207 | DL-Leucine ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| DLM-9423 | DL-Leucine ( $\mathrm{D}_{10}, 98 \%$ ) |

CTM: manufactured following ICH Q7, Section XIX
MPT: microbiologically and pyrogen tested.
Chemical purity (CP) is $98 \%$ or greater, unless otherwise indicated. For research use only. Not for use in diagnostic procedures.

| Catalog No. | Description |
| :---: | :---: |
| NLM-355 | DL-Leucine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CLM-468 | L-Leucine (1-1 ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-468-MPT | L-Leucine ( $1-1{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-2014 | L-Leucine ( $2-1{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-3524 | L-Leucine (1,2-13 $\mathrm{C}_{2}, 99 \%$ ) |
| CLM-3524-MPT | L-Leucine (1,2-13 $\mathrm{C}_{2}, 99 \%$ ) |
| CLM-2262-CTM | L-Leucine ( ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| CLM-2262-H | L-Leucine ( ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| CLM-2262-H-MPT | L-Leucine ( ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| DLM-1259 | L-Leucine ( $5,5,5-\mathrm{D}_{3}, 99 \%$ ) |
| DLM-1259-CTM | L-Leucine ( $5,5,5-\mathrm{D}_{3}, 99 \%$ ) |
| DLM-1259-MPT | L-Leucine ( $5,5,5-\mathrm{D}_{3}, 99 \%$ ) |
| DLM-4212 | L-Leucine (isopropyl-D ${ }_{7}, 98 \%$ ) |
| DLM-567 | L-Leucine ( $\mathrm{D}_{10}, 98 \%$ ) |
| DLM-567-MPT | L-Leucine ( $\mathrm{D}_{10}, 98 \%$ ) |
| NLM-142 | L-Leucine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| NLM-142-MPT | L-Leucine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| OLM-2041 | L-Leucine ( ${ }^{18} \mathrm{O}_{2}, 94 \%$ ) |
| CNLM-615 | L-Leucine ( $1-{ }^{13} \mathrm{C}, 99 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-615-MPT | L-Leucine ( $1-{ }^{13} \mathrm{C}, 99 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-3450 | L-Leucine ( $2-{ }^{13} \mathrm{C}, 99 \%$; ${ }^{15} \mathrm{~N}, 95-99 \%$ ) |
| CNLM-281-H | L-Leucine ( ${ }^{13} \mathrm{C}_{6}, 99 \%$; ${ }^{15} \mathrm{~N}, 99 \%$ ) |
| CNLM-281-H-MPT | L-Leucine ( ${ }^{13} \mathrm{C}_{6}, 99 \%$; ${ }^{15} \mathrm{~N}, 99 \%$ ) |
| DNLM-4642 | L-Leucine ( $\mathrm{D}_{10}, 98 \%$; ${ }^{15} \mathrm{~N}, 97 \%$ ) |
| CDNLM-6808 | L-Leucine ( ${ }^{13} \mathrm{C}_{6}, 97-99 \%$; $\mathrm{D}_{10}, 97-99 \%$; ${ }^{15} \mathrm{~N}, 97-99 \%$ ) |
| ULM-8203 | L-Leucine (unlabeled) |
| ULM-8203-MPT | L-Leucine (unlabeled) |
| CLM-10684 | L-Leucine•HCI (1-13C, 99\%) |
| CLM-749 | DL-Lysine $2 \mathrm{HCl}\left(1-1{ }^{13} \mathrm{C}, 99 \%\right)$ |
| DLM-8941 | DL-Lysine.2HCl (4,4,5,5-D ${ }_{4}$, 96-98\%) |
| NLM-1031 | DL-Lysine $2 \mathrm{HCl}\left(\varepsilon^{-15} \mathrm{~N}, 98 \%\right)$ |
| CNLM-3452 | DL-Lysine $2 \mathrm{HCl}\left(1-{ }^{13} \mathrm{C}, 99 \% ; \varepsilon-{ }^{15} \mathrm{~N}, 99 \%\right)$ |
| CNLM-3453 | DL-Lysine $2 \mathrm{HCl}\left(2-{ }^{13} \mathrm{C}, 99 \% ; \varepsilon-{ }^{15} \mathrm{~N}, 99 \%\right)$ |
| CLM-653 | L-Lysine•2HCl (1-13 $\mathrm{C}, 99 \%)$ |
| CLM-653-MPT | L-Lysine-2HCl (1-13 ${ }^{13}$, 99\%) |
| CLM-632 | L-Lysine $2 \mathrm{HCl}\left(6-{ }^{13} \mathrm{C}, 99 \%\right)$ |
| CLM-2247-H | L-Lysine $2 \mathrm{HCl}\left({ }^{13} \mathrm{C}_{6}, 99 \%\right)$ |
| DLM-2640 | L-Lysine-2HCI (4,4,5,5-D $\left.{ }_{4}, 96-98 \%\right)$ |
| DLM-2640-MPT | L-Lysine $2 \mathrm{HCl}\left(4,4,5,5-\mathrm{D}_{4}, 96-98 \%\right)$ |
| DLM-2641 | L-Lysine-2HCl (3,3,4,4,5,5,6,6-D $\left.{ }_{8}, 98 \%\right)$ |
| DLM-570 | L-Lysine $2 \mathrm{HCl}\left(\mathrm{D}_{9}, 98 \%\right)$ |
| NLM-143 | L-Lysine $2 \mathrm{HCl}\left(\alpha-{ }^{15} \mathrm{~N}, 95-99 \%\right)$ |
| NLM-143-MPT | L-Lysine-2 $\mathrm{HCl}\left(\alpha-{ }^{-15} \mathrm{~N}, 95-99 \%\right)$ |
| NLM-1554 | L-Lysine $2 \mathrm{HCl}\left({ }^{15} \mathrm{~N}_{2}, 98 \%\right)$ |
| NLM-631 | L-Lysine•2HCl ( $\varepsilon^{-15} \mathrm{~N}, 98 \%$ ) |
| CNLM-7821 | L-Lysine-2 $\mathrm{HCl}\left(1-{ }^{13} \mathrm{C}, 99 \% ; \alpha-{ }^{15} \mathrm{~N}, 98 \%\right)$ |
| CNLM-3454 | L-Lysine $2 \mathrm{HCl}\left(6-{ }^{13} \mathrm{C}, 99 \% ; \varepsilon{ }^{-15} \mathrm{~N}, 98 \%\right)$ |
| CNLM-291-H | L-Lysine $2 \mathrm{HCl}\left({ }^{13} \mathrm{C}_{6}, 99 \%\right.$; $\left.{ }^{15} \mathrm{~N}_{2}, 99 \%\right)$ |
| CNLM-291-H-MPT | L-Lysine $2 \mathrm{HCl}\left({ }^{13} \mathrm{C}_{6}, 99 \%\right.$; $\left.{ }^{15} \mathrm{~N}_{2}, 99 \%\right)$ |
| DNLM-7545 | L-Lysine-2HCl ( $\mathrm{D}_{9}, 98 \%$; $\left.{ }^{15} \mathrm{~N}_{2}, 98 \%\right)$ |
| CDNLM-6810 | L-Lysine-2 HCl $\left({ }^{13} C_{6}, 97-99 \% ; D_{9}, 97-99 \% ;{ }^{15} \mathrm{~N}_{2}, 97-99 \%\right)$ |
| ULM-8766 | L-Lysine•2HCl (unlabeled) |

## Amino Acids and Their Derivatives (continued)

| Catalog No. | Description |
| :---: | :---: |
| CLM-7356 | D-Methionine ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) CP 96\% |
| CLM-6191 | DL-Methionine (1-13 ${ }^{13}$, 99\%) |
| DLM-10774 | DL-Methionine ( $S$-methyl-D ${ }_{3}, 98 \%$ ) |
| DLM-2933 | DL-Methionine ( $3,3,4,4-\mathrm{D}_{4}, 98 \%$ ) |
| DLM-9019 | DL-Methionine ( $3,3,4,4-\mathrm{D}_{4} ;$ methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| CLM-3267 | L-Methionine (1-13 $\mathrm{C}, 99 \%)$ |
| CLM-3267-MPT | L-Methionine (1-13 $\mathrm{C}, 99 \%)$ |
| CLM-206 | L-Methionine (methyl- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-893-H | L-Methionine ( ${ }^{13} \mathrm{C}_{5}$, 99\%) |
| DLM-431 | L-Methionine (methyl-D ${ }_{3}$, 98\%) |
| DLM-431-MPT | L-Methionine (methyl-D ${ }_{3}$, 98\%) |
| DLM-6797 | L-Methionine ( $2,3,3,4,4-\mathrm{D}_{5}$; methyl-D ${ }_{3}$, 98\%) |
| NLM-752 | L-Methionine ( ${ }^{15} \mathrm{~N}, 96-98 \%$ ) |
| CDLM-760 | L-Methionine ( $1-{ }^{13} \mathrm{C}, 99 \%$; methyl-D ${ }_{3}, 98 \%$ ) |
| CDLM-760-MPT | L-Methionine ( $1-{ }^{13} \mathrm{C}, 99 \%$; methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| CDLM-9289 | L-Methionine (methyl- ${ }^{13} \mathrm{C}, 99 \%$; methyl-D ${ }_{3}, 98 \%$ ) |
| CDLM-8885 | L-Methionine ( $2,3,3,4,4-\mathrm{D}_{5}, 98 \%$; methyl- ${ }^{13} \mathrm{CH}_{3}, 99 \%$ ) |
| CNLM-7807 | L-Methionine ( $1-{ }^{13} \mathrm{C}, 99 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-9774 | L-Methionine ( $1,2,3,4-{ }^{-13} \mathrm{C}_{4}, 99 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-759-H | L-Methionine ( ${ }^{13} \mathrm{C}_{5}, 99 \%$; ${ }^{15} \mathrm{~N}, 99 \%$ ) |
| DNLM-7179 | L-Methionine ( $\mathrm{D}_{8}, 98 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CDNLM-6798 | L-Methionine $\left({ }^{13} \mathrm{C}_{5}, 97-99 \% ; \mathrm{D}_{8}, 97-99 \% ;{ }^{15} \mathrm{~N}, 97-99 \%\right)$ |
| CLM-8002 | L-Methionine sulfone (1-13 $\mathrm{C}, 99 \%)$ |
| CNLM-10424 | $\beta$ - $N$-Methylamino-L-alanine ( ${ }^{13} \mathrm{C}_{3}, 99 \%$; ${ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| ULM-10493 | $\beta-\mathrm{N}$-Methylamino-L-alanine HCl (unlabeled) $\mathrm{CP} 97 \%$ |
| DLM-10673 | 3-Methylcrotonylglycine (glycine-2,2-D ${ }_{2}, 98 \%$ ) |
| CLM-7104 | 3-Nitro-L-tyrosine (ring- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) CP 94\% |
| CLM-1036 | L-Ornithine. $\mathrm{HCl}\left(1,2-{ }^{13} \mathrm{C}_{2}, 99 \%\right)$ |
| CLM-4724-H | L-Ornithine. $\mathrm{HCl}\left({ }^{13} \mathrm{C}_{5}, 99 \%\right)$ |
| DLM-4261 | L-Ornithine- $\mathrm{HCl}\left(5,5-\mathrm{D}_{2}, 98 \%\right)$ |
| DLM-6046 | L-Ornithine $\cdot \mathrm{HCl}\left(4,4,5,5-\mathrm{D}_{4}, 95 \%\right)$ |
| DLM-2969 | L-Ornithine. $\mathrm{HCl}\left(3,3,4,4,5,5-\mathrm{D}_{6}, 98 \%\right)$ |
| DLM-6669 | L-Ornithine• $\mathrm{HCl}\left(\mathrm{D}_{7}, 98 \%\right)$ |
| NLM-2212 | L-Ornithine $\cdot \mathrm{HCl}\left(\alpha-{ }^{15} \mathrm{~N}, 98 \%\right)$ |
| NLM-2174 | L-Ornithine•HCl ( $5-{ }^{15} \mathrm{~N}, 98 \%$ ) |
| NLM-3610 | L-Ornithine. $\mathrm{HCl}\left({ }^{15} \mathrm{~N}_{2}, 98 \%\right)$ |
| CDLM-3873 | L-Ornithine•HCl ( $\left.5-{ }^{13} \mathrm{C}, 99 \% ; 4,4,5,5-\mathrm{D}_{4}, 95 \%\right)$ |
| CNLM-7578-H | L-Ornithine• $\mathrm{HCl}\left({ }^{13} \mathrm{C}_{5}, 99 \%\right.$; $\left.{ }^{15} \mathrm{~N}_{2}, 99 \%\right)$ |
| DLM-4526 | D-Phenylalanine (ring-D ${ }_{5}$, 97\%) |
| CLM-761 | DL-Phenylalanine (1-13C, 99\%) |
| DLM-2983 | DL-Phenylalanine (2-D, 98\%) |
| DLM-2986 | DL-Phenylalanine (ring- $\mathrm{D}_{5}, 98 \%$ ) |
| NLM-3434 | DL-Phenylalanine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CLM-762 | L-Phenylalanine (1-13C, 99\%) |
| CLM-762-CTM | L-Phenylalanine ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-762-HP-MPT | L-Phenylalanine ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) <0.2\% D |
| CLM-762-MPT | L-Phenylalanine ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-1631 | L-Phenylalanine (2-13C, 99\%) CP 97\% |
| CLM-1053 | L-Phenylalanine ( $3-1{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-1055 | L-Phenylalanine (ring- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |


| Catalog No. | Description |
| :---: | :---: |
| CLM-1055-MPT | L-Phenylalanine (ring- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| CLM-2250-H | L-Phenylalanine ( ${ }^{13} \mathrm{C}_{9}, 99 \%$ ) |
| DLM-2984 | L-Phenylalanine (2-D, 95\%) |
| DLM-2985 | L-Phenylalanine (3,3-D ${ }_{2}$, 98\%) |
| DLM-1258 | L-Phenylalanine (ring- $\mathrm{D}_{5}$, 98\%) |
| DLM-1258-MPT | L-Phenylalanine (ring- $\mathrm{D}_{5}$, 98\%) |
| DLM-372 | L-Phenylalanine ( $\mathrm{D}_{8}, 98 \%$ ) |
| DLM-372-MPT | L-Phenylalanine ( $\mathrm{D}_{8}, 98 \%$ ) |
| NLM-108 | L-Phenylalanine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| NLM-108-MPT | L-Phenylalanine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-7611 | L-Phenylalanine ( $2,3-{ }^{13} \mathrm{C}_{2}, 99 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-575-H | L-Phenylalanine ( ${ }^{13} \mathrm{C}, 9,99 \%$; ${ }^{15} \mathrm{~N}, 99 \%$ ) |
| DNLM-7180 | L-Phenylalanine ( $\mathrm{D}_{8}, 98 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CDNLM-6811 | L-Phenylalanine $\left({ }^{13} \mathrm{C}_{9}, 97-99 \% ; \mathrm{D}_{8}, 97-99 \% ;{ }^{15} \mathrm{~N}, 97-99 \%\right)$ |
| ULM-8205 | L-Phenylalanine (unlabeled) |
| CLM-2479 | DL-Proline (1-13C, 99\%) |
| DLM-2657 | DL-Proline (2,3,3,4,4,5,5-D ${ }_{7}, 97-98 \%$ ) |
| CLM-510 | L-Proline ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-2260-H | L-Proline ( ${ }^{13} \mathrm{C}_{5}, 99 \%$ ) |
| DLM-10775 | L-Proline ( $2,5,5-\mathrm{D}_{3}, 98 \%$ ) |
| DLM-487 | L-Proline ( $\mathrm{D}_{7}, 97-98 \%$ ) |
| NLM-835 | L-Proline ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-7822 | L-Proline (1-13 ${ }^{13}$, 99\%; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-436-H | L-Proline ( ${ }^{13} \mathrm{C}_{5}, 99 \%$; ${ }^{15} \mathrm{~N}, 99 \%$ ) |
| DNLM-7562 | L-Proline ( $\mathrm{D}_{7}, 98 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CDNLM-6812 | L-Proline ( ${ }^{13} \mathrm{C}_{5}, 97-99 \%$; $\mathrm{D}_{7}, 97-99 \%$; ${ }^{15} \mathrm{~N}, 97-99 \%$ ) |
| ULM-8333 | L-Proline (unlabeled) |
| DLM-6874 | Sarcosine• $\mathrm{HCl}(N$-methylglycine• HCl$)$ (methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| CNLM-9699 | Sarcosine• $\mathrm{HCl}(N$-methylglycine• HCl$)$ $\left({ }^{13} \mathrm{C}_{3}, 99 \% ;{ }^{15} \mathrm{~N}, 98 \%\right)$ |
| CLM-1075 | DL-Serine (1-1 ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-496 | DL-Serine ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-497 | DL-Serine (3-13C, 99\%) |
| DLM-1073 | DL-Serine ( $2,3,3-\mathrm{D}_{3}, 98 \%$ ) |
| NLM-1531 | DL-Serine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-4207 | DL-Serine ( ${ }^{13} \mathrm{C}_{3}, 98 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CLM-1573 | L-Serine ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-2013 | L-Serine ( $2-{ }^{-13} \mathrm{C}, 99 \%$ ) |
| CLM-1572 | L-Serine ( $3-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-1574-H | L-Serine ( ${ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| DLM-161 | L-Serine (3,3-D $2,98 \%$ ) |
| DLM-582 | L-Serine ( $2,3,3-\mathrm{D}_{3}, 98 \%$ ) |
| DLM-582-MPT | L-Serine ( $2,3,3-\mathrm{D}_{3}, 98 \%$ ) |
| NLM-2036 | L-Serine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| OLM-9960 | L-Serine (carboxyl- ${ }^{18} \mathrm{O}_{2}, 95 \%$ ) |
| CNLM-7814 | L-Serine ( $1-1{ }^{13} \mathrm{C}, 99 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-474-H | L-Serine ( ${ }^{13} \mathrm{C}_{3}, 99 \%$; ${ }^{15} \mathrm{~N}, 99 \%$ ) |
| DNLM-6863 | L-Serine ( $2,3,3-\mathrm{D}_{3}, 98 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CDNLM-6813 | L-Serine ( ${ }^{13} \mathrm{C}_{3}, 97-99 \% ; \mathrm{D}_{3}, 97-99 \%$; ${ }^{15} \mathrm{~N}, 97-99 \%$ ) |
| DLM-10873 | L-Serine, $N$-acetyl ( $2,3,3-\mathrm{D}_{3}, 98 \%$ ) |

CTM: manufactured following ICH Q7, Section XIX
MPT: microbiologically and pyrogen tested.
Chemical purity (CP) is $98 \%$ or greater, unless otherwise indicated For research use only. Not for use in diagnostic procedures.

| Catalog No. | Description |
| :---: | :---: |
| CLM-3949 | Sodium glutamate $\cdot \mathrm{XH}_{2} \mathrm{O}\left({ }^{13} \mathrm{C}_{5}, 97-98 \%\right)$ may be hydrate |
| CLM-447 | L-Threonine ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-2261 | L-Threonine ( ${ }^{13} \mathrm{C}_{4}, 97-99 \%$ ) |
| DLM-1693 | L-Threonine ( $\mathrm{D}_{5}, 98 \%$ ) |
| NLM-742 | L-Threonine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CDLM-9307 | L-Threonine (4-1 ${ }^{13} \mathrm{C}, 97 \% ; 2,3-\mathrm{D}_{2}, 96-98 \%$ ) |
| CNLM-587 | L-Threonine ( ${ }^{13} \mathrm{C}_{4}, 97-99 \%$; ${ }^{15} \mathrm{~N}, 97-99 \%$ ) |
| DNLM-7367 | L-Threonine ( $\mathrm{D}_{5}, 97 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CDNLM-6814 | L-Threonine ( ${ }^{13} \mathrm{C}_{4}, 97-99 \%$; $\mathrm{D}_{5}, 97-99 \%$; ${ }^{15} \mathrm{~N}, 97-99 \%$ ) |
| ULM-8800 | L-Threonine (unlabeled) |
| CLM-778 | L-Tryptophan (1-13 $\mathrm{C}, 99 \%$ ) |
| CLM-1543 | L-Tryptophan (indole-2-13 $\mathrm{C}, 98 \%$ ) |
| CLM-716 | L-Tryptophan (indole-3-13 ${ }^{13} \mathrm{C}, 95-99 \%$ ) |
| CLM-717 | L-Tryptophan (indole-4-13C, 99\%) CP 95\% |
| CLM-4290-H | L-Tryptophan ( ${ }^{13} \mathrm{C}_{11}, 99 \%$ ) |
| DLM-1092 | L-Tryptophan (indole-D ${ }_{5}$, 98\%) |
| DLM-6903 | L-Tryptophan ( $\mathrm{D}_{8}, 97-98 \%$ ) |
| NLM-1208 | L-Tryptophan (indole- ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| NLM-1695 | L-Tryptophan ( $\alpha$ - ${ }^{15} \mathrm{~N}, 95-99 \%$ ) |
| NLM-800 | L-Tryptophan ( ${ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| CNLM-2475-H | L-Tryptophan ( ${ }^{13} \mathrm{C}_{11}, 99 \%$; ${ }^{5} \mathrm{~N}_{2}, 99 \%$ ) |
| DNLM-6904 | L-Tryptophan ( $\mathrm{D}_{8}, 98 \%$; ${ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| CDNLM-6816 | L-Tryptophan $\left({ }^{13} \mathrm{C}_{11}, 97-99 \% ; \mathrm{D}_{8}, 97-99 \% ;{ }^{15} \mathrm{~N}_{2}, 97-99 \%\right)$ |
| CLM-7103 | 3-Chloro-L-tyrosine (ring- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) CP 95\% |
| CLM-448 | DL-Tyrosine ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| DLM-137 | DL-Tyrosine (3,3-D $\left.{ }_{2}, 98 \%\right)$ |
| DLM-2914 | DL-Tyrosine (ring-3,5-D ${ }_{2}$, 98\%) |
| CLM-776 | L-Tyrosine (1-13 $\mathrm{C}, 99 \%$ ) |
| CLM-437 | L-Tyrosine ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-3378 | L-Tyrosine ( $3-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-622 | L-Tyrosine (phenol-4- ${ }^{13} \mathrm{C}, 95-99 \%$ ) |
| CLM-623 | L-Tyrosine (phenol-3,5-1 ${ }^{13} \mathrm{C}_{2}, 95-99 \%$ ) |
| CLM-1542 | L-Tyrosine (ring- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| CLM-1542-MPT | L-Tyrosine (ring- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| CLM-2263-H | L-Tyrosine ( ${ }^{13} \mathrm{C}_{9}, 99 \%$ ) |
| DLM-2317 | L-Tyrosine ( $3,3-\mathrm{D}_{2}, 98 \%$ ) |
| DLM-2317-MPT | L-Tyrosine (3,3-D ${ }_{2}, 98 \%$ ) |
| DLM-449 | L-Tyrosine (ring-3,5-D ${ }_{2}, 98 \%$ ) |


| Catalog No. | Description |
| :---: | :---: |
| DLM-449-MPT | L-Tyrosine (ring-3,5- $\mathrm{D}_{2}, 98 \%$ ) |
| DLM-2917 | L-Tyrosine (ring-2,6-D $2,2-\mathrm{D}, 98 \%$ ) |
| DLM-451 | L-Tyrosine (ring-D ${ }_{4}, 98 \%$ ) |
| DLM-451-MPT | L-Tyrosine (ring-D ${ }_{4}, 98 \%$ ) |
| DLM-589 | L-Tyrosine ( $\mathrm{D}_{7}, 98 \%$ ) |
| NLM-590 | L-Tyrosine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| NLM-590-MPT | L-Tyrosine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| OLM-621 | L-Tyrosine (phenol- ${ }^{17}$ O, 35-40\%) |
| OLM-8696 | L-Tyrosine (phenol- ${ }^{18} \mathrm{O}, 85-90 \%$ ) |
| CDLM-2369 | L-Tyrosine (ring- ${ }^{13} \mathrm{C}_{6}, 99 \% ; 3,3-\mathrm{D}_{2}, 30 \%$ ) |
| CNLM-7809 | L-Tyrosine ( $1-{ }^{13} \mathrm{C}, 99 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-7610 | L-Tyrosine ( $2,3-{ }^{13} \mathrm{C}_{2}, 99 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-439-H | L-Tyrosine ( ${ }^{13} \mathrm{C}_{9}, 99 \%$; ${ }^{15} \mathrm{~N}, 99 \%$ ) |
| DNLM-7373 | L-Tyrosine ( $\mathrm{D}_{7}, 97-98 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CDNLM-6815 | L-Tyrosine ( ${ }^{13} \mathrm{C}_{9}, 97-99 \%$; $\mathrm{D}_{7}, 97-99 \%$; ${ }^{15} \mathrm{~N}, 97-99 \%$ ) |
| CLM-166 | DL-Valine (1-13C, 99\%) |
| CLM-3277 | DL-Valine ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| DLM-311 | DL-Valine ( $\mathrm{D}_{8}, 98 \%$ ) |
| NLM-236 | DL-Valine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CLM-470 | L-Valine ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-470-MPT | L-Valine ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-3050 | L-Valine ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-9217 | L-Valine (dimethyl- ${ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-2249-H | L-Valine ( ${ }^{13} \mathrm{C}_{5}, 99 \%$ ) |
| DLM-7732 | L-Valine (3-D, 98\%) |
| DLM-4364 | L-Valine (2,3-D ${ }_{2}, 98 \%$ ) |
| DLM-488 | L-Valine ( $\mathrm{D}_{8}, 98 \%$ ) |
| NLM-316 | L-Valine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-3466 | L-Valine (1-13 ${ }^{13}$, 99\%; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-8678 |  |
| CNLM-442-H | L-Valine ( ${ }^{13} \mathrm{C}_{5}, 99 \%$; ${ }^{15} \mathrm{~N}, 99 \%$ ) |
| DNLM-4643 | L-Valine ( $\mathrm{D}_{8}, 96 \%$; ${ }^{15} \mathrm{~N}, 96 \%$ ) |
| CDNLM-4281 | L-Valine ( ${ }^{13} \mathrm{C}_{5}, 95-97 \% ; 2,3-\mathrm{D}_{2}, 97 \%$; ${ }^{15} \mathrm{~N}, 96-99 \%$ ) |
| CDNLM-6817 | L-Valine ( ${ }^{13} \mathrm{C}_{5}, 97-99 \% ; \mathrm{D}_{8}, 97-99 \%$; ${ }^{15} \mathrm{~N}, 97-99 \%$ ) |

## > Please visit isotope.com for a complete listing of amino acids and their derivatives.

See pages 28-34 for metabolite mixtures comprising amino acids.

## MPT: microbiologically and pyrogen tested.

Chemical purity (CP) is $98 \%$ or greater, unless otherwise indicated. For research use only. Not for use in diagnostic procedures.

## Bile Acids

| Catalog No. | Description |
| :---: | :---: |
| CLM-2709 |  |
| DLM-6780* | Chenodeoxycholic acid ( $2,2,4,4-\mathrm{D}_{4}, 98 \%$ ) |
| DLM-9327 | Chenodeoxycholic acid ( $2,2,3,4,4-\mathrm{D}_{5}, 98 \%$ ) |
| DLM-9541* | Chenodeoxycholic acid ( $2,2,3,4,4,6,6,7,8-\mathrm{D}_{9}, 98 \%$ ) |
| ULM-9540 | Chenodeoxycholic acid (unlabeled) |
| CLM-2710 | Cholic acid ( $24-{ }^{13} \mathrm{C}, 99 \%$ ) |
| DLM-2611* | Cholic acid ( $2,2,4,4-\mathrm{D}_{4}, 98 \%$ ) |
| DLM-9549 | Cholic acid (2,2,3,4,4-D $\left.{ }_{5}, 98 \%\right)$ |
| ULM-9543 | Cholic acid (unlabeled) |
| CLM-3364 | Deoxycholic acid ( $24-{ }^{13} \mathrm{C}, 98 \%$ ) CP 97\% |
| DLM-2824* | Deoxycholic acid (2,2,4,4-D ${ }_{4}, 98 \%$ ) |
| DLM-9546* | Deoxycholic acid (2,2,4,4,11,11-D. ${ }_{6}, 98 \%$ ) |
| ULM-9545 | Deoxycholic acid (unlabeled) |
| DLM-7804* | Glycochenodeoxycholic acid (2,2,4,4-D ${ }_{4}, 98 \%$ ) CP 97\% |
| DLM-9550* | Glycochenodeoxycholic acid (2,2,3,4,4,6,6,7,8-D ${ }_{9}, 98 \%$ ) CP 97\% |
| ULM-9942 | Glycochenodeoxycholic acid, sodium salt (unlabeled) |
| CLM-191 | Glycocholic acid (glycine-1- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| DLM-2742* | Glycocholic acid ( $2,2,4,4-\mathrm{D}_{4}, 98 \%$ ) may contain $\sim 4 \% \mathrm{H}_{2} \mathrm{O}$ |
| ULM-9551 | Glycocholic acid, hydrate (unlabeled) |
| DLM-9554* | Glycodeoxycholic acid (2,2,4,4-D ${ }_{4}$, 98\%) |
| DLM-9553* | Glycodeoxycholic acid (2,2,4,4,11,11-D $\left.{ }_{6}, 98 \%\right)$ |
| ULM-9552 | Glycodeoxycholic acid, sodium salt (unlabeled) |
| DLM-9556* | Glycolithocholic acid ( $2,2,4,4-\mathrm{D}_{4}, 98 \%$ ) |
| ULM-9555 | Glycolithocholic acid (unlabeled) |
| DLM-9558* | Glycoursodeoxycholic acid (2,2,4,4-D ${ }^{\text {4, }}$, 98\%) CP 97\% |
| ULM-9557 | Glycoursodeoxycholic acid (unlabeled) |
| DLM-9560* | Lithocholic acid (2,2,4,4-D ${ }_{4}, 98 \%$ ) |
| ULM-9559 | Lithocholic acid (unlabeled) |
| DLM-10627 | $\alpha$-Muricholic acid (2,2,3,4,4-D ${ }_{5}$, 99\%) |
| ULM-10621 | $\alpha$-Muricholic acid (unlabeled) |


| Catalog No. | Description |
| :---: | :---: |
| DLM-10626 | $\beta$-Muricholic acid (2,2,3,4,4-D ${ }_{5}$, 99\%) |
| ULM-10620 | $\beta$-Muricholic acid (unlabeled) |
| DLM-10628 | $\gamma$-Muricholic acid (2,2,3,4,4-D $\left.{ }_{5}, 99 \%\right)$ |
| ULM-10622 | $\gamma$-Muricholic acid (unlabeled) |
| DLM-10629 | $\omega$-Muricholic acid ( $2,2,3,4,4-\mathrm{D}_{5}, 99 \%$ ) |
| ULM-10623 | $\omega$-Muricholic acid (unlabeled) |
| DLM-9562* | Taurochenodeoxycholic acid, sodium salt (2,2,4,4-D ${ }_{4}, 98 \%$ ) CP 97\% |
| DLM-9563* | Taurochenodeoxycholic acid, sodium salt ( $2,2,3,4,4,6,6,7,8-D_{9}, 98 \%$ ) |
| ULM-9561 | Taurochenodeoxycholic acid, sodium salt (unlabeled) |
| DLM-9572* | Taurocholic acid, sodium salt ( $2,2,4,4-\mathrm{D}_{4}, 98 \%$ ) |
| ULM-9571 | Taurocholic acid, sodium salt, hydrate (unlabeled) CP 97 |
| DLM-9568* | Taurodeoxycholic acid, sodium salt ( $2,2,4,4-\mathrm{D}_{4}, 98 \%$ ) |
| DLM-9567* | Taurodeoxycholic acid, sodium salt (2,2,4,4,11,11-D. ${ }_{6}$, 98\%) |
| ULM-9943 | Taurodeoxycholic acid, sodium salt, hydrate (unlabeled) |
| DLM-9570* | Taurolithocholic acid, sodium salt ( $2,2,4,4-\mathrm{D}_{4}, 98 \%$ ) |
| CNLM-10251 | Taurocholic acid, sodium salt (taurine- ${ }^{13} \mathrm{C}_{2}, 99 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| ULM-9569 | Taurolithocholic acid, sodium salt (unlabeled) |
| DLM-9882* | Tauroursodeoxycholic acid, sodium salt ( $2,2,4,4-\mathrm{D}_{4}, 98 \%$ ) |
| CNLM-10250 | Tauroursodeoxycholic acid, sodium salt (taurine- ${ }^{13} \mathrm{C}_{2}, 99 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| ULM-9885 | Tauroursodeoxycholic acid, dihydrate (unlabeled) |
| CLM-3412 | Ursodeoxycholic acid ( $24-{ }^{13} \mathrm{C}, 99 \%$ ) |
| DLM-9574* | Ursodeoxycholic acid (2,2,4,4-D ${ }_{4}, 98 \%$ ) CP 95\% |
| ULM-9573 | Ursodeoxycholic acid (unlabeled) |

Please visit isotope.com for a complete listing of bile acids.

## Caffeine and Its Metabolites

| Catalog No. | Description |
| :---: | :---: |
| CNLM-9240 | 5-Acetylamino-6-amino-3-methyluracil (AAMU) <br> (2,4,5,6- ${ }^{13} \mathrm{C}_{4}, 99 \% ; 1,3-{ }^{-15} \mathrm{~N}, 6$-amino- $\left.{ }^{15} \mathrm{~N}, 98 \%\right)$ CP 97\% |
| CLM-728 | Caffeine (3-methyl- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-514 | Caffeine (trimethyl- ${ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| NLM-332 | Caffeine ( $1,3-{ }^{15} \mathrm{~N}_{2}, 99 \%$ ) |
| CNLM-333 | Caffeine ( $2-{ }^{-13} \mathrm{C}, 99 \% ; 1,3-{ }^{-15} \mathrm{~N}_{2}, 98 \%$ ) |
| CNLM-9241 | $\begin{aligned} & \text { 1,3-Dimethyluric acid } \\ & \left(2,4,5,6-{ }^{13} \mathrm{C}_{4}, 99 \% ; 1,3,9-{ }^{-15} \mathrm{~N}_{3}, 98 \%\right) \end{aligned}$ |
| CNLM-9242 | 1,7-Dimethyluric acid <br> ( $2,4,5,6-{ }_{-13}{ }^{13} \mathrm{C}_{4}, 99 \% ; 1,3,9-{ }^{-15} \mathrm{~N}_{3}, 98 \%$ ) |
| DLM-9245 | 1,7-Dimethylxanthine (paraxathine) (dimethyl-D ${ }_{6}, 98 \%$ ) |
| CNLM-9243 | 1,7-Dimethylxanthine (paraxanthine) <br> (2,4,5,6-13C $\left.4,99 \% ; 1,3,9-{ }^{15} \mathrm{~N}_{3}, 98 \%\right)$ |
| CLM-522 | Ethyl acetoacetate ( $1,3-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-523 | Ethyl acetoacetate ( $2,4-{ }^{-13} \mathrm{C}_{2}, 99 \%$ ) |


| Catalog No. | Description |
| :---: | :---: |
| CNLM-9246 | 1-Methyluric acid ( $2,4,5,6-{ }^{-13} \mathrm{C}_{4}, 99 \% ; 1,3,9-{ }^{15} \mathrm{~N}_{3}, 98 \%$ ) |
| CNLM-9248 | 7-Methyluric acid ( $2,4,5,6-{ }^{-13} \mathrm{C}_{4}, 99 \% ; 1,3,9-{ }^{15} \mathrm{~N}_{3}, 98 \%$ ) |
| CDLM-9249 | $\begin{aligned} & \text { 1-Methylxanthine } \\ & \text { (1-methyl, } \left.6 \text { - }{ }^{13} C_{2}, 99 \% ; \text { 1-methyl-D } 3_{3}, 98 \%\right) \text { CP 97\% } \end{aligned}$ |
| CNLM-9252 | 1-Methylxanthine ( $\left.2,4,5,6-{ }^{13} \mathrm{C}_{4}, 99 \% ; 1,3,9-{ }^{15} \mathrm{~N}_{3}, 98 \%\right)$ |
| CNLM-9250 | 3-Methylxanthine ( $\left.2,4,5,6-{ }^{13} \mathrm{C}_{4}, 99 \% ; 1,3,9-{ }^{15} \mathrm{~N}_{3}, 98 \%\right)$ |
| CNLM-9251 | 7-Methylxanthine ( $2,4,5,6-{ }^{13} \mathrm{C}_{4}, 99 \% ; 1,3,9-9{ }^{15} \mathrm{~N}_{3}, 98 \%$ ) |
| DLM-10436 | Theobromine (3,7-dimethylxanthine) (7-methyl- ${ }_{3}, 98 \%$ ) |
| DLM-8565 | Theobromine (3,7-dimethylxanthine) (dimethyl- $\mathrm{D}_{6}, 98 \%$ ) |
| CLM-6154 | Theophylline (dimethyl- ${ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CNLM-444 | Theophylline ( $2-{ }^{13} \mathrm{C}, 99 \% ; 1,3-{ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| CNLM-9253 | $\begin{aligned} & \text { 1,3,7-Trimethyluric acid } \\ & \left(2,4,5,6-{ }^{13} \mathrm{C}_{4}, 99 \% ; 1,3,9-{ }^{-15} \mathrm{~N}_{3}, 98 \%\right) \\ & \hline \end{aligned}$ |

[^1]
## Carbohydrates

| Catalog No. | Description |
| :---: | :---: |
| CLM-7642 | D-Arabinitol (U- $\left.{ }^{13} \mathrm{C}_{5}, 98 \%\right)$ |
| CLM-715 | D-Arabinose (1-13 $\left.{ }^{13}, 99 \%\right)$ |
| CLM-1288 | D-Arabinose ( $2-1{ }^{13} \mathrm{C}, 98 \%$ ) |
| CLM-8477 | D-Arabinose ( $\mathrm{U}^{13} \mathrm{C}_{5}, 99 \%$ ) |
| DLM-1379 | D-Arabinose (2-D, 97\%) |
| CLM-1824 | 2-Deoxy-D-glucose (1-13C, 99\%) |
| CLM-2122 | 2-Deoxy-D-glucose (6-13C, 99\%) |
| CLM-10466 | 2-Deoxy-D-glucose (U-1 ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| DLM-6732 | 2-Deoxy-D-glucose (1-D, 98\%) |
| DLM-6940 | 2-Deoxy-D-glucose ( $\mathrm{D}_{8}, 98 \%$ ) |
| CLM-9601 | 2-Deoxy-D-glucose-6-phosphate, disodium salt (6-13C, 99\%) |
| CLM-7266 | 2-Deoxyribose ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| DLM-9068 | Diglycolic acid ( $\mathrm{L}_{4}, 98 \%$ ) |
| CLM-9207 | Erythritol (U-13 $\left.\mathrm{C}_{4}, 99 \%\right)$ |
| CLM-1118 | D-Erythrose ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) $1.2 \%$ in $\mathrm{H}_{2} \mathrm{O}$ |
| CLM-1387 | D-Erythrose ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) $1.2 \%$ in $\mathrm{H}_{2} \mathrm{O}$ |
| CLM-8944 | D-Erythrose (4-13C, 99\%) $1.2 \%$ in $\mathrm{H}_{2} \mathrm{O}$ |
| CLM-7863 |  |
| CLM-1201 | D-Fructose (1-13 $\mathrm{C}, 99 \%)$ |
| CLM-1527 | D-Fructose ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-7660 | D-Fructose (3-13C, 99\%) |
| CLM-7661 | D-Fructose (4-13 $\mathrm{C}, 99 \%)$ |
| CLM-7662 | D-Fructose ( $5-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-1388 | D-Fructose (6-13 $\mathrm{C}, 99 \%)$ |
| CLM-2462 | D-Fructose ( $1-{ }^{13} \mathrm{C}, 99 \% ; 6-{ }^{13} \mathrm{C}, 97 \%$ ) |
| CLM-528 | D-Fructose (1,2-13 $\left.\mathrm{C}_{2}, 99 \%\right)$ |
| CLM-10546 | D-Fructose ( $4,5-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-8415 | D-Fructose ( $1,2,3-{ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| CLM-1553 | D-Fructose ( $\mathrm{U}-{ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| CLM-1553-MPT | D-Fructose (U- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| DLM-6050 | D-Fructose (1-D, 97\%) |
| DLM-1389 | D-Fructose (6,6-D $\left.{ }_{2}, 98 \%\right)$ |
| ULM-10676 | D-Fructose (unlabeled) |
| CLM-6678 | D-Fructose-1,6-bisphosphate, sodium salt, hydrate (1-13C, 99\%) |
| CLM-8962 | D-Fructose-1,6-bisphosphate, sodium salt, hydrate $\left(\mathrm{U}-{ }^{13} \mathrm{C}_{6}, 98 \%\right)$ |
| CLM-8616 | D-Fructose-6-phosphate-2 $\mathrm{Na}^{+} \cdot \mathrm{XH}_{2} \mathrm{O}\left(\mathrm{U}-{ }^{13} \mathrm{C}_{6}, 99 \%\right)$ may contain up to $\sim 10 \%{ }^{13} \mathrm{C}_{6}$ glucose-6-phosphate |
| CLM-3705 | L-Fucose (1-13C, 99\%) |
| CLM-219 | L-Fucose ( $6-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-9605 | L-Fucose (U- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| CLM-529 | D-Galactitol ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-744 | D-Galactose ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-744-MPT | D-Galactose ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-745 | D-Galactose ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-4217 | D-Galactose (1,2-13 $\left.\mathrm{C}_{2}, 99 \%\right)$ |
| CLM-1570 | D-Galactose (U- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| DLM-1390 | D-Galactose (1-D, 98\%) |
| DLM-1391 | D-Galactose (2-D, 98\%) |

CTM: manufactured following ICH Q7, Section XIX
MPT: microbiologically and pyrogen tested.
Chemical purity (CP) is $98 \%$ or greater, unless otherwise indicated. For research use only. Not for use in diagnostic procedures.

| Catalog No. | Description |
| :---: | :---: |
| CLM-8998 | D-Galactose-1-phosphate, dipotassium salt ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-9873 | D-Galactose-1-phosphate, dipotassium salt ( $1,2-{ }^{13} C_{2}, 99 \%$ ) |
| CLM-9874 | D-Galactose-1-phosphate, dipotassium salt (galactose- ${ }^{13} \mathrm{C}_{6}$, 99\%) |
| CLM-10786 | N-Acetyl-D-galactosamie (galactose- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| CLM-9452 | $\alpha$-D-Glucopyranosyl-1-phosphate, dipotassium salt monohydrate ( ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| CLM-9883 | D-Glucosamine. $\mathrm{HCl}\left({ }^{(13} \mathrm{C}_{6}, 99 \%\right)$ |
| CLM-4819 |  |
| CLM-420 | D-Glucose (1-13C, 98-99\%) |
| CLM-420-MPT | D-Glucose (1-13C, 98-99\%) |
| CLM-746 | D-Glucose ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-746-MPT | D-Glucose ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-1393 | D-Glucose (3-13C, 99\%) |
| CLM-1394 | D-Glucose (4-13C, 99\%) |
| CLM-1395 | D-Glucose ( $5-{ }^{13} \mathrm{C}, 98 \%$ ) |
| CLM-481 | D-Glucose (6-13 $\mathrm{C}, 99 \%)$ |
| CLM-2717 | D-Glucose (1-13 $\left.{ }^{13}, 99 \% ; 6-{ }^{13} \mathrm{C}, 97 \%\right)$ |
| CLM-2717-MPT | D-Glucose ( $\left.1-{ }^{13} \mathrm{C}, 99 \% ; 6-{ }^{13} \mathrm{C}, 97 \%\right)$ |
| CLM-504 | D-Glucose (1,2-13 $\left.\mathrm{C}_{2}, 99 \%\right)$ |
| CLM-8942 | D-Glucose ( $2,3-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-6750 | D-Glucose ( $3,4-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-6750-MPT | D-Glucose ( $3,4-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-8787 | D-Glucose ( $4,5-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-4673 | D-Glucose ( $1,2,3-{ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| CLM-8770 | D-Glucose ( $4,5,6-{ }^{13} \mathrm{C}_{3}, 98 \%$ ) |
| CLM-8946 | D-Glucose ( $2,3,4,5,6-{ }^{13} \mathrm{C}_{5}, 99 \%$ ) |
| CLM-1396 | D-Glucose (U- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| CLM-1396-MPT | D-Glucose (U-1 ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| DLM-1150 | D-Glucose (1-D, 98\%) |
| DLM-1271 | D-Glucose (2-D, 98\%) |
| DLM-3557 | D-Glucose (3-D, 97-98\%) |
| DLM-9294 | D-Glucose (4-D, 98\%) |
| DLM-6754 | D-Glucose (5-D, 98\%) |
| DLM-349 | D-Glucose (6,6-D ${ }_{2}, 99 \%$ ) |
| DLM-349-CTM | D-Glucose (6,6-D ${ }_{2}, 99 \%$ ) |
| DLM-349-MPT | D-Glucose (6,6-D ${ }_{2}, 99 \%$ ) |
| DLM-2062 | D-Glucose (1,2,3,4,5,6,6-D $7,97-98 \%)$ |
| DLM-2062-MPT | D-Glucose (1,2,3,4,5,6,6-D $7,97-98 \%)$ |
| DLM-9047 | D-Glucose (U-D ${ }_{12}, 98 \%$ ) |
| CDLM-6064 | D-Glucose (1-13C, 99\%; 1-D, 98\%) |
| CDLM-999 | D-Glucose (1-13C, 98\%; 2-D, 98\%) |
| CDLM-4895 | D-Glucose ( $\left.1-{ }^{13} \mathrm{C}, 99 \% ; 6-{ }^{13} \mathrm{C}, 97 \% ; 6,6-\mathrm{D}_{2}, 98 \%\right)$ |
| CDLM-3813-50 | D-Glucose ( $\mathrm{U}-{ }^{13} \mathrm{C}_{6}, 98 \% ; 1,2,3,4,5,6,6-\mathrm{D}_{7}, 50 \%$ ) |
| CDLM-3813 | D-Glucose (U- $\left.{ }^{13} \mathrm{C}_{6}, 99 \% ; 1,2,3,4,5,6,6-\mathrm{D}_{7}, 97-98 \%\right)$ |
| CDLM-3813-MPT | D-Glucose (U- $\left.{ }^{13} \mathrm{C}_{6}, 99 \% ; 1,2,3,4,5,6,6-\mathrm{D}_{7}, 97-98 \%\right)$ |
| ULM-10677 | D-Glucose (unlabeled) |
| CLM-1966 | L-Glucose (1-13C, 99\%) |
| CLM-1399 | L-Glucose (2-13C, 99\%) |
| CLM-8813 | D-Glucose-1-phosphate, dicyclohexylammonium salt, monohydrate ( $\mathrm{U}^{1{ }^{13} \mathrm{C}_{6}, ~ 99 \% \text { ) CP 95\% }}$ |
| CLM-8367 | D-Glucose-6-phosphate, disodium salt, hydrate (U- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |

## Carbohydrates (continued)

| Catalog No. | Description |
| :---: | :---: |
| ULM-8947 | D-Glucose-6-phosphate, disodium salt, hydrate (unlabeled) |
| DLM-7826 | myo-Inositol (2-D, 91\%) |
| DLM-2725 | myo-Inositol (1,2,3,4,5,6-D. $\left.{ }_{6}, 98 \%\right)$ |
| CLM-4423 | Lactose $\cdot \mathrm{H}_{2} \mathrm{O}$ (glucose- ${ }^{13} \mathrm{C}_{6}, 98 \%$ ) |
| CLM-4518 | Lactose ureide $2 \mathrm{H}_{2} \mathrm{O}$ (ureide- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| ULM-4519 | Lactose ureide. $2 \mathrm{H}_{2} \mathrm{O}$ (unlabeled) |
| CLM-1127 | D-Lyxose (1-13 ${ }^{13}$, 99\%) |
| CLM-1525 | D-Lyxose (2-13C, 99\%) |
| CLM-1128 | D-Lyxose (5-13C, 99\%) |
| DLM-1187 | D-Lyxose (1-D, 98\%) |
| DLM-1188 | D-Lyxose (2-D, 98\%) |
| CLM-2470 | L-Lyxose ( $1,2-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-2642 | D-Maltose. $\mathrm{H}_{2} \mathrm{O}\left(\mathrm{U}-{ }^{13} \mathrm{C}_{12}, 99 \%\right)$ |
| CLM-10759 | Maltotetraose (U- ${ }^{13} \mathrm{C}_{24}, 99 \%$ ) CP 90\% |
| CLM-1189 | D-Mannitol ( $1-{ }^{13} \mathrm{C}, 98 \%$ ) |
| CLM-4416 | D-Mannitol ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-10764 | D-Mannitol ( $1,2-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-6733 | D-Mannitol (U- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| CLM-9393 | L-Mannitol ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-358 | D-Mannose ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-1523 | D-Mannose ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-9064 | D-Mannose (3-13C, 99\%) |
| CLM-9394 | D-Mannose (4- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-9063 | D-Mannose ( $5-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-1192 | D-Mannose ( $6-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-6567 | D-Mannose (U- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| DLM-1193 | D-Mannose (1-D, 98\%) |
| DLM-1194 | D-Mannose (2-D, 98\%) |
| DLM-1195 | D-Mannose (6,6-D ${ }_{2}, 98 \%$ ) |
| CLM-1218 | L-Mannose (1-13C, 99\%) |
| CLM-1196 | D-Ribitol (1-13C, 99\%) |
| CLM-768 | D-Ribose ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-1069 | D-Ribose ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-1066 | D-Ribose ( $5-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-4602 | D-Ribose (1,2-13 $\left.\mathrm{C}_{2}, 99 \%\right)$ |
| CLM-4830 | D-Ribose ( $2,3,4,5-{ }^{13} \mathrm{C}_{4}, 99 \%$ ) |
| CLM-3652 | D-Ribose (U- ${ }^{13} \mathrm{C}_{5}, 98 \%$ ) |
| DLM-1070 | D-Ribose (1-D, 98\%) |
| DLM-1197 | D-Ribose (2-D, 98\%) |
| DLM-6559 | D-Ribose (3-D, 98\%) |
| DLM-7778 | D-Ribose ( $5,5-\mathrm{D}_{2}, 98 \%$ ) |
| ULM-10678 | D-Ribose (unlabeled) |
| CLM-8780 | Sodium D-gluconate ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-8781 | Sodium D-gluconate (U- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |


| Catalog No. | Description |
| :---: | :---: |
| CLM-1565 | D-Sorbitol ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-8529 | D-Sorbitol ( $\mathrm{U}-{ }^{13} \mathrm{C}_{6}, 98 \%$ ) |
| DLM-3320 | Sorbitol ( $1,1^{\prime}-\mathrm{D}_{2}, 98 \%$ ) |
| CLM-9811 | D-Sucrose (fructose- ${ }^{13} \mathrm{C}_{6}, 98 \%$ ) |
| CLM-10823 | D-Sucrose (glucose-1,2-13C $\mathrm{C}_{2}, 99 \%$ ) |
| CLM-8091 | D-Sucrose (glucose- ${ }^{13} \mathrm{C}_{6}, 98 \%$ ) |
| CLM-7757 | D-Sucrose ( ${ }^{13} \mathrm{C}_{12}, 98 \%$ ) |
| CLM-1203 | D-Talitol ( $1-{ }^{-13} \mathrm{C}, 99 \%$ ) |
| CLM-1204 | D-Talose ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-1139 | D-Threose ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) $1.8 \%$ in $\mathrm{H}_{2} \mathrm{O}$ |
| CLM-1207 | D-Threose ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) $1.8 \%$ in $\mathrm{H}_{2} \mathrm{O}$ |
| CLM-1295 | D-Xylitol ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-1214 | D-Xylitol ( $5-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-7608 | D-Xylitol (U-13 ${ }^{13}$, 99\%) |
| CLM-1140 | D-Xylose (1-13C, 99\%) |
| CLM-1524 | D-Xylose ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-8593 | D-Xylose (3-13C, 99\%) |
| CLM-9083 | D-Xylose (4- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-1219 | D-Xylose ( $5-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-2456 | D-Xylose (1,2-13 $\left.\mathrm{C}_{2}, 99 \%\right)$ |
| CLM-6140 | D-Xylose (U- ${ }^{13} \mathrm{C}_{5}, 99 \%$ ) |
| DLM-1215 | D-Xylose (1-D, 99\%) |
| DLM-1216 | D-Xylose (2-D, 98\%) |
| DLM-7121 | D-Xylose ( $\mathrm{D}_{6}, 98 \%$ ) |

## Please visit isotope.com for a complete listing of carbohydrates.

See pages 30-34 for metabolite mixtures comprising carbohydrates.

Chemical purity (CP) is 98\% or greater, unless otherwise indicated For research use only. Not for use in diagnostic procedures.

## Carnitine/Acylcarnitines

| Catalog No. | Description |
| :---: | :---: |
| DLM-3555 | L-Carnitine (trimethyl-D. ${ }_{9}$, 98\%) |
| ULM-7801 | L-Carnitine (unlabeled) |
| DLM-3820 | L-Carnitine HCl (dimethyl- $\mathrm{D}_{6}$, 98\%) |
| DLM-1871 | L-Carnitine $\cdot \mathrm{HCl}$ (methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| ULM-9173 | L-Carnitine $\cdot \mathrm{HCl}$ (unlabeled) |
| ULM-10431 | DL-Carnitine $\cdot \mathrm{HCl}, \mathrm{O}$-acetyl (unlabeled) |
| ULM-10703 | DL-Carnitine $\cdot \mathrm{HCl}, \mathrm{O}$-butyryl (unlabeled) |
| ULM-10704 | DL-Carnitine•HCl, O-isovaleryl (unlabeled) |
| ULM-10705 | DL-Carnitine•HCl, O-myristoyl (unlabeled) |
| ULM-10433 | DL-Carnitine•HCI, O-palmitoyl (unlabeled) CP 97\% |
| ULM-10702 | DL-Carnitine $\cdot \mathrm{HCl}, \mathrm{O}$-propionyl (unlabeled) |
| ULM-10432 | DL-Carnitine• $\mathrm{HCl}, \mathrm{O}$-octanoyl (unlabeled) |
| DLM-754 | L-Carnitine• $\mathrm{HCl}, \mathrm{O}$-acetyl ( N -methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| DLM-3821 | L-Carnitine•HCl, O-acetyl ( $\mathrm{N}, \mathrm{N}$-dimethyl-D ${ }_{6}, 98 \%$ ) CP 97\% |
| ULM-7802 | L-Carnitine• $\mathrm{HCl}, \mathrm{O}-\mathrm{acetyl}$ (unlabeled) |
| DLM-3861 | L-Carnitine• $\mathrm{HCl}, \mathrm{O}$-butyryl ( N -methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| ULM-7704 | L-Carnitine $\cdot \mathrm{HCl}, \mathrm{O}$-butyryl (unlabeled) |
| DLM-9067 | L-Carnitine• $\mathrm{HCl}, \mathrm{O}$-decanoyl ( N -methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| ULM-7195 | L-Carnitine•HCl, O-decanoyl (unlabeled) |
| DLM-8162 | L-Carnitine•HCl, O-dodecanoyl ( N -methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| DLM-8215 | L-Carnitine-HCl, O-dodecanoyl ( $\mathrm{N}, \mathrm{N}, \mathrm{N}$-trimethyl-D ${ }_{9}, 98 \%$ ) |
| ULM-7199 | L-Carnitine $\cdot \mathrm{HCl}, \mathrm{O}$-dodecanoyl (unlabeled) |
| DLM-9276 | L-Carnitine•HCl, O-hexanoyl ( N -methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| ULM-7198 | L-Carnitine•HCl, O-hexanoyl (unlabeled) |
| DLM-6718 | L-Carnitine•HCl, O-hexacosanoyl ( N -methyl-D ${ }_{3}, 98 \%$ ) CP 95\% |
| ULM-6719 | L-Carnitine• $\mathrm{HCl}, \mathrm{O}$-hexacosanoyl (unlabeled) CP 95\% |
| DLM-3974 | L-Carnitine•HCl, O-isovaleryl ( $\mathrm{N}, \mathrm{N}, \mathrm{N}$-trimethyl-D ${ }_{9}, 98 \%$ ) |
| ULM-4697 | L-Carnitine•HCl, O-isovaleryl (unlabeled) |
| DLM-4425 | L-Carnitine- $\mathrm{HCl}, \mathrm{O}$-myristoyl ( $\mathrm{N}, \mathrm{N}, \mathrm{N}$-trimethyl-D ${ }_{9}, 98 \%$ ) |
| ULM-7737 | L-Carnitine•HCl, O-myristoyl (unlabeled) |


| Catalog No. | Description |
| :---: | :---: |
| DLM-8271 | L-Carnitine•HCl, O-octadecanoyl ( N -methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| ULM-7196 | L-Carnitine•HCl, O-octadecanoyl (unlabeled) CP 97\% |
| DLM-755 | L-Carnitine• $\mathrm{HCl}, \mathrm{O}$-octanoyl ( N -methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| ULM-7770 | L-Carnitine• $\mathrm{HCl}, \mathrm{O}$-octanoyl (unlabeled) |
| DLM-1263 | L-Carnitine•HCl, O-palmitoyl ( N -methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| ULM-7738 | L-Carnitine $\cdot \mathrm{HCl}, \mathrm{O}$-palmitoyl (unlabeled) |
| DLM-3973 | L-Carnitine• $\mathrm{HCl}, \mathrm{O}$-propionyl ( N -methyl-D ${ }_{3}, 98 \%$ ) |
| ULM-7705 | L-Carnitine. $\mathrm{HCl}, \mathrm{O}$-propionyl (unlabeled) |
| DLM-8746 | L-Carnitine•HCl, O-dec-2-enoyl (95\% E) ( $\mathrm{N}, \mathrm{N}, \mathrm{N}$-trimethyl- $\mathrm{D}_{9}, 98 \%$ ) |
| ULM-8744 | L-Carnitine• $\mathrm{HCl}, \mathrm{O}$-tetradec-2-enoyl, 90\% E (unlabeled) |
| ULM-8198 | L-Carnitine•HCl, O-2-decenoyl (unlabeled) |
| ULM-8623 | L-Carnitine (mono) $\mathrm{ClO}_{4}$, benzyl ester (unlabeled) |
| DLM-3975 | L-Carnitine (mono).ClO ${ }_{4}, \mathrm{O}$-glutaryl ( N -methyl- $\mathrm{D}_{3}, ~ 98 \%$ ) CP 97\% |
| ULM-7594 | L-Carnitine (mono) $\mathrm{ClO}_{4}$, O-glutaryl (unlabeled) |
| ULM-8621 | L-Carnitine (mono) $\mathrm{ClO}_{4}, \mathrm{O}-3-\mathrm{DL}-\mathrm{hydroxybutyryl} \mathrm{(unlabeled)}$ |
| DLM-9189 | L-Carnitine (mono).ClO ${ }_{4}, \mathrm{O}-3$-DL-hydroxypalmitoyl ( $N$-methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| ULM-8620 | L-Carnitine (mono).ClO ${ }_{4}$, O-3-DL-hydroxypalmitoyl (unlabeled) CP 97\% |
| DLM-8272 | L-Carnitine $-\mathrm{ClO}_{4}, 3$-hydroxyisovaleryl ( N -methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| ULM-8237 | L-Carnitine $\mathrm{ClO}_{4}$, 3-hydroxyisovaleryl (unlabeled) |
| DLM-11049 | L-Carnitine $\cdot \mathrm{ClO}_{4}, \mathrm{O}$-malonyl ( N -methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| ULM-8743 | L-Carnitine $\cdot \mathrm{ClO}_{4}, \mathrm{O}$-malonyl (unlabeled) CP 97\% |

## Please visit the MS/MS Standards section of isotope.com for a complete listing of carnitine/acylcarnitines.

## See page 28 for carnitine/acylcarnitines mixtures.

## Drugs and Their Metabolites

| Catalog No. | Description |
| :---: | :---: |
| CLM-2436 | Acetaminophen (carbonyl- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-10619 | Acetaminophen (ring- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| DLM-10575 | Aldox ( $\mathrm{D}_{6}, 98 \%$ ) CP 96\% |
| DLM-10574 | Alexidine $2 \mathrm{HCl}\left(\mathrm{D}_{10}, 98 \%\right.$ ) CP 97\% |
| CLM-630 | Aminopyrine ( $\mathrm{N}, \mathrm{N}$-dimethyl- ${ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| DLM-2762 | Amitriptyline. $\mathrm{HCl}\left(\mathrm{N}\right.$-methyl- $\left.\mathrm{D}_{3}, 98 \%\right)$ |
| CLM-6585 | Aspirin (acetyl-1-13 C, 99\%) |
| CLM-3655 | AZT (methyl- ${ }^{13} \mathrm{C}, 99 \%$ ) CP 96\% |
| CLM-10608 | 1,2-Benzisothiazol-3(2H)-one (ring- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| DLM-1566 | Benztropine mesylate ( N -methyl- $\mathrm{D}_{3}, 98 \%$ ) CP 95\% |
| DLM-2790 | Buspirone $\cdot \mathrm{HCl}$ (butyl- $\mathrm{D}_{8}, 98 \%$ ) |
| CLM-1608 | Chloral hydrate (trichloromethyl- ${ }^{13} \mathrm{C}, 97 \%$ ) |
| DLM-10609 | 5-Chloro-2-methyl-4-isothiazolin-3-one ( $N$-methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| CLM-10630 ${ }^{+}$ | Clobazam (ring-[ $\chi$ ] ${ }^{-13} \mathrm{C}_{6}, 98 \%$ ) $\mathrm{CP}>95 \%$ |
| CLM-10631 ${ }^{+}$ | Clonazapam (ring-[ $\chi$ ] ${ }^{-13} \mathrm{C}_{6}, 98 \%$ ) $\mathrm{CP}>95 \%$ |
| DLM-1287* | Clonidine• $\mathrm{HCl}\left(4,4,5,5\right.$-imidazoline- ${ }_{4}, 98 \%$ ) CP 95\% |
| DLM-2816 | Clozapine (4-methylpiperazinyl-D ${ }_{4}, 97 \%$ ) |
| DLM-1819* | DL-Cotinine (methyl- ${ }_{3}, 98 \%$ ) |
| DLM-3020 | Desipramine $\mathrm{HCl}\left(2,4,6,8-\mathrm{D}_{4}, 98 \%\right)$ |
| DLM-7504 | Dexamethasone (4,6 $\left.6,21,21-D_{4}, 96 \%\right)$ may contain D at $\mathrm{C}-2$ |
| CLM-10632 ${ }^{+}$ | Diazepam (ring-[ $\alpha$ ] ${ }^{13} \mathrm{C}_{6}, 98 \%$ ) $\mathrm{CP}>95 \%$ |
| DLM-1886 | Diazepam (phenyl- $\mathrm{D}_{5}$, 98\%) |
| DLM-3025 | 5,5-Diphenylhydantoin (phenyl- $\mathrm{D}_{5}, 98 \%$ ) |
| DLM-324 | 5,5-Diphenylhydantoin (diphenyl- $\mathrm{D}_{10}, 98 \%$ ) |
| CNLM-411 | 5,5-Diphenylhydantoin ( $2-{ }^{13} \mathrm{C}, 99 \%$; $1,3-{ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| DLM-2745 | Enalapril maleate (phenyl- $\mathrm{D}_{5}, 98 \%$ ) |
| DLM-2744 | Enalaprilat $\cdot \mathrm{H}_{2} \mathrm{O}$ (phenyl- $\mathrm{D}_{5}, 98 \%$ ) |
| CLM-123 | Erythromycin ( N -methyl- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-3672 | Erythromycin ( $\mathrm{N}, \mathrm{N}$-dimethyl- ${ }^{13} \mathrm{C}_{2}, \sim 90 \%$ ) 90-95\% Erythromycin A |
| CDLM-10030 ${ }^{+}$ | Erythromycin ( N -methyl- ${ }^{13} \mathrm{C}, 99 \%$; $\mathrm{D}_{3}, 98 \%$ ) CP 97\% |
| CLM-165 | Erythromycin, lactobionate salt ( N -methyl- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-3758 | Erythromycin, lactobionate salt ( $\mathrm{N}, \mathrm{N}$-dimethyl- ${ }^{13} \mathrm{C}_{2}, \sim 90 \%$ ) |
| CLM-10404* | Estradiol undecanoate ( $2,3,4-{ }^{-13} \mathrm{C}_{3}, 98 \%$ ) CP 95\% |
| DLM-9855* | Everolimus (2-hydroxyethyl-D ${ }_{4}, 98 \%$ ) |
| CDLM-10835 | Everolimus [40-O-(2-hydroxyethyl- ${ }^{13} \mathrm{C}_{2}, 99 \%$; $\mathrm{D}_{4}, 98 \%$ )] |
| ULM-9856* | Everolimus (unlabeled) |
| CLM-10405 | Fenoprofen, sodium salt, hydrate (ring- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| DLM-3996 | Glybenclamide (cyclohexylamine- $\mathrm{D}_{11}, 98 \%$ ) |
| DLM-10541 | lopromide ( $N$-methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| CLM-6943* | Ibuprofen (propionic- ${ }^{-13} \mathrm{C}_{3}, 99 \%$ ) |
| ULM-7275* | Ibuprofen (unlabeled) |

## MPT: microbiologically and pyrogen tested

*Compounds available in dry and solution forms.

+ Compounds available in solution only.
Chemical purity (CP) is $98 \%$ or greater, unless otherwise indicated. For research use only. Not for use in diagnostic procedures.

| Catalog No. | Description |
| :---: | :---: |
| DLM-3035 | Imipramine•HCI (2,4,6,8-D $\left.{ }_{4}, 98 \%\right)$ CP 97\% |
| CLM-7118 | Ketoconazole (carbonyl- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CNLM-7633 | Lamotrigine (5,6-1 ${ }^{13} \mathrm{C}_{2}, 99 \% ; 5$-amino- ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-7633-MPT | Lamotrigine (5,6- ${ }^{13} \mathrm{C}_{2}, 99 \% ; 5$-amino- ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CLM-10633 ${ }^{+}$ | Lorazepam (ring-[ $\alpha$ ] ${ }^{13} \mathrm{C}_{6}, 98 \%$ ) $\mathrm{CP}>95 \%$ |
| DLM-7861 | Metformin $\cdot \mathrm{HCl}$ (dimethyl- $\mathrm{D}_{6}, 99 \%$ ) |
| CLM-1280 | Methacetin (methoxy- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-10639+ | Midazolam (ring-[ $\alpha$ ] ${ }^{13} \mathrm{C}_{6}, 98 \%$ ) CP $>95 \%$ |
| DLM-10407 | Moricizine hydrochloride ( $\mathrm{D}_{8}, 98 \%$ ) CP 95\% |
| CNLM-10634 ${ }^{+}$ | Naltrexone (9,15,16- ${ }^{13} \mathrm{C}_{3}, 98 \%$; ${ }^{17-15} \mathrm{~N}, 98 \%$ ) CP $>95 \%$ |
| CLM-7522 | Naproxen, sodium salt (O-methyl- ${ }^{13} \mathrm{C}, 98 \%$ ) |
| CLM-3914* | DL-Nicotine ( $3^{\prime}, 44^{\prime}, 5^{\prime}-{ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| DLM-1818 | DL-Nicotine (methyl- ${ }_{3}, 98 \%$ ) |
| CLM-10635 ${ }^{+}$ | Nordiazepam (ring-[ $\alpha$ ] ${ }^{-13} \mathrm{C}_{6}, 98 \%$ ) CP $>95 \%$ |
| DLM-1885 | Nordiazepam (phenyl-D ${ }_{5}, 98 \%$ ) |
| DLM-9017 | DL-Nornicotine (pyridine-D ${ }_{4}, 98 \%$ ) |
| DLM-3038 | Nortriptyline. HCl (methyl- ${ }_{3}, 98 \%$ ) |
| DLM-10618 | Obeticholic acid ( $2,2,4,4-\mathrm{D}_{4}, 98 \%$ ) |
| CLM-10636 ${ }^{+}$ | Oxazepam (ring-[a] ${ }^{13} \mathrm{C}_{6}, 98 \%$ ) $\mathrm{CP}>95 \%$ |
| DLM-1888 | Oxazepam (phenyl- $\mathrm{D}_{5}, 98 \%$ ) |
| DLM-9254 | Paclitaxel (12-benzoyloxy-ring-D ${ }_{5}$, 98\%) CP 97\% |
| CLM-1296 | Phenacetin (ethoxy-1-13 ${ }^{13}$, 99\%) |
| DLM-433 | Phenobarbital (ethyl- $\mathrm{D}_{5}, 98 \%$ ) |
| CLM-10637 ${ }^{+}$ | Prazepam (ring-[ $\alpha$ ] ${ }^{13} \mathrm{C}_{6}, 98 \%$ ) CP $>95 \%$ |
| CLM-10557 | Probucol (propyl- ${ }^{13} \mathrm{C}_{3}, 99 \%$ ) CP 96\% |
| DLM-9220 | Rapamycin ( $\mathrm{D}_{3}, 98 \%$ ) |
| DLM-2659 | DL-Secobarbital (1-methyl- $\mathrm{D}_{3}$, butyl-2,2-D ${ }_{2}, 98 \%$ ) |
| ULM-10473 ${ }^{+}$ | Stanozolol (unlabeled) |
| CLM-3045* | Sulfamethazine (phenyl- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| ULM-7220 ${ }^{+}$ | Sulfamethazine (unlabeled) |
| CLM-10638 ${ }^{+}$ | Temazepam (ring-[ $\alpha$ ]- ${ }^{13} \mathrm{C}_{6}, 98 \%$ ) CP $>95 \%$ |
| CLM-7119 | Temozolomide (methyl- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-7491 | cis-(+/-)-Tramadol $\cdot \mathrm{HCl}$ (methoxy- ${ }^{-13} \mathrm{C}, 99 \%$ ) |
| CLM-10640 ${ }^{+}$ | Triazolam (ring-[ $\alpha$ ] ${ }^{13} \mathrm{C}_{6}, 98 \%$ ) $\mathrm{CP}>95 \%$ |
| CLM-7988 ${ }^{+}$ | Trimethoprim (pyrimidine-4,5,6- ${ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| ULM-7989 ${ }^{+}$ | Trimethoprim (unlabeled) |
| CDLM-10540 | Yohimbine (methyl ${ }^{13} \mathrm{C}, 99 \%$; methyl- $\mathrm{D}_{3}$ ester, 98\%) |
| CLM-10641 ${ }^{+}$ | $\begin{aligned} & \text { Zolpidem (carbonyl-1, } 2-{ }^{-13} \mathrm{C}_{2}, 98 \% \text {; amide- }{ }^{15} \mathrm{~N}, 98 \% \text { ) } \\ & \mathrm{CP}>95 \% \end{aligned}$ |

## > Please visit isotope.com for a complete listing of drug standards.

都

## Fatty Acids and Lipids

| Catalog No. | Description |
| :---: | :---: |
| DLM-2115 | Adipic acid ( $\mathrm{D}_{10}, 98 \%$ ) |
| CLM-10894 | Adipic acid, disodium salt ( ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| DLM-1234 | Arachidic acid (methyl-D. ${ }_{3}$, 98\%) CP 97\% |
| DLM-1233 | Arachidic acid ( $\left.\mathrm{D}_{39}, 98 \%\right)$ |
| DLM-1661-N | Arachidonic acid ( $5,6,8,9,11,12,14,15-\mathrm{D}_{8}, 98 \%$ ) |
| CLM-9666 | Butyric acid ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-9768 | Butyryl coenzyme A, lithium salt (butyryl- ${ }^{13} C_{4}, 99 \%$ ) CP 95\% |
| CLM-9950 | Decanoic acid ( ${ }^{13} \mathrm{C}_{10}, 98 \%$ ) |
| DLM-2006 | Decanoic acid (methyl-D. ${ }_{3}, 98 \%$ ) |
| DLM-270 | Decanoic acid ( $\mathrm{D}_{19}, 98 \%$ ) |
| ULM-9721 | $N$-Decanoyl-D-sphingosine (ceramide D18:1/10:0) (unlabeled) CP 97\% |
| CLM-8388 | Docosahexaenoic acid ( $\mathrm{U}^{1{ }^{13}} \mathrm{C}_{22}$, 99\%) may contain 5\% DPA* |
| DLM-10012 | Docosahexaenoic acid ( $21,21,22,22,22-\mathrm{D}_{5}, 98 \%$ ) |
| ULM-10013 | Docosahexaenoic acid (unlabeled) |
| DLM-10015 | Docosahexaenoic acid, ethyl ester (21,21,22,22,22-D ${ }_{5}, 98 \%$ ) CP 95\% |
| ULM-10016 | Docosahexaenoic acid, ethyl ester (unlabeled) CP 95\% |
| CLM-8398 | Docosahexaenoic acid, methyl ester (docosahexaenoate-U- ${ }^{13} \mathrm{C}_{22}, 99 \%$ ) may contain 5\% DPA |
| DLM-10014 | Docosahexaenoic acid, methyl ester (21,21,22,22,22-D, $98 \%$ ) CP 97\% |
| CLM-9909 | Docosanoic acid ( $1,2,3,4,5,6-{ }^{13} \mathrm{C}_{6}, 99 \%$ ) CP 95\% |
| DLM-9180 | Docosanoic acid (22,22,22-D ${ }_{3}, 98 \%$ ) |
| DLM-9951 | Docosanoic acid (3,3,5,5-D ${ }_{4}, 98 \%$ ) CP 95\% |
| DLM-4703 | Docosanoic acid ( $\mathrm{D}_{43}, 98 \%$ ) |
| DLM-2274 | Dodecylphosphocholine ( $\mathrm{D}_{38}, 98 \%$ ) |
| ULM-2313 | Dodecylphosphocholine (unlabeled) CP 90\% |
| DLM-9720 | cis-5,8,11,14,17-Eicosapentaenoic acid (19,19,20,20,20-D ${ }_{5}, 98 \%$ ) |
| ULM-10024 | cis-5,8,11,14,17-Eicosapentaenoic acid (unlabeled) |
| CLM-8389 | Eicosapentaenoic acid (U- ${ }^{13} \mathrm{C}_{20}, 98 \%$ ) |
| CLM-8399 | Eicosapentaenoic acid, methyl ester (eicosapentaenoate-U- ${ }^{13} \mathrm{C}_{20}, 90 \%$ ) |
| CLM-8274 | Ethyl hexanoate (hexanoate- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| CLM-4338 | DL-Glycerol ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) aqueous solution |
| CLM-1397 | Glycerol ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-1397-MPT | Glycerol ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-1857 | Glycerol ( $1,3-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-1510 | Glycerol ( ${ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| CLM-1510-MPT | Glycerol ( ${ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| DLM-10430 | Glycerol (2-D, 95-98\%) aqueous solution |
| DLM-1229 | Glycerol (1,1,2,3,3-D. ${ }_{5}, 99 \%$ ) |
| DLM-1229-MPT | Glycerol (1,1,2,3,3-D $\left.{ }_{5}, 99 \%\right)$ |
| DLM-558 | Glycerol ( $\mathrm{D}_{8}, 99 \%$ ) |
| DLM-1326 | Glycerol [(OD) ${ }_{3}$, 98\%] |
| CDLM-7745 | Glycerol ( ${ }^{13} \mathrm{C}_{3}, 99 \%$; $\mathrm{D}_{8}, 98 \%$ ) CP 95\% |
| DLM-1308 | Heptadecanoic acid (methyl-D ${ }_{3}$, 98\%) |
| DLM-6905 | Heptadecanoic acid ( $\mathrm{D}_{33}, 98 \%$ ) |

## *DPA: docosapentaenoic acid

MPT: microbiologically and pyrogen tested
Chemical purity (CP) is 98\% or greater, unless otherwise indicated. For research use only. Not for use in diagnostic procedures.

| Catalog No. | Description |
| :---: | :---: |
| DLM-1820 | Heptanoic acid (2,2,3,3-D ${ }_{4}, 98 \%$ ) |
| DLM-2731 | Heptanoic acid ( $\mathrm{D}_{13}, 98 \%$ ) |
| CLM-9790 | Hexacosanoic acid (1,2,3,4,5,6-1 ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| DLM-9953 | Hexacosanoic acid (3,3,5,5-D ${ }_{4}, 98 \%$ ) CP 95\% |
| DLM-8510 | Hexacosanoic acid (12,12,13,13-D $4,98 \%$ ) |
| DLM-2922 | DL-3-Hydroxymyristic acid (2,2,3,4,4-D $\left.{ }_{5}, 96 \%\right)$ |
| CLM-2095 | Isovaleric acid ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-2095-MPT | Isovaleric acid (1-13C, 99\%) |
| DLM-2938 | Isovaleric acid ( $\mathrm{D}_{9}, 98 \%$ ) |
| CLM-1586 | Lauric acid (1-13C, 99\%) |
| DLM-3062 | Lauric acid (methyl-D ${ }_{3}, 99 \%$ ) |
| DLM-563 | Lauric acid ( $\mathrm{D}_{23}, 98 \%$ ) |
| CLM-9688 | Linoleic acid (18:2) (1-13C, 99\%) |
| CLM-6855 | Linoleic acid (18:2) (U- $\left.{ }^{13} \mathrm{C}_{18}, 98 \%\right)$ <10\% cis, trans isomer, CP 94\% |
| CLM-2119 | Linoleic acid (18:2), ethyl ester ( $1-1{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-3960 | Linoleic acid (18:2), ethyl ester (linoleate-U- ${ }^{13} \mathrm{C}_{18}, 98 \%$ ) CP 95\% |
| CLM-3960-MPT | Linoleic acid (18:2), ethyl ester (linoleate-U- ${ }^{13} \mathrm{C}_{18}, 98 \%$ ) CP 95\% |
| DLM-227 | Linoleic acid (18:2), ethyl ester (17,17,18,18,18-D $\mathrm{D}_{5}, 98 \%$ ) |
| DLM-766 | Linoleic acid (18:2), ethyl ester ( $\mathrm{D}_{31}, 98 \%$ ) CP 95\% |
| CLM-8395 | Linoleic acid (18:2), methyl ester (linoleate-U- ${ }^{13} \mathrm{C}_{18}, 98 \%$ ) CP 95\% |
| DLM-9663 | Linoleic acid (18:2), methyl ester ( $\mathrm{D}_{31}, 98 \%$ ) CP 95\% |
| CLM-6229 | Linoleic acid (18:2), potassium salt ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-8835 | Linoleic acid (18:2), potassium salt ( $\mathrm{U}-{ }^{13} \mathrm{C}_{18}, 98 \%$ ) (may have up to 5\% isomers) CP 97\% |
| CLM-8835-MPT | Linoleic acid (18:2), potassium salt (U- ${ }^{13} \mathrm{C}_{18}, 98 \%$ ) (may have up to 5\% isomers) CP 97\% |
| CLM-8386 | Linolenic acid (18:3) ( $\mathrm{U}-{ }^{13} \mathrm{C}_{18}, 98 \%$ ) CP 95\% |
| DLM-9348 | Linolenic acid (18:3) (17,17,18,18,18-D ${ }_{5}, 98 \%$ ) CP 90\% |
| DLM-2351 | Linolenic acid (18:3), ethyl ester (17,17,18, 18, 18-D ${ }_{5}, 98 \%$ ) CP 95\% |
| CLM-8396 | Linolenic acid (18:3), methyl ester (linolenate-U- ${ }^{18} \mathrm{C}_{18}, 98 \%$ ) CP 95\% |
| DLM-10520 | LYSO-PC 20:0 (eicosanoyl-12,12,13,13-D ${ }_{4}, 98 \%$ ) |
| ULM-10521 | LYSO-PC-20:0 (unlabeled) |
| CLM-10499 | LYSO-PC 22:0 (docosanoyl-1,2,3,4,5,6-13 $\left.\mathrm{C}_{6}, 99 \%\right)$ |
| DLM-10500 | LYSO-PC 22:0 (docosanoyl-12,12,13,13-D ${ }_{4}, 98 \%$ ) |
| ULM-10498 | LYSO-PC-22:0 (unlabeled) |
| CLM-10496 | LYSO-PC 24:0 (tetracosanoyl-1,2,3,4,5,6-13C $\mathrm{C}_{6}, 99 \%$ ) |
| DLM-10497 | LYSO-PC 24:0 (tetracosanoyl-12,12,13,13-D ${ }_{4}, 98 \%$ ) |
| ULM-10495 | LYSO-PC-24:0 (unlabeled) |
| CLM-9792 | LYSO-PC 26:0 (hexacosanoyl-1,2,3,4,5,6-13C ${ }_{6}, 99 \%$ ) |
| ULM-9791 | LYSO-PC 26:0 (unlabeled) |
| DLM-8375 | Mixed triglycerides (U-D, 97\%) |
| CLM-1844 | Myristic acid (1-13C, 99\%) |
| CLM-3665 | Myristic acid ( $1,2,3-{ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| DLM-1039 | Myristic acid (methyl-D ${ }_{3}, 98 \%$ ) |
| DLM-7487 | Myristic acid ( $13,13,14,14,14-\mathrm{D}_{5}, 98 \%$ ) |
| DLM-208 | Myristic acid ( $\mathrm{D}_{27}, 98 \%$ ) |
| CLM-6228 | Myristic acid, potassium salt (1-13 $\mathrm{C}, 99 \%)$ |
| CLM-8695 | Myristic acid, sodium salt (1,2,3-13 $\left.\mathrm{C}_{3}, 99 \%\right)$ |

Fatty Acids and Lipids (continued)

| Catalog No. | Description |
| :---: | :---: |
| CLM-8724 | Nonanoic acid (U- ${ }^{13} \mathrm{C}_{9}, 98 \%$ ) |
| DLM-7490 | Nonanoic acid (9,9,9-D ${ }_{3}, 98 \%$ ) |
| DLM-9501 | Nonanoic acid ( $\mathrm{D}_{17}, 98 \%$ ) |
| CLM-293 | Octanoic acid (1-13 $\mathrm{C}, 99 \%)$ |
| CLM-293-MPT | Octanoic acid ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-3827 | Octanoic acid (1,2-13 $\left.\mathrm{C}_{2}, 99 \%\right)$ |
| CLM-2721 | Octanoic acid ( $1,2,3,4-{ }^{13} \mathrm{C}_{4}, 99 \%$ ) |
| CLM-3981 | Octanoic acid ( ${ }^{13} \mathrm{C}_{8}, 99 \%$ ) |
| DLM-619 | Octanoic acid-D ${ }_{15}$ ( $\mathrm{D}, 98 \%$ ) |
| CLM-3707 | 2-Octanoyl-1,3-distearin (octanoic-1-1 ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-3707-MPT | 2-Octanoyl-1,3-distearin (octanoic-1-1 ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-4258 | 2-Octanoyl-1,3-distearin (octanoyl-1,2-13 $\mathrm{C}_{2}, 99 \%$ ) |
| ULM-9722 | N-Octanoyl-D-sphingosine (ceramide D18:1/8:0) (unlabeled) |
| DLM-6726 | $N$-Octyl $\beta$-glucoside ( $\mathrm{D}_{24}, 98 \%$ ) |
| CLM-2492 | Oleic acid (methyl- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-149 | Oleic acid (1-13 ${ }^{13}, 99 \%$ ) |
| CLM-149-MPT | Oleic acid (1-13 ${ }^{13}$, 99\%) |
| CLM-460 | Oleic acid (U-13 $\mathrm{C}_{18}, 98 \%$ ) |
| CLM-460-MPT | Oleic acid (U-13 $\mathrm{C}_{18}, 98 \%$ ) |
| DLM-689 | Oleic acid (9,10-D ${ }_{2}, 97 \%$ ) |
| DLM-689-MPT | Oleic acid (9,10-D ${ }_{2}, 97 \%$ ) |
| DLM-1891 | Oleic acid ( $\mathrm{D}_{33}, 98 \%$ ) |
| ULM-10649 | Oleic acid (unlabeled) |
| DLM-8747 | Oleic acid, ethyl ester ( $\mathrm{D}_{33}, 98 \%$ ) CP 95\% |
| CLM-4337 | Oleic acid, methyl ester (oleate-U- ${ }^{13} \mathrm{C}_{18}$, 98\%) |
| CLM-4477 | Oleic acid, potassium salt ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-8856 | Oleic acid, potassium salt (U- ${ }^{13} \mathrm{C}_{18}, 98 \%$ ) CP 95\% |
| DLM-8837 | $\begin{aligned} & \text { Oleic acid, potassium salt } \\ & \left(15,15,16,16,17,17,18,18,18-\mathrm{D}_{9}, 98 \%\right) \end{aligned}$ |
| CLM-6230 | Oleic acid, sodium salt ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-8763 | Oleic acid, sodium salt (U- ${ }^{13} \mathrm{C}_{18}, 98 \%$ ) |
| CLM-9583 | N-Oleoyl-D-sphingosine (ceramide d18:1/18:1 (9z)) (oleoyl-U- ${ }^{13} \mathrm{C}_{18}$, $99 \%$ ) CP 95\% |
| ULM-9581 | N-Oleoyl-D-sphingosine (ceramide d18:1/18:1 (9z)) (unlabeled) CP 95\% |
| CLM-150 | Palmitic acid (1-13 $\mathrm{C}, 99 \%$ ) |
| CLM-150-MPT | Palmitic acid ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-2120 | Palmitic acid ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-214 | Palmitic acid (1,2-13 $\left.\mathrm{C}_{2}, 99 \%\right)$ |
| CLM-7896 | Palmitic acid ( $1,2,3,4-{ }^{13} \mathrm{C}_{4}, 99 \%$ ) |
| CLM-7896-MPT | Palmitic acid ( $1,2,3,4-{ }^{13} \mathrm{C}_{4}, 99 \%$ ) |
| CLM-409 |  |
| CLM-409-MPT | Palmitic acid ( $\mathrm{U}^{1{ }^{13} \mathrm{C}_{16}, 98 \% \text { ) }}$ |
| DLM-8673 | Palmitic acid (12-D, 98\%) |
| DLM-1153 | Palmitic acid (2,2-D $2,98 \%$ ) |
| DLM-2890 | Palmitic acid (9,9-D $2,98 \%$ ) |
| DLM-2891 | Palmitic acid ( $13,13-\mathrm{D}_{2}, 98 \%$ ) |
| DLM-611 | Palmitic acid (methyl-D ${ }_{3}, 98 \%$ ) |
| DLM-2893 | Palmitic acid (7,7,8,8-D ${ }_{4}, 98 \%$ ) |
| DLM-2893-MPT | Palmitic acid (7,7,8,8-D $\left.{ }_{4}, 98 \%\right)$ |


| Catalog No. | Description |
| :---: | :---: |
| DLM-2894 | Palmitic acid ( $11,11,12,12-\mathrm{D}_{4}, 98 \%$ ) |
| DLM-9424 | Palmitic acid ( $13,13,14,14,15,15,16,16,16-\mathrm{D}_{9}, 98 \%$ ) |
| DLM-2895 | Palmitic acid (9,9,...16,16,16-D ${ }_{17}, 98 \%$ ) CP 97\% |
| DLM-215 | Palmitic acid ( $\mathrm{D}_{31}, 98 \%$ ) |
| DLM-215-MPT | Palmitic acid ( $\mathrm{D}_{31}, 98 \%$ ) |
| ULM-10680 | Palmitic acid (unlabeled) |
| CLM-3957 | Palmitic acid, ethyl ester (palmitate-U- ${ }^{13} \mathrm{C}_{16}, 98 \%$ ) CP 95\% |
| DLM-8793 | Palmitic acid, ethyl ester ( $\mathrm{D}_{31}, 98 \%$ ) |
| CLM-8390 | Palmitic acid, methyl ester (palmitate-U- ${ }^{13} \mathrm{C}_{16}, 98 \%$ ) |
| CLM-2241 | Palmitoleic acid (U- ${ }^{13} \mathrm{C}_{16}, 98 \%$ ) CP 97\% |
| CLM-3958 | Palmitoleic acid, ethyl ester (palmitoleate-U- ${ }^{13} \mathrm{C}_{16}, 98 \%$ ) CP 97\% |
| CLM-8391 | Palmitoleic acid, methyl ester (palmitoleate-U- ${ }^{13} \mathrm{C}_{16}, 98 \%$ ) CP 97\% |
| CLM-9582 | $N$-Palmitoyl-D-sphingosine (ceramide d18:1/16:0) (palmitoyl-U- ${ }^{13} \mathrm{C}_{16}, 99 \%$ ) CP 95\% |
| ULM-9580 | $N$-Palmitoyl-D-sphingosine (ceramide d18:1/16:0) (unlabeled) CP 95\% |
| DLM-1307 | Pentadecanoic acid (methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| DLM-572 | Pentanoic acid ( $\mathrm{D}_{9}, 98 \%$ ) |
| DLM-4341 | DL- $\alpha$-Phosphatidylcholine, dihexanoyl (DHPC) ( $\mathrm{D}_{40}, 98 \%$ ) CP 95\% |
| DLM-605 | L- $\alpha$-Phosphatidylcholine, dimyristoyl (DMPC) (dimyristoyl- $\mathrm{D}_{54}$, 97\%) CP 95\% |
| CLM-9668 | DL- $\alpha$-PhosphatidyIcholine, dipalmitoyl (DPPC) (U- ${ }^{13} \mathrm{C}_{40}, 98 \%$ ) CP 95\% |
| DLM-8256 | DL- $\alpha$-Phosphatidylcholine, dipalmitoyl (DPPC) ( $\left.\mathrm{D}_{80}, 98 \%\right)$ CP 95\% |
| DLM-606 | L- $\alpha$-Phosphatidylcholine, dipalmitoyl (DPPC) (dipalmitoyl-D ${ }_{62}$, 98\%) CP 95\% |
| DLM-7557 | L-Phosphatidylglycerol, dipalmitoyl (DPPG) (dipalmitoyl-D ${ }_{62}, 98 \%$ ) |
| DLM-6998 | Phytanic acid (3-methyl-D ${ }^{\text {, }}$, 98\%) CP 95\% |
| CLM-1889 | Potassium palmitate ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-6865 | Potassium palmitate ( $1,2,3,4-{ }^{13} \mathrm{C}_{4}, 99 \%$ ) |
| CLM-3943 | Potassium palmitate ( $\mathrm{U}-{ }^{13} \mathrm{C}_{16}, 98 \%$ ) |
| CLM-3943-MPT | Potassium palmitate ( $\mathrm{U}-{ }^{13} \mathrm{C}_{16}, 98 \%$ ) |
| DLM-3773 | Potassium palmitate (2,2-D $\left.{ }_{2}, 97 \%\right)$ |
| DLM-3773-MPT | Potassium palmitate (2,2-D ${ }_{2}, 97 \%$ ) |
| DLM-6199 | Potassium palmitate (methyl-D ${ }_{3}, 98 \%$ ) |
| DLM-6033 | Potassium palmitate ( $7,7,8,8-\mathrm{D}_{4}, 98 \%$ ) |
| DLM-6033-MPT | Potassium palmitate (7,7,8,8-D $4,98 \%$ ) |
| DLM-8302 | Pristanic acid (2-methyl-D ${ }_{3}, 98 \%$ ) CP 95\% |
| DLM-197 | Sodium dodecyl sulfate ( $\mathrm{L}_{25}, 98 \%$ ) |
| CLM-1948 | Sodium octanoate (1-13C, 99\%) |
| CLM-1948-MPT | Sodium octanoate ( $1-1{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-3876 | Sodium octanoate ( $1,2,3,4-{ }^{13} \mathrm{C}_{4}, 99 \%$ ) |
| CLM-3980 | Sodium octanoate ( $2,4,6,8-{ }^{13} \mathrm{C}_{4}, 99 \%$ ) |
| CLM-9617 | Sodium octanoate ( ${ }^{13} \mathrm{C}_{8}, 99 \%$ ) |
| CLM-174 | Sodium palmitate ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-174-MPT | Sodium palmitate ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-6059 |  |

MPT: microbiologically and pyrogen tested.
Chemical purity (CP) is 98\% or greater, unless otherwise indicated
For research use only. Not for use in diagnostic procedures.

| Catalog No. | Description |
| :---: | :---: |
| ULM-9579 | Sphingosine (unlabeled) CP 95\% |
| CLM-490 | Stearic acid (methyl- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-676 | Stearic acid ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-6990 | Stearic acid (U- ${ }^{13} \mathrm{C}_{18}, 98 \%$ ) CP 97\% |
| DLM-1154 | Stearic acid (methyl-D ${ }_{3}, 98 \%$ ) |
| DLM-2712 | Stearic acid (17,17,18,18,18-D ${ }_{5}, 98 \%$ ) |
| DLM-379 | Stearic acid ( $\mathrm{S}_{35}, 98 \%$ ) |
| CLM-8731 | Stearic acid, ethyl ester (stearate-U- ${ }^{13} \mathrm{C}_{18}, 98 \%$ ) |
| CLM-8394 | Stearic acid, methyl ester (stearate-U- ${ }^{13} \mathrm{C}_{18}, 98 \%$ ) CP $95 \%$ |
| CLM-6227 | Stearic acid, potassium salt (1-13 ${ }^{1 /}$, 99\%) |
| CLM-10365 | Stearic acid, sodium salt (U-13 $\left.\mathrm{C}_{18}, 98 \%\right) \mathrm{CP} 97 \%$ |
| CLM-9932 | Tetracosanoic acid ( $1,2,3,4,5,6-{ }^{13} \mathrm{C}_{6}, 99 \%$ ) CP 96\% |
| DLM-9952 | Tetracosanoic acid (3,3,5,5-D $\left.{ }_{4}, 98 \%\right)$ CP 95\% |
| DLM-9179 | Tetracosanoic acid (9,9,10,10-D ${ }_{4}, 98 \%$ ) |
| DLM-7302 | Tetracosanoic acid ( $\mathrm{D}_{47}, 98 \%$ ) |
| CNLM-8110 | Tiglylglycine (glycine- ${ }^{13} \mathrm{C}_{2}, 98 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| DLM-1392 | Tridecanoic acid ( $\mathrm{D}_{25}, 98 \%$ ) |
| CLM-162 | Trioctanoin (1,1,1-13 $\left.\mathrm{C}_{3}, 99 \%\right)$ |
| CLM-162-MPT | Trioctanoin (1,1,1-13 $\left.\mathrm{C}_{3}, 99 \%\right)$ |
| CLM-163 | Triolein (1,1,1-13 $\left.\mathrm{C}_{3}, 99 \%\right)$ |


| Catalog No. | Description |
| :---: | :---: |
| CLM-163-MPT | Triolein (1,1,1-13 $\left.\mathrm{C}_{3}, 99 \%\right)$ |
| CLM-164 | Tripalmitin (1,1,1-13 $\left.\mathrm{C}_{3}, 99 \%\right)$ |
| CLM-164-MPT | Tripalmitin (1,1,1-13 $\left.\mathrm{C}_{3}, 99 \%\right)$ |
| CLM-350 | Tripalmitin ( $2,2,2-{ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| CLM-8445 | Tripalmitin (glyceryl- ${ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| CLM-9468 | Tripalmitin ( $1,1,1,2,2,2,3,3,3,4,4,4-{ }^{13} \mathrm{C}_{12}, 99 \%$ ) |
| DLM-9986 | Tripalmitin (glyceryl-D ${ }_{5}, 98-99 \%$ ) |
| DLM-9462 | Tripalmitin (trispalmitoyl-D ${ }_{93}, 98 \%$ ) |
| DLM-9044 | Tripalmitin ( $\mathrm{D}_{98}, 98 \%$ ) |
| DLM-7875 | Tristearin (tristearoyl-D ${ }_{105}, 98 \%$ ) |
| CLM-3399 | Valproic acid ( $1,2,3,3{ }^{\prime}-1{ }^{13} \mathrm{C}_{4}, 99 \%$ ) |
| DLM-4291 | Valproic acid ( $4,4,4^{\prime}, 4^{\prime}-\mathrm{D}_{4}, 98 \%$ ) |
| DLM-7876 | Valproic acid (propyl-1,1-D ${ }_{2}$, pentanoic-3,3-D ${ }_{2}, 98 \%$ ) |
| DLM-8875 | Valproic acid ( $\mathrm{D}_{15}, 98 \%$ ) |

## Please visit isotope.com for a complete listing of fatty acids and lipids.

See pages 29-33 for metabolite mixtures comprising fatty acids and lipids.

## Flavonoids

| Catalog No. | Description |
| :---: | :---: |
| CLM-9256 | (+/-)-Catechin ( $2,3,4-{ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| CLM-10554 | (+/-)-Catechin gallate ( $2,3,4-{ }^{13} \mathrm{C}_{3}, 99 \%$ ) CP 97\% |
| CLM-9257 | (+/-)-Epicatechin ( $2,3,4-{ }^{-13} \mathrm{C}_{3}, 99 \%$ ) CP 97\% |
| ULM-10550 | (+/-)-Epicatechin (unlabeled) CP 97\% |
| CLM-10553 | (+/-)-Epicatechin gallate (2,3,4-1 ${ }^{13} \mathrm{C}_{3}, 99 \%$ ) CP 97\% |
| CLM-10555 | (+/-)-Epigallocatechin ( $2,3,4-{ }^{13} \mathrm{C}_{3}, 99 \%$ ) CP 97\% |
| CLM-10551 | (+/-)-Epigallocatechin gallate ( $2,3,4-{ }^{13} \mathrm{C}_{3}, 99 \%$ ) CP 97\% |


| Catalog No. | Description |
| :---: | :---: |
| CLM-9756 | Galangin (2,3,4-13 $\mathrm{C}_{3}, 99 \%$ ) CP 95\% |
| ULM-10281 | Galangin (unlabeled) |
| CLM-10556 | (+/-)-Gallocatechin (2,3,4-1 ${ }^{13} \mathrm{C}_{3}, 99 \%$ ) CP 97\% |
| CLM-10552 | (+/-)-Gallocatechin gallate ( $2,3,4-{ }^{13} \mathrm{C}_{3}, 99 \%$ ) CP 97\% |
| CLM-9755 | Kaempferol (2,3,4-13 $\mathrm{C}_{3}, 99 \%$ ) CP 95\% |
| CLM-9754 | Myricetin ( $2,3,4-4{ }^{13} \mathrm{C}_{3}, 99 \%$ ) CP 95\% |
| CLM-9753 | Quercetin (2,3,4-13 $\mathrm{C}_{3}$, 99\%) CP 95\% |
| CLM-9259 | Resveratrol (4-hydroxyphenyl- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |

## MRI/MRS Tracers

| Catalog No. | Description |
| :---: | :---: |
| CLM-317 | Acetic acid ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-318 | Acetic acid ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-113 | Acetic acid (1,2-13 $\mathrm{C}_{2}, 99 \%$ ) |
| CLM-548 | Choline chloride (1,2-13 $\mathrm{C}_{2}, 99 \%$ ) |
| CLM $344{ }^{+}$ | Ethanol ( $1-{ }^{13} \mathrm{C} 99 \%$ ) <6\% $\mathrm{H}_{2} \mathrm{O}$ |
| CLM-130 ${ }^{+}$ | Ethanol ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) <6\% $\mathrm{H}_{2} \mathrm{O}$ |
| CLM-551 ${ }^{+}$ | Ethanol (1,2- $\left.{ }^{13} \mathrm{C}_{2}, 99 \%\right)<6 \% \mathrm{H}_{2} \mathrm{O}$ |
| CLM-2291 | Ethanolamine ( ${ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-3911 | Ethanolamine $\cdot \mathrm{HCl}\left(1-{ }^{13} \mathrm{C}, 99 \%\right)$ |
| CLM-274 | Ethanolamine. $\mathrm{HCl}\left(1,2-{ }^{13} \mathrm{C}_{2}, 99 \%\right)$ |
| CLM-522 | Ethyl acetoacetate ( $1,3-{ }^{-13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-523 | Ethyl acetoacetate ( $2,4-{ }^{-13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-1529 | Fumaric acid ( ${ }^{13} \mathrm{C}_{4}, 99 \%$ ) |
| CLM-4338 ${ }^{+}$ | DL-Glycerol ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-1397 | Glycerol ( $2-{ }^{-13} \mathrm{C}, 99 \%$ ) |
| CLM-1857 | Glycerol (1,3-13 ${ }_{2}, 99 \%$ ) |
| DLM-10430 ${ }^{+}$ | Glycerol (2-D, 95-98\%) |
| DLM-1229 | Glycerol (1,1,2,3,3-D $\left.{ }_{5}, 99 \%\right)$ |
| CLM-9675 | 1,2-Glycerol carbonate (carbonyl- ${ }^{13} \mathrm{C}, 99 \%$ ) CP $>97 \%$ |
| CLM-8065 | L-Malic acid ( ${ }^{13} \mathrm{C}_{4}, 99 \%$ ) |
| CLM-1189 | D-Mannitol ( $1-{ }^{13} \mathrm{C}, 98 \%$ ) |
| CLM-646 | Propionic acid ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-647 | Propionic acid ( ${ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| CLM-8077 | Pyruvic acid ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-8849 | Pyruvic acid ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) CP 95\% |
| CLM-9505 | Pyruvic acid ( $1,2-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |


| Catalog No. | Description |
| :---: | :---: |
| CLM-156 | Sodium acetate ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-381 | Sodium acetate ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-440 | Sodium acetate (1,2-13 $\left.\mathrm{C}_{2}, 99 \%\right)$ |
| CLM-1256 | Sodium butyrate ( $1-{ }^{-13} \mathrm{C}, 99 \%$ ) |
| CLM-10426 | Sodium butyrate ( ${ }^{13} \mathrm{C}_{4}, 99 \%$ ) |
| CLM-3706 | Sodium D-3-hydroxybutyrate ( $2,4-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-1577 ${ }^{+}$ | Sodium L-lactate ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) $20 \%$ w/w in $\mathrm{H}_{2} \mathrm{O}$ |
| CLM-1578 ${ }^{+}$ | Sodium L-lactate ( $3-{ }^{-13} \mathrm{C}, 98 \%$ ) $20 \% \mathrm{w} / \mathrm{w}$ in $\mathrm{H}_{2} \mathrm{O}$ |
| CLM-1579 ${ }^{+}$ | Sodium L-lactate ( ${ }^{13} \mathrm{C}_{3}, 98 \%$ ) 20\% w/w in $\mathrm{H}_{2} \mathrm{O}$ |
| DLM-9071 ${ }^{+}$ | Sodium L-lactate (3,3,3-D $\mathrm{D}_{3}, 98 \%$ ) 20\% w/w in $\mathrm{H}_{2} \mathrm{O}$ |
| CLM-771 | Sodium propionate (1-13 $\mathrm{C}, 99 \%)$ |
| CLM-1506 | Sodium propionate ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-4573 | Sodium propionate ( $3-{ }^{-13} \mathrm{C}, 99 \%$ ) |
| CLM-3042 | Sodium propionate ( $2,3-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-1865 | Sodium propionate ( ${ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| CLM-1082 | Sodium pyruvate ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-1580 | Sodium pyruvate ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-1575 | Sodium pyruvate (3-13C, 99\%) |
| CLM-1565 | D-Sorbitol ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-8529 | D-Sorbitol ( ${ }^{13} \mathrm{C}_{6}, 98 \%$ ) |
| CLM-9371 | Succinic acid, disodium salt (2,3-13 $\left.\mathrm{C}_{2}, 99 \%\right)$ |

## Please visit isotope.com for a complete listing of MRI/MRS products.

[^2] For research use only. Not for use in diagnostic procedures.

## MS/MS Standards

| Catalog No. | Description |
| :---: | :---: |
| DLM-10520 | LYSO-PC 20:0 (eicosanoyl-12,12,13,13-D ${ }_{4}$, 98\%) |
| ULM-10521 | LYSO-PC 20:0 (unlabeled) |
| CLM-10499 | LYSO-PC 22:0 (docosanoyl-1,2,3,4,5,6-13 ${ }_{6}$, 99\%) |
| DLM-10500 | LYSO-PC 22:0 (docosanoyl-12,12,13,13-D ${ }_{4}, 98 \%$ ) |
| ULM-10498 | LYSO-PC 22:0 (unlabeled) |
| CLM-10496 | LYSO-PC 24:0 (tetracosanoyl-1, 2, 3, 4, 5,6-1 ${ }^{13}{ }_{6}, 99 \%$ ) |
| DLM-10497 | LYSO-PC 24:0 (tetracosanoyl-12,12,13,13-D ${ }_{4}, 98 \%$ ) |
| ULM-10495 | LYSO-PC 24:0 (unlabeled) |
| CLM-9792 | LYSO-PC 26:0 (hexacosanoyl-1, 2, 3, 4, 5,6-1 ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| DLM-10501 | LYSO-PC 26:0 (hexacosanoyl-12,12,13,13-D ${ }_{4}, 98 \%$ ) |
| ULM-9791 | LYSO-PC 26:0 (unlabeled) |
| NSK-NI | Acid sphingomyelinase substrate and internal standard |
| NSK-KR | Galactocerebrosidase substrate and internal standard |
| NSK-FA | $\alpha$-Galactosidase substrate and internal standard |
| NSK-GA | Glucocerebrosidase substrate and internal standard |
| NSK-MP | $\alpha$-L-Iduronidase substrate and internal standard |
| NSK-PO | Lysosomal $\alpha$-Glucosidase substrate and internal standard |
| CLM-3678 | Adenosine (ribose- ${ }^{13} \mathrm{C}_{5}, 98 \%$ ) CP 97\% |
| CNLM-3946 | $\beta$-Alanine ( ${ }^{13} \mathrm{C}_{3}, 98 \%$; ${ }^{5} \mathrm{~N}, 96-99 \%$ ) |
| CLM-9308 | DL-Alanine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-9007-CA | L-Argininosuccinic acid, barium salt- $2 \mathrm{H}_{2} \mathrm{O}$ (arginine- ${ }^{13} \mathrm{C}_{6}, 99 \%$; ${ }^{15} \mathrm{~N}_{4}, 99 \%$ ) CP 90\% |
| ULM-9008-CA | L-Argininosuccinic acid, barium salt•3 $3 \mathrm{H}_{2} \mathrm{O}$ (unlabeled) CP 90\% |
| CLM-7933 | Creatine (guanidino- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| DLM-1302 | Creatine (methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| DLM-3653 | Creatinine ( N -methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| CLM-4579 | 2'-Deoxyadenosine $\cdot \mathrm{H}_{2} \mathrm{O}$ (ribose- ${ }^{13} \mathrm{C}_{5}, 99 \%$ ) |
| DLM-6013 | Ethylmalonic acid (methyl-D ${ }_{3}, 98 \%$ ) |


| Catalog No. | Description |
| :---: | :---: |
| CLM-1570 | D-Galactose (U- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| DLM-9998 | Guanidinoacetic acid (2,2-D ${ }_{2}, 97 \%$ ) |
| DLM-3619 | DL-Homocystine ( $\left.3,3,3^{\prime}, 3^{\prime} 4,4,44^{\prime}, 4^{\prime}-\mathrm{D}_{8}, 98 \%\right)$ |
| CLM-8742 | allo-Isoleucine ( ${ }^{(3)} C_{6}, 97-99 \%$ ) |
| DLM-1505 | allo-Isoleucine ( $\mathrm{D}_{10}, 98 \%$ ) |
| CLM-2247-H | L-Lysine $2 \mathrm{HCl}\left({ }^{13} \mathrm{C}_{6}, 99 \%\right)$ |
| DLM-2640 | L-Lysine-2HCl (4,4,5,5-D $\left.{ }_{4}, 96-98 \%\right)$ |
| DLM-2312 | DL-2-methylcitric acid (methyl- ${ }_{3}$, $98 \%$ ) CP 90\% |
| CLM-8111 | 3-Methylcrotonylglycine (glycine- ${ }^{13} \mathrm{C}_{2}, 98 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CLM-9426 | Methylmalonic acid ( ${ }^{13} \mathrm{C}_{4}, 99 \%$ ) |
| DLM-387 | Methylmalonic acid (methy-D ${ }_{3}, 98 \%$ ) |
| ULM-10578 | Methylmalonic acid, disodium salt (unlabeled) CP 95\% |
| CLM-4724 | L-Ornithine. $\mathrm{HCl}\left({ }^{13} \mathrm{C}_{5}, 98 \%\right)$ |
| DLM-2969 | L-Ornithine. $\mathrm{HCl}\left(3,3,4,4,5,5-\mathrm{D}_{6}, 98 \%\right)$ |
| NLM-1048 | Orotic acid• $\mathrm{H}_{2} \mathrm{O}\left(1,3-{ }^{15} \mathrm{~N}_{2}, 98 \%\right)$ |
| CLM-10604 | Phenylpyruvic acid, sodium salt ( ${ }^{13} \mathrm{C}_{9}, 99 \%$ ) |
| CLM-2260 | L-Proline ( ${ }^{13} \mathrm{C}_{5}, 99 \%$ ) |
| DLM-487 | L-Proline ( $\mathrm{D}_{7}, 97-98 \%$ ) |
| ULM-8333 | L-Proline (unlabeled) |
| CLM-7944 | 3-(5-Methyl-1H-pyrazol-3-yl)propanoic acid (methyl- ${ }^{13} \mathrm{C}$, pyrazolyl- ${ }^{13} \mathrm{C}_{3}, 3-{ }^{13} \mathrm{C}, 99 \%$ ) |
| NLM-1072 | Sarcosine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CNLM-8183 | Suberylglycine (glycine- ${ }^{13} \mathrm{C}_{2}, 98 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) CP 95\% |
| DLM-10758 | Trisodium 2-methylcitrate (methyl-D ${ }_{3}, 98 \%$ ) (racemic mixture of diastereomers) CP 90\% |
| CLM-4290-H | L-Tryptophan ( ${ }^{\left.1{ }^{3} \mathrm{C}_{11}, 99 \%\right)}$ |
| DLM-6903 | L-Tryptophan ( $\mathrm{D}_{8}, 97-98 \%$ ) |

Please visit isotope.com for a complete listing of MS/MS standards.

## Neurotransmitters

| Catalog No. | Description |
| :---: | :---: |
| DLM-11029 | N-Acetyl-5-hydroxytryptamine (acetyl- $\mathrm{D}_{3}$, 98\%) |
| CLM-8666 | 4-Aminobutyric acid ( ${ }^{13} \mathrm{C}_{4}, 97-99 \%$ ) |
| CLM-548 | Choline chloride (1,2-13 $\left.\mathrm{C}_{2}, 99 \%\right)$ |
| DLM-549 | Choline chloride (trimethyl- $\mathrm{D}_{9}, 98 \%$ ) |
| DLM-549-MPT | Choline chloride (trimethyl- $\left.\mathrm{D}_{9}, 98 \%\right)$ |
| CLM-3368 | Dopamine $\cdot \mathrm{HCl}$ (2-(3,4-dihydroxyphenyl)- ethylamine $\cdot \mathrm{HCl})$ (1- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-3369 | Dopamine•HCI (2-(3,4-dihydroxyphenyl)- ethylamine•HCI) (ring- $\left.{ }^{13} \mathrm{C}_{6}, 99 \%\right)$ |
| DLM-2833 | Dopamine•HCI (2-(3,4-dihydroxyphenyl)- ethylamine•HCI) (1,1-D ${ }_{2}, 93 \%$ ) CP 96-98\% |
| DLM-2834 | Dopamine•HCI (2-(3,4-dihydroxyphenyl)- ethylamine•HCI) (2,2-D, $97-98 \%)$ |
| DLM-2181 | Dopamine•HCl (2-(3,4-dihydroxyphenyl)- ethylamine•HCl) (ring- $\mathrm{D}_{3}, 98 \%$ ) |
| DLM-2498 | Dopamine $\cdot \mathrm{HCl}(2-(3,4-$ dihydroxyphenyl)- ethylamine $\cdot \mathrm{HCl})$ (1,1,2,2-D, $97-98 \%)$ |


| Catalog No. | Description |
| :---: | :---: |
| DLM-2290 | $\begin{aligned} & \text { Dopamine•HCl (2-(3,4-dihydroxyphenyl)- ethylamine•HCI) } \\ & \text { (ring-D } \left.{ }_{3}, 95 \% ; 2,2-D_{2}, 95 \%\right) \end{aligned}$ |
| CNLM-3445 | Dopamine• $\mathrm{HCl}(2$-(3,4-dihydroxyphenyl)- ethylamine-HCl) $\left(1-{ }^{13} \mathrm{C}, 99 \% ;{ }^{15} \mathrm{~N}, 99 \%\right)$ |
| CLM-674 | L-Glutamic acid (1-13C, 99\%) |
| CLM-1800-H | L-Glutamic acid ( ${ }^{13} \mathrm{C}_{5}, 99 \%$ ) |
| DLM-556 | L-Glutamic acid ( $2,3,3,4,4-\mathrm{D}_{5}, 98 \%$ ) |
| CNLM-554-H | L-Glutamic acid ( ${ }^{13} \mathrm{C}_{5}, 99 \%$; ${ }^{15} \mathrm{~N}, 99 \%$ ) |
| DLM-2911 | Histamine $\cdot 2 \mathrm{HCl}\left(\alpha, \beta, \beta, \beta-\mathrm{D}_{4}, 98 \%\right)$ |
| CLM-9936-C | 5-Hydroxyindole-3-acetic acid ( $3 \alpha, 4,5,6,7,7 \alpha-{ }^{13} \mathrm{C}_{6}, 98 \%$ ) |
| DLM-3560 | DL-Metanephrine $\cdot \mathrm{HCl}\left(\alpha, \beta, \beta-\mathrm{D}_{3}, 98 \%\right)$ |
| DLM-2950 | $\mathrm{N}-\tau$-Methylhistamine $\cdot 2 \mathrm{HCl}\left(\mathrm{N}\right.$-methyl- $\left.\mathrm{D}_{3}, 98 \%\right)$ |
| DLM-8820 | DL-Norepinephrine. HCl (ring- $\mathrm{D}_{3}, 1,2,2-\mathrm{D}_{3}, 99 \%$ ) |
| DLM-8609 | DL-Normetanephrine. $\mathrm{HCl}\left(\alpha, \beta, \beta-\mathrm{D}_{3}, 98 \%\right)$ |
| DLM-11030 | Serotonin. $\mathrm{HCl}\left(\alpha, \alpha, \beta, \beta-\mathrm{D}_{4}, 98 \%\right) \mathrm{CP} 96 \%$ |
| DLM-8075 | Tyramine• $\mathrm{HCl}\left(1,1,2,2-\mathrm{D}_{4}, 98 \%\right)$ |

Please visit isotope.com for a complete listing of neurotransmitters.

## MPT: microbiologically and pyrogen tested.

Chemical purity (CP) is $98 \%$ or greater, unless otherwise indicated. For research use only. Not for use in diagnostic procedures.

## Nucleic Acids

| Catalog No. | Description |
| :---: | :---: |
| CLM-1654 | Adenine ( $8-{ }^{13} \mathrm{C}, 95 \%$ ) |
| NLM-6924 | Adenine $\cdot \mathrm{HCl}\left({ }^{15} \mathrm{~N}_{5}, 98 \%\right)$ |
| CLM-7674 | Adenosine ( $3^{\prime}-1{ }^{13} \mathrm{C}, 98 \%$ ) |
| CLM-3698 | Adenosine (ribose-2- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-3678 | Adenosine (ribose- ${ }^{13} \mathrm{C}_{5}, 98 \%$ ) CP 97\% |
| DLM-7676 | Adenosine (ribose-1-D, 98\%) |
| DLM-7677 | Adenosine (ribose-2-D, 97\%) |
| DLM-7678 | Adenosine (ribose-5,5-D ${ }_{2}, 98 \%$ ) |
| CNLM-3806-CA | Adenosine ( ${ }^{13} \mathrm{C}_{10}, 98 \%$; $\left.{ }^{15} \mathrm{~N}_{5}, 96-98 \%\right)$ |
| NLM-9750-SL | Adenosine ( $\mathrm{U}-{ }^{15} \mathrm{~N}_{5}, 96-98 \%$ ) |
| CNLM-3802 | Adenosine 5'-monophosphate ( ${ }^{13} \mathrm{C}_{10}, 98 \% ;{ }^{15} \mathrm{~N}_{5}, 96-98 \%$ ) |
| NLM-3792-SL | Adenosine 5'-monophosphate, lithium salt ( $\mathrm{U}-{ }^{-1} \mathrm{~N}_{5}, 96-98 \%$ ) |
| DLM-7514-CA ${ }^{+}$ | Adenosine 5'-triphosphate (ATP), ammonium salt (D, 97\%) CP >90\% |
| DLM-8815-CA ${ }^{+}$ | Adenosine 5'-triphosphate (ATP), ammonium salt (2-D, 97\%) CP >90\% |
| DLM-8922-CA ${ }^{+}$ | Adenosine $5^{\prime}$-triphosphate (ATP), ammonium salt (ribose-3', $4^{\prime}, 5^{\prime}, 5^{\prime \prime}-D_{4}, 98 \%$ ) CP $>90 \%$ |
| NLM-3987-CA ${ }^{+}$ | Adenosine $5^{\prime}$-triphosphate (ATP), ammonium salt $\left({ }^{15} \mathrm{~N}_{5}, 98-99 \%\right) \mathrm{CP}>90 \%$ |
| CNLM-4265-CA ${ }^{+}$ | Adenosine 5'-triphosphate (ATP), ammonium salt $\left({ }^{13} \mathrm{C}_{10}, 98-99 \% ;{ }^{15} \mathrm{~N}_{5}, 98-99 \%\right) \mathrm{CP}>90 \%$ |
| CLM-3605 | Adenosine. $\mathrm{H}_{2} \mathrm{O}$ (ribose-1-13 $\mathrm{C}, 99 \%$ ) CP 95\% |
| CLM-3611 | Cytidine (ribose-1-13 ${ }^{13}$, 99\%) |
| CLM-3699 | Cytidine (ribose-2-13 ${ }^{13}$, 99\%) |
| CLM-3679 | Cytidine (ribose- ${ }^{13} \mathrm{C}_{5}, 98 \%$ ) |
| DLM-7681 | Cytidine (ribose-5,5-D ${ }_{2}$, 98\%) |
| NLM-3797 | Cytidine ( ${ }^{15} \mathrm{~N}_{3}, 96-98 \%$ ) |
| CNLM-3807 | Cytidine ( ${ }^{13} \mathrm{C}_{9}, 98 \%$; $\left.{ }^{15} \mathrm{~N}_{3}, 96-98 \%\right)$ |
| NLM-3793-SL | Cytidine $5^{\prime}$-monophosphate, lithium salt ( $\mathrm{U}-{ }^{15} \mathrm{~N}_{3}, 96-98 \%$ ) CP $>90 \%$ |
| CNLM-3803-SL+ | Cytidine $5^{\prime}$-monophosphate, lithium salt ( $\mathrm{U}-{ }^{13} \mathrm{C}_{9}, 98 \% ; \mathrm{U}^{15} \mathrm{~N}_{3}, 96-98 \%$ ) (in solution) $\mathrm{CP}>90 \%$ |
| DLM-8924-CA ${ }^{+}$ | Cytidine $5^{\prime}$-triphosphate (CTP), ammonium salt (5-D, ribose-3', $4^{\prime}, 5^{\prime}, 5^{\prime \prime}-D_{4}, 97 \%$ ) CP $>90 \%$ |
| DLM-9267-CA ${ }^{+}$ | Cytidine $5^{\prime}$-triphosphate (CTP), ammonium salt (5,6-D ${ }_{2}, 97 \%$ ) CP 90\% |
| DLM-8594-CA ${ }^{+}$ | Cytidine $5^{\prime}$-triphosphate (CTP), ammonium salt (cytosine-5-D, 6-H; ribose-1, 2,3,4,5,5-D ${ }_{6}$, 96-97\%) |
| DLM-7515-CA ${ }^{+}$ | Cytidine $5^{\prime}$-triphosphate (CTP), ammonium salt ( $\mathrm{D}_{8}, 97 \%$ ) CP >90\% |
| NLM-4266-CA ${ }^{+}$ | Cytidine $5^{\prime}$-triphosphate (CTP), ammonium salt $\left({ }^{15} \mathrm{~N}_{3},>96 \%\right) \mathrm{CP}>90 \%$ |
| CNLM-4267-CA ${ }^{+}$ | Cytidine 5'-triphosphate (CTP), ammonium salt $\left.{ }^{13} \mathrm{C}_{9}, 99 \% ;{ }^{15} \mathrm{~N}_{3}, 96-98 \%\right) \mathrm{CP}>90 \%$ |
| DLM-9101-CA | Cytidine $\cdot \mathrm{H}_{2} \mathrm{O}\left(5,6-\mathrm{D}_{2}, 98 \%\right) \mathrm{CP} 95 \%$ |
| CLM-1001 | Cytosine ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CNLM-4424 | Cytosine ( $2-{ }^{13} \mathrm{C}, 99 \% ; 1,3-{ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| DLM-4750 | 2-Deoxy-D-ribose ( $5,5-\mathrm{D}_{2}, 98 \%$ ) |
| NLM-3919-SL | 2'-Deoxyadenosine 5'-monophosphate ( $\mathrm{U}^{15} \mathrm{~N}_{5}, 98 \%$ ) |

*Compounds available in dry and solution forms
+Compounds available in solution only.
\#Compounds available in dry and solution forms; chemical purity varies 95-98\%
Chemical purity (CP) is 98\% or greater, unless otherwise indicated.
For research use only. Not for use in diagnostic procedures.

| Catalog No. | Description |
| :---: | :---: |
| CNLM-3918-SL | 2'-Deoxyadenosine 5'-monophosphate, lithium salt $\left(\mathrm{U}-{ }^{13} \mathrm{C}_{10}, 98 \% ; \mathrm{U}-{ }^{15} \mathrm{~N}_{5}, 98 \%\right)$ |
| CNLM-6219-CA ${ }^{+}$ | 2'-Deoxyadenosine 5'-triphosphate (dATP) $\left({ }^{13} \mathrm{C}_{10}, 98 \% ;{ }^{15} \mathrm{~N}_{5}, 96-98 \%\right) \mathrm{CP}>90 \%$ |
| DLM-7507-SL ${ }^{+}$ | 2-Deoxyadenosine 5'-triphosphate (dATP), lithium salt (U-D, 97\%) CP >90\% |
| NLM-6215-SL ${ }^{+}$ | 2'-Deoxyadenosine 5'-triphosphate (dATP), lithium salt ( $\mathrm{U}-{ }^{15} \mathrm{~N}_{5}, 98 \%$ ) CP $>90 \%$ |
| NLM-6829 | 2'-Deoxyadenosine phosphoramidite ( ${ }^{15} \mathrm{~N}_{5}, ~ 98 \%$ ) CP 95\% |
| CNLM-6828 | 2'-Deoxyadenosine phosphoramidite <br> ( ${ }^{13} \mathrm{C}_{10}, 98 \%$; ${ }^{15} \mathrm{~N}_{5}, 98 \%$ ) CP $95 \%$ |
| CLM-3700 | $2^{\prime}$-Deoxyadenosine $\cdot \mathrm{H}_{2} \mathrm{O}$ (deoxyribose-1-13 $\mathrm{C}, 99 \%$ ) |
| CLM-3701 | $2{ }^{\prime}$-Deoxyadenosine $\cdot \mathrm{H}_{2} \mathrm{O}$ (deoxyribose-2- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-7682 | 2'-Deoxyadenosine $\cdot \mathrm{H}_{2} \mathrm{O}$ (ribose-5-5 ${ }^{13} \mathrm{C}, 98 \%$ ) |
| CLM-4579 | 2'-Deoxyadenosine $\mathrm{H}_{2} \mathrm{O}$ (ribose- ${ }^{13} \mathrm{C}_{5}, 99 \%$ ) |
| DLM-7683 | 2'-Deoxyadenosine $\cdot \mathrm{H}_{2} \mathrm{O}$ (ribose-5,5- $\mathrm{D}_{2}, 98 \%$ ) |
| NLM-3895 | 2'-Deoxyadenosine. $\mathrm{H}_{2} \mathrm{O}\left({ }^{15} \mathrm{~N}_{5}, 96-98 \%\right)$ |
| NLM-3897 | 2'-Deoxycytidine ( ${ }^{15} \mathrm{~N}_{3}, 96-98 \%$ ) |
| NLM-3921 | 2'-Deoxycytidine 5'-monophosphate ( ${ }^{15} \mathrm{~N}_{3}, 96 \%$ ) |
| DLM-7508-SL ${ }^{+}$ | 2-Deoxycytidine 5'-triphosphate, lithium salt (U-D, 97\%) CP >90\% |
| NLM-6216-SL+ | 2'-Deoxycytidine 5'-triphosphate, lithium salt (U- ${ }^{15} \mathrm{~N}_{3}, 98 \%$ ) CP $>90 \%$ |
| CNLM-6220-SL ${ }^{+}$ | 2'-Deoxycytidine 5'-triphosphate, lithium salt (U- ${ }^{13} \mathrm{C}_{9}, 98 \% ; \mathrm{U}^{-15} \mathrm{~N}_{3}, 98 \%$ ) CP $>90 \%$ |
| NLM-6827 | $2^{\prime}$-Deoxycytidine phosphoramidite ( ${ }^{15} \mathrm{~N}_{3}, 97-98 \%$ ) CP 95\% |
| CNLM-6830 | 2'-Deoxycytidine phosphoramidite ( ${ }^{13} \mathrm{C}_{9}, 98 \% ;{ }^{15} \mathrm{~N}_{3}$, $98 \%$ ) CP $95 \%$ |
| CLM-3702 | 2'-Deoxycytidine. $\mathrm{H}_{2} \mathrm{O}$ (deoxyribose-2- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-7684 | 2'-Deoxycytidine $\mathrm{H}_{2} \mathrm{O}$ (ribose-1-13 ${ }^{13}$, 98\%) |
| DLM-7685 | 2'-Deoxycytidine. $\mathrm{H}_{2} \mathrm{O}$ (ribose-5,5- $\mathrm{D}_{2}, 98 \%$ ) |
| CNLM-3900-CA | $2^{\prime}$-Deoxyguanosine ( ${ }^{13} \mathrm{C}_{10}, 98 \%$; ${ }^{15} \mathrm{~N}_{5}, 96-98 \%$ ) |
| NLM-6835-SL ${ }^{+}$ | $2^{\prime}$-Deoxyguanosine $5^{\prime}$-monophosphate ( $\left({ }^{-15} \mathrm{~N}_{5}, 98 \%\right)$ $\text { CP }>90 \%$ |
| CNLM-6836-SL | 2'-Deoxyguanosine 5'-monophosphate (U- ${ }^{13} \mathrm{C}, 98 \%$ U- ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| NLM-6217-CA ${ }^{+}$ | 2'-Deoxyguanosine 5'-triphosphate (DTP), ammonium salt ( $\left.{ }^{15} N_{5} ; ~ 98-99 \%\right)$ CP $>90 \%$ |
| CNLM-6221-CA ${ }^{+}$ | 2'-Deoxyguanosine 5'-triphosphate (DTP), ammonium salt ( ${ }^{13} \mathrm{C}_{10}, 98 \%$; ${ }^{15} \mathrm{~N}_{5}, 96-98 \%$ ) CP $>90 \%$ |
| DLM-7509-SL ${ }^{+}$ | 2-Deoxyguanosine 5'-triphosphate (DTP), lithium salt (U-D, 97\%) CP >90\% |
| NLM-6217-SL+ | 2'-Deoxyguanosine 5'-triphosphate (DTP), lithium salt $\left(\mathrm{U}-{ }^{15} \mathrm{~N}_{5}, 98 \%\right) \mathrm{CP}>90 \%$ |
| NLM-6826 | 2'-Deoxyguanosine phosphoramidite ( ${ }^{15} \mathrm{~N}_{5}, 98 \%$ ) CP 95\% |
| CNLM-6825 | 2'-Deoxyguanosine phosphoramidite ${ }^{(13} \mathrm{C}_{10}, 98 \%$; ${ }^{15} \mathrm{~N}_{5}, 98 \%$ ) CP 95\% |
| CLM-7686 | $2^{\prime}$-Deoxyguanosine $\cdot \mathrm{H}_{2} \mathrm{O}$ (ribose-1- ${ }^{13} \mathrm{C}, 98 \%$ ) |
| DLM-7687 | 2'-Deoxyguanosine. $\mathrm{H}_{2} \mathrm{O}$ (ribose-5,5-D ${ }_{2}, 98 \%$ ) |
| NLM-3899-CA | 2'-Deoxyguanosine. $\mathrm{H}_{2} \mathrm{O}\left({ }^{15} \mathrm{~N}_{5}, 98 \%\right) \mathrm{CP} 95 \%$ |
| CNLM-8771-CA ${ }^{+}$ | 2'-Deoxyuridine, ammonium salt $\left({ }^{13} \mathrm{C}_{9}, 98-99 \% ;{ }^{15} \mathrm{~N}_{2}, 98-99 \%\right) \mathrm{CP} 90 \%$ |
| DLM-4391 | 5,6-Dihydrothymine ( $5,6,6-\mathrm{D}_{3}$, methyl- $\mathrm{D}_{3}, 95 \%$ ) |
| CNLM-4510 | 5,6-Dihydrouracil ( ${ }^{13} \mathrm{C}_{4}, 99 \%$; ${ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| CNLM-3752 | Fapyadenine (formyl- ${ }^{13} \mathrm{C}, 98 \%$; diamino- ${ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| NLM-798 | 5-Fluorouracil (1,3-15 $\mathrm{N}_{2}, 99 \%$ ) |
| CNLM-3916 | 5-Fluorouracil ( ${ }^{13} \mathrm{C}_{4}, 99 \%$; ${ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |


| Catalog No. | Description |
| :---: | :---: |
| DLM-1846 | Guanidine• $\mathrm{DCI}\left(\mathrm{D}_{6}, 98 \%\right)$ |
| CLM-1019 | Guanine ( $8-{ }^{13} \mathrm{C}, 98 \%$ ) |
| NLM-6925 | Guanine ( ${ }^{15} \mathrm{~N}_{5}, 98 \%$ ) |
| CNLM-3990 | Guanine ( $8-{ }^{-13} \mathrm{C}, 98 \% ; 7,9-{ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| NLM-3798 | Guanosine ( ${ }^{15} \mathrm{~N}_{5}, 96-98 \%$ ) |
| NLM-3794-SL | Guanosine 5'-monophosphate, Iyophilized powder (U- ${ }^{15} \mathrm{~N}_{5}, 98 \%$ ) CP $>90 \%$ |
| CNLM-3804-SL* | Guanosine 5'-monophosphate, lithium salt (U- ${ }^{13} \mathrm{C}_{10}, 98 \%$; U- ${ }^{15} \mathrm{~N}_{5}, 98 \%$ ) CP $>90 \%$ |
| DLM-7516-CA ${ }^{+}$ | Guanosine 5'-triphosphate (GTP), ammonium salt (D, 97\%) CP >90\% |
| DLM-8923-CA ${ }^{+}$ | Guanosine $5^{\prime}$-triphosphate (GTP), ammonium salt (ribose-3', 4', $5^{\prime}, 5^{\prime \prime}-D_{4}, 98 \%$ ) CP >90\% |
| NLM-4268-CA ${ }^{+}$ | Guanosine $5^{\prime}$-triphosphate (GTP), ammonium salt ( ${ }^{15} \mathrm{~N}_{5}, 98-99 \%$ ) (in solution) CP $>90 \%$ |
| CNLM-4269-CA ${ }^{+}$ | Guanosine 5'-triphosphate (GTP), ammonium salt $\left({ }^{13} \mathrm{C}_{10}, 99 \% ;{ }^{15} \mathrm{~N}_{5}, 98 \%\right) \mathrm{CP}>90 \%$ |
| CLM-7688 | Guanosine. $\mathrm{H}_{2} \mathrm{O}$ (ribose-1-13 $\mathrm{C}, 98 \%$ ) |
| DLM-7689 | Guanosine. $\mathrm{H}_{2} \mathrm{O}$ (ribose-5,5- $\mathrm{D}_{2}, 98 \%$ ) |
| CNLM-3808-CA | Guanosine. $\mathrm{H}_{2} \mathrm{O}\left({ }^{13} \mathrm{C}_{10}, 98 \%\right.$; $\left.{ }^{15} \mathrm{~N}_{5}, 96-98 \%\right)$ |
| NLM-6715 | 8 -Hydroxy-2'-deoxyguanosine ( ${ }^{15} \mathrm{~N}_{5}, 98 \%$ ) CP 95\% |
| CNLM-4392 | 5 -Hydroxycytosine ( $2-{ }^{13} \mathrm{C}, 99 \%$; $1,3-{ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| CLM-8042 | Hypoxanthine ( ${ }^{13} \mathrm{C}_{5}, 99 \%$ ) |
| DLM-8658 | Hypoxanthine (2,8-D $\left.{ }_{2}, 98 \%\right)$ |
| DLM-2923 | Hypoxanthine (2,8,9-D $\left.{ }_{3}, \mathrm{OD}, 98 \%\right)$ |
| NLM-8500 | Hypoxanthine ( ${ }^{5} \mathrm{~N}_{4}, 98 \%$ ) |
| CNLM-7894 | Hypoxanthine ( ${ }^{13} \mathrm{C}_{5}, 99 \%$; ${ }^{15} \mathrm{~N}_{4}, 98 \%$ ) |
| NLM-4264 | Inosine ( ${ }^{15} \mathrm{~N}_{4}, 95 \%$ ) |
| NLM-8712-CA ${ }^{+}$ | Inosine 5'-monophosphate, ammonium salt ( ${ }^{15} \mathrm{~N}_{4}, 98-99 \%$ ) CP $>90 \%$ |
| DLM-7471 | 3-Methyladenine (methyl-D ${ }_{3}, 98 \%$ ) |
| DLM-7473 | 6-O-Methylguanine (methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| DLM-7472 | 7-Methylguanine (methyl-D ${ }_{3}, 98 \%$ ) |
| CLM-10671 | Nicotinamide adenine dinucleotide (NAD ${ }^{+}$), $\mathrm{NH}_{4}$ salt (ribose- ${ }^{13} \mathrm{C}_{5}$, 98\%) CP 96\% |
| NLM-1048 | Orotic acid• $\mathrm{H}_{2} \mathrm{O}\left(1,3-{ }^{-15} \mathrm{~N}_{2}, 98 \%\right)$ |
| NLM-1048-MPT | Orotic acid• $\mathrm{H}_{2} \mathrm{O}\left(1,3-{ }^{-15} \mathrm{~N}_{2}, 98 \%\right)$ |
| CNLM-10662 | Orotic acid $\cdot \mathrm{H}_{2} \mathrm{O}\left(2-{ }^{13} \mathrm{C}, 99 \% ; 1,3-{ }^{15} \mathrm{~N}_{2}, 98 \%\right)$ |
| NLM-10907 | Orotic acid, sodium salt ( ${ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| CLM-9427-CA | 1-(5'-Phosphoribosyl)-5-amino-4-imidazole-carboxamide salt-2 $\mathrm{NH}_{4}{ }^{+}$(ribose- ${ }^{13} \mathrm{C}_{5}, 99 \%$ ) CP 90\% |
| CLM-3629 | Ribothymidine (ribose-1-13 ${ }^{13}$, 99\%) |
| NLM-7565-SL | RNA standard ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CLM-6622 | Taurine ( $1,2{ }^{-13} \mathrm{C}_{2}, 98 \%$ ) |
| DLM-8057 | Taurine ( $\mathrm{D}_{4}, 98 \%$ ) CP 95\% |
| NLM-4472 | Taurine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CLM-4289 | Thymidine (deoxyribose-1-13C, 99\%) |
| CLM-3703 | Thymidine (deoxyribose-2- ${ }^{-13} \mathrm{C}, 99 \%$ ) |
| CLM-7692 | Thymidine (deoxyribose-3-13 ${ }^{13}$, 99\%) |
| CLM-3647 | Thymidine (methyl- ${ }^{13} \mathrm{C}, 98 \%$ ) |
| DLM-7691 | Thymidine (ribose-5,5-D ${ }_{2}, 98 \%$ ) |

GMP: good manufacturing practices grade
MPT: microbiologically and pyrogen tested.
*Compounds available in dry and solution forms.
+Compounds available in solution only.
Chemical purity (CP) is $98 \%$ or greater, unless otherwise indicated. For research use only. Not for use in diagnostic procedures.

| Catalog No. | Description |
| :---: | :---: |
| DLM-3327 | Thymidine (methyl-D ${ }_{3}$, ring-6-D, 97\%) CP 95\% |
| NLM-3901 | Thymidine ( ${ }^{15} \mathrm{~N}_{2}, 96-98 \%$ ) |
| NLM-3901-MPT | Thymidine ( ${ }^{15} \mathrm{~N}_{2}, 96-98 \%$ ) |
| CNLM-3902 | Thymidine ( ${ }^{13} \mathrm{C}_{10}, 98 \%$; ${ }^{5} \mathrm{~N}_{2}, 96-98 \%$ ) |
| NLM-3925 | Thymidine $5^{\prime}$-monophosphate ( ${ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| CNLM-3924-SL | Thymidine 5'-monophosphate $\left(\mathrm{U}-{ }^{13} \mathrm{C}_{10}, 98 \% ; \mathrm{U}^{15} \mathrm{~N}_{2}, 98 \%\right)$ |
| DLM-7510-SL ${ }^{+}$ | Thymidine 5'-triphosphate (TTP), lithium salt (U-D, 97\%) CP >90\% |
| NLM-6218-SL ${ }^{+}$ | Thymidine 5'-triphosphate (TTP), lithium salt (U- ${ }^{15} \mathrm{~N}_{2}, 98 \%$ ) CP $>90 \%$ |
| CNLM-6222-SL ${ }^{+}$ | Thymidine 5'-triphosphate (TTP), lithium salt (U- ${ }^{-13} \mathrm{C}_{10}, 98 \% ; \mathrm{U}-{ }^{15} \mathrm{~N}_{2}, 98 \%$ ) CP $>90 \%$ |
| NLM-6823 | Thymidine phosphoramidite ( ${ }^{15} \mathrm{~N}_{2}, 96-98 \%$ ) CP 95\% |
| CNLM-6824 | Thymidine phosphoramidite ( ${ }^{13} \mathrm{C}_{10}, 98 \%$; ${ }^{15} \mathrm{~N}_{2}, 98 \%$ ) CP 95\% |
| CLM-3764 | Thymine (6-13 ${ }^{13}$, 99\%) |
| DLM-1089 | Thymine ( $\alpha, \alpha, \alpha, 6-D_{4}, 98 \%$ ) |
| NLM-3995 | Thymine ( $1,3-{ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| CNLM-6945 | Thymine ( ${ }^{13} \mathrm{C}_{5}, 98 \%$; ${ }^{5} \mathrm{~N}_{2}, 98 \%$ ) |
| CLM-3276 | Uracil ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-3276-GMP | Uracil ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-3276-MPT | Uracil ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-692 | Uracil ( $4,5-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| DLM-8633 | Uracil (5-D, 98\%) |
| DLM-8502 | Uracil ( $5,6-\mathrm{D}_{2}, 98 \%$ ) |
| NLM-637 | Uracil ( $1,3-{ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| CNLM-3917 | Uracil ( ${ }^{13} \mathrm{C}_{4}, 99 \%$; ${ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| NLM-1697 | Uric acid ( $1,3-{ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| NLM-1697-MPT | Uric acid ( $1,3-{ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| CLM-3630 | Uridine (ribose-1-13C, 99\%) |
| CNLM-3809 | Uridine ( ${ }^{13} \mathrm{C}_{9}, 98 \%$; ${ }^{15} \mathrm{~N}_{2}, 96-98 \%$ ) |
| DLM-7693 | Uridine (ribose-5,5-D ${ }_{2}, 98 \%$ ) |
| NLM-812 | Uridine ( ${ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| NLM-3795 | Uridine 5'-monophosphate ( ${ }^{15} \mathrm{~N}_{2}, 96-98 \%$ ) |
| CNLM-3805-SL ${ }^{+}$ | Uridine 5'-monophosphate, lithium salt (U- ${ }^{13} \mathrm{C}_{9}, 98 \%$; $\mathrm{U}-{ }^{15} \mathrm{~N}_{2}, 96-98 \%$ ) (in solution) $\mathrm{CP}>90 \%$ |
| DLM-8925-CA ${ }^{+}$ | Uridine 5'-triphosphate (UTP), ammonium salt (5-D, ribose-3', $4^{\prime}, 5^{\prime}, 5^{\prime \prime}-D_{4}, 98 \%$ ) (in solution) $C P>90 \%$ |
| DLM-9100-CA ${ }^{+}$ | Uridine $5^{\prime}$-triphosphate (UTP), ammonium salt (5,6-D ${ }_{2}, 98 \%$ ) CP $>90 \%$ |
| DLM-8637-CA ${ }^{+}$ | Uridine 5'-triphosphate (UTP), ammonium salt (uracil-5-D, 6-H; ribose-1,2,3,4,5,5-D $6,96-97 \%)$ CP >90\% |
| DLM-7517-CA ${ }^{+}$ | Uridine 5'-triphosphate (UTP), ammonium salt ( $\mathrm{D}_{8}, 97 \%$ ) CP 90\% |
| NLM-4270-CA | Uridine 5'-triphosphate (UTP), ammonium salt ( ${ }^{15} \mathrm{~N}_{2}, 98-99 \%$ ) CP $>90 \%$ |
| CNLM-4271-CA ${ }^{+}$ | Uridine 5'-triphosphate (UTP), ammonium salt $\left({ }^{13} \mathrm{C}_{9}, 99 \% ;{ }^{15} \mathrm{~N}_{2}, 98 \%\right) \mathrm{CP}>90 \%$ |
| NLM-1698 | Xanthine ( $1,3-{ }^{-15} \mathrm{~N}_{2}, 98 \%$ ) CP 90\% |
| CLM-8700-CA ${ }^{+}$ | Xanthosine-5'-monophosphate, ammonium salt $\left.{ }^{13} \mathrm{C}_{10}, 98 \%\right)$ CP $>90 \%$ |

## Please visit isotope.com for a complete listing of nucleic acids.

See pages 31-33 for metabolite mixtures comprising nucleic acids.

## Organic Acids, Their Derivatives, and Conjugate Salts

| Catalog No. | Description |
| :---: | :---: |
| CLM-317 | Acetic acid ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-318 | Acetic acid ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-113 | Acetic acid (1,2-13 ${ }_{2}, 99 \%$ ) |
| CLM-9878 | trans-Aconitic acid ( $2,4,4{ }^{\prime}-{ }^{13} \mathrm{C}_{3}, 99 \%$ ) CP 95\% |
| CLM-11066 | cis-Aconitic acid, tripotassium salt ( ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) CP 95\% |
| CLM-7337 | Citric acid (1,5- $\left.{ }^{13} \mathrm{C}_{2}, 98 \%\right)$ |
| CLM-148 | Citric acid ( $2,4-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-9876 | Citric acid (1,5,6-carboxyl- ${ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| CLM-9021 | Citric acid ( ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) CP 97\% |
| DLM-3487 | Citric acid ( $2,2,4,4-\mathrm{D}_{4}, 98 \%$ ) |
| ULM-10650 | Citric acid (unlabeled) |
| DLM-10776 | L-Citrulline (2,3,3,4,4,5,5-D ${ }_{7}, 98 \%$ ) |
| CLM-7933 | Creatine (guanidino- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| DLM-1302 | Creatine (methyl-D ${ }_{3}, 98 \%$ ) CP 97\% |
| DLM-1302-MPT | Creatine (methyl- ${ }_{3}, 98 \%$ ) CP 97\% |
| CLM-1529 | Fumaric acid ( ${ }^{13} \mathrm{C}_{4}, 99 \%$ ) |
| DLM-1539 | Fumaric acid ( $2,3-\mathrm{D}_{2}, 98 \%$ ) |
| DLM-7654 | Fumaric acid ( $\mathrm{D}_{4}, 98 \%$ ) |
| CDLM-6062 | Fumaric acid (1-13 $\left.\mathrm{C}, 99 \% ; 2,3-\mathrm{D}_{2}, 98 \%\right)$ |
| CDLM-8473 | Fumaric acid ( $1,4{ }^{13} \mathrm{C}_{2}, 99 \% ; 2,3-\mathrm{D}_{2}, 98 \%$ ) |
| ULM-10653 | Fumaric acid (unlabeled) |
| CLM-10890 | Fumaric acid, disodium salt ( ${ }^{13} \mathrm{C}_{4}, 99 \%$ ) |
| CLM-10661 | L-Glyceric acid, calcium salt dihydrate ( ${ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| CLM-373 | Homovanillic acid (1,2-13 ${ }_{2}, 98-99 \%$ ) |
| DLM-2738 | Homovanillic acid (phenyl- $\mathrm{D}_{3}, 2,2-\mathrm{D}_{2}, 96-98 \%$ ) |
| COLM-376 | ```Homovanillic acid```  |
| CLM-10351 | DL-2-Hydroxyglutaric acid, disodium salt ( ${ }^{(13} \mathrm{C}_{5}, 99 \%$ ) |
| ULM-10479 | DL-2-Hydroxyglutaric acid, disodium salt (unlabeled) |
| DLM-9104 | (RS)-2-Hydroxyglutaric acid, disodium salt (2,3,3-D $;$ OD, $98 \%$ ) CP 95\% |
| CLM-6820 | $\alpha$-Ketobutyric acid, sodium salt (methyl- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-6164 | $\alpha$-Ketobutyric acid, sodium salt ( ${ }^{13} \mathrm{C}_{4}, 98 \%$ ) |
| CDLM-7318 | $\alpha$-Ketobutyric acid, sodium salt (methyl- ${ }^{13} \mathrm{C}, 99 \% ; 3,3-\mathrm{D}_{2}, 98 \%$ ) |
| CDLM-7353 | $\alpha$-Ketobutyric acid, sodium salt ( $4-{ }^{13} \mathrm{C}, 99 \% ; 3,3,4,4-\mathrm{D}_{4}, 98 \%$ ) |
| CDLM-4611 | $\alpha$-Ketobutyric acid, sodium salt ( $\left.{ }^{13} \mathrm{C}_{4}, 98 \% ; 3,3-\mathrm{D}_{2}, 98 \%\right)$ |
| CLM-2411 | $\alpha$-Ketoglutaric acid ${ }^{13} \mathrm{C}_{5}, 99 \%$ ) $\mathrm{CP}>90 \%$ |
| DLM-9476 | $\alpha$-Ketoglutaric acid ( $\mathrm{D}_{6}, 98 \%$ ) |
| CLM-4442 | $\alpha$-Ketoglutaric acid, disodium salt (1,2,3,4- ${ }^{13} \mathrm{C}_{4}, 99 \%$ ) CP 97\% |
| ULM-10648 | $\alpha$-Ketoglutaric acid, disodium salt, hydrate (unlabeled) CP 90\% |
| CLM-2093 | $\alpha$-Ketoisocaproic acid, sodium salt (1-13 $\mathrm{C}, 99 \%$ ) |
| CLM-4826 | $\alpha$-Ketoisocaproic acid, sodium salt (1,2-13 $\left.\mathrm{C}_{2}, 99 \%\right)$ |
| CLM-4785 | $\alpha$-Ketoisocaproic acid, sodium salt ( ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| DLM-1944 | $\alpha$-Ketoisocaproic acid, sodium salt (methyl- ${ }_{3}, 98 \%$ ) |
| DLM-1944-MPT | $\alpha$-Ketoisocaproic acid, sodium salt (methyl-D ${ }_{3}, 98 \%$ ) |
| DLM-4214 | $\alpha$-Ketoisocaproic acid, sodium salt (isopropyl- $\mathrm{D}_{7}, 98 \%$ ) |
| CLM-6821 | $\alpha$-Ketoisovaleric acid, sodium salt (dimethyl- ${ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-4418 | $\alpha$-Ketoisovaleric acid, sodium salt ( ${ }^{13} \mathrm{C}_{5}, 98 \%$ ) |

CTM: manufactured following ICH Q7, Section XIX
MPT: microbiologically and pyrogen tested.

| Catalog No. | Description |
| :---: | :---: |
| DLM-4646 | $\alpha$-Ketoisovaleric acid, sodium salt ( $\mathrm{D}_{7}, 98 \%$ ) |
| CDLM-7317 | $\alpha$-Ketoisovaleric acid, sodium salt <br> (3-methyl- ${ }^{13} \mathrm{C}, 99 \% ; 3,4,4,4-\mathrm{D}_{4}, 98 \%$ ) |
| CDLM-8446 | $\alpha$-Ketoisovaleric acid, sodium salt (dimethyl- ${ }^{13} \mathrm{C}_{2}, 98 \%$; 3-methyl- $\mathrm{D}_{2}, 4,4-\mathrm{D}_{2}, 98 \%$ ) |
| CDLM-7354 | $\alpha$-Ketoisovaleric acid, sodium salt <br> (3-methyl- ${ }^{13}$ C, 99\%; 3-methyl- $D_{2}, 3,4,4,4, D_{4}, 98 \%$ ) |
| CDLM-8100 | $\alpha$-Ketoisovaleric acid, sodium salt $\text { (1,2,3,4- } \left.{ }^{13} C_{4}, 99 \% ; 3,4^{\prime}, 4^{\prime}, 4^{\prime}-D_{4}, 97-98 \%\right)$ |
| CDLM-4418 | $\alpha$-Ketoisovaleric acid, sodium salt ( ${ }^{13} \mathrm{C}_{5}, 98 \%$; 3-D, 98\%) |
| DLM-7842 | L-Kynurenine sulfate (ring-D ${ }_{4}, 3,3-\mathrm{D}_{2}, 97 \%$ ) CP 95\% |
| CLM-9884 | L-Kynurenine sulfate $\cdot 1 / 2 \mathrm{H}_{2} \mathrm{O}\left({ }^{(13} \mathrm{C}_{10}, 99 \%\right)$ |
| DLM-1129 | Maleic acid (2,3-D ${ }_{2}, 98 \%$ ) |
| CLM-310 | Maleic anhydride ( $1,4-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-312 | Maleic anhydride ( $2,3-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-6019 | Maleic anhydride ( ${ }^{13} \mathrm{C}_{4}, 99 \%$ ) |
| DLM-1853 | Maleic anhydride ( $\mathrm{D}_{2}, 98 \%$ ) |
| DLM-9045 | DL-Malic acid ( $2,3,3-\mathrm{D}_{3}, 98 \%$ ) |
| CLM-8065 | L-Malic acid ( ${ }^{13} \mathrm{C}_{4}, 99 \%$ ) |
| CLM-10826 | Malic acid, disodium salt monohydrate $\left({ }^{13} \mathrm{C}_{4}, 99 \%\right)$ |
| DLM-2312 | DL-2-Methylcitric acid (methyl- ${ }_{3}, 98 \%$ ) CP 90\% |
| CLM-4285 | 3-Methylglutaconic acid ( $2,4-{ }^{13} \mathrm{C}_{2}, 3$-methyl- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-9426 | Methylmalonic acid ( ${ }^{13} \mathrm{C}_{4}, 99 \%$ ) |
| DLM-387 | Methylmalonic acid (methyl-D ${ }_{3}$, 98\%) |
| ULM-10578 | Methylmalonic acid, disodium salt (unlabeled) CP 95\% |
| CNLM-9247 | 3-Methyluric acid ( $\left.2,4,5,6-{ }^{13} \mathrm{C}_{4}, 99 \% ; 1,3,9-{ }^{-1} \mathrm{~N}_{3}, 98 \%\right)$ |
| CLM-3551 | Potassium phosphoenol pyruvate ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-2723 | Potassium phosphoenol pyruvate ( $3-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-3398 | Potassium phosphoenol pyruvate ( $2,3-{ }^{-13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-646 | Propionic acid ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-647 | Propionic acid ( ${ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| DLM-2488 | Propionic acid (2,2-D ${ }_{2}, 98 \%$ ) |
| DLM-1137 | Propionic acid (methyl-D. ${ }_{3}, 98 \%$ ) |
| DLM-1919 | Propionic acid ( $\mathrm{D}_{5}, 98 \%$ ) |
| DLM-599 | Propionic acid ( $\mathrm{D}_{6}, 98 \%$ ) |
| CLM-8077 | Pyruvic acid ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-8077-CTM | Pyruvic acid ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-8849 | Pyruvic acid ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) CP 95\% |
| CLM-9505 | Pyruvic acid (1,2-13 $\left.\mathrm{C}_{2}, 99 \%\right)$ |
| DLM-10675 | Pyruvic acid ( $\mathrm{D}_{4}, 98 \%$ ) |
| CDLM-10674 | Pyruvic acid (1-13C, 99\%; $\mathrm{D}_{4}, 98 \%$ ) |
| CLM-2471 | Sodium acetate - ${ }^{13} \mathrm{C}$ depleted ( $1,2-{ }^{-12} \mathrm{C}_{2}, 99.95 \%$ ) |
| CLM-156 | Sodium acetate ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-156-CTM | Sodium acetate ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-156-MPT | Sodium acetate ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-381 | Sodium acetate ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-381-MPT | Sodium acetate ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-440 | Sodium acetate (1,2-13 $\left.\mathrm{C}_{2}, 99 \%\right)$ |
| CLM-440-CTM | Sodium acetate (1,2-13 $\left.\mathrm{C}_{2}, 99 \%\right)$ |
| CLM-440-MPT | Sodium acetate (1,2-13 $\left.\mathrm{C}_{2}, 99 \%\right)$ |
| DLM-3126 | Sodium acetate ( $\mathrm{D}_{3}, 99 \%$ ) |
| DLM-3126-MPT | Sodium acetate ( $\mathrm{D}_{3}, 99 \%$ ) |
| OLM-1077 | Sodium acetate ( ${ }^{18} \mathrm{O}_{2}, 95 \%$ ) |
| CDLM-611 | Sodium acetate (1-13 ${ }^{10}, 99 \%$; $\mathrm{B}_{3}, 98 \%$ ) |

Chemical purity (CP) is $98 \%$ or greater, unless otherwise indicated.
For research use only. Not for use in diagnostic procedures.

| Catalog No. | Description |
| :---: | :---: |
| CDLM-1240 | Sodium acetate ( $2-{ }^{13} \mathrm{C}, 99 \%$; $\mathrm{D}_{3}, 98 \%$ ) |
| CDLM-3457 | Sodium acetate ( $1,2-{ }^{13} \mathrm{C}_{2}, 99 \%$; $\mathrm{D}_{3}, 98 \%$ ) |
| CLM-1256 | Sodium butyrate (1-13 $\mathrm{C}, 99 \%)$ |
| CLM-4780 | Sodium butyrate ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| DLM-641 | Sodium butyrate ( $3,3,4,4,4-\mathrm{D}_{5}, 98 \%$ ) |
| DLM-7616 | Sodium butyrate ( $\mathrm{D}_{7}, 98 \%$ ) |
| CLM-583 | Sodium formate ( ${ }^{13} \mathrm{C}, 99 \%$ ) |
| OLM-8123 | Sodium formate ( ${ }^{18} \mathrm{O}_{2}, 95 \%$ ) |
| CLM-3706 | Sodium D-3-hydroxybutyrate ( $2,4-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-3706-MPT | Sodium D-3-hydroxybutyrate ( $2,4-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-3853 | Sodium D-3-hydroxybutyrate ( ${ }^{13} \mathrm{C}_{4}, 99 \%$ ) CP 97\% |
| CLM-3853-MPT | Sodium D-3-hydroxybutyrate ( ${ }^{13} \mathrm{C}_{4}, 99 \%$ ) CP 97\% |
| DLM-10415 ${ }^{+}$ | Sodium DL-3-hydroxybutyrate ( $\mathrm{D}_{4}, 98 \%$ ) CP 95\% |
| CLM-10768 | Sodium D-lactate ( ${ }^{13} \mathrm{C}_{3}, 98 \%$ ) $20 \%$ w/w in $\mathrm{H}_{2} \mathrm{O}$ |
| CLM-1577 | Sodium L-lactate (1-13 ${ }^{13}$, 99\%) $20 \%$ w/w in $\mathrm{H}_{2} \mathrm{O}$ |
| CLM-1577-MPT | Sodium L-lactate ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) $20 \%$ w/w in $\mathrm{H}_{2} \mathrm{O}$ |
| CLM-1578 | Sodium L-lactate ( $3-{ }^{13} \mathrm{C}, 98 \%$ ) $20 \%$ w/w in $\mathrm{H}_{2} \mathrm{O}$ |
| CLM-1578-MPT | Sodium L-lactate ( $3-{ }^{13} \mathrm{C}, 98 \%$ ) $20 \%$ w/w in $\mathrm{H}_{2} \mathrm{O}$ |
| CLM-1579 | Sodium L-lactate ( ${ }^{13} \mathrm{C}_{3}, 98 \%$ ) $20 \% \mathrm{w} / \mathrm{w}$ in $\mathrm{H}_{2} \mathrm{O}$ |
| CLM-1579-MPT | Sodium L-lactate ( ${ }^{(33} \mathrm{C}_{3}, 98 \%$ ) $20 \% \mathrm{w} / \mathrm{w}$ in $\mathrm{H}_{2} \mathrm{O}$ |
| CLM-1579-N | Sodium L-lactate ( ${ }^{(3)} \mathrm{C}_{3}, 98 \%$ ) |
| DLM-9071 | Sodium L-lactate ( $3,3,3-\mathrm{D}_{3}, 98 \%$ ) $20 \%$ w/w in $\mathrm{H}_{2} \mathrm{O}$ |
| DLM-9071-MPT | Sodium L-lactate ( $3,3,3-\mathrm{D}_{3}, 98 \%$ ) $20 \% \mathrm{w} / \mathrm{w}$ in $\mathrm{H}_{2} \mathrm{O}$ |
| ULM-10651 | Sodium L-lactate (unlabeled) |
| CLM-771 | Sodium propionate ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-771-MPT | Sodium propionate ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-1506 | Sodium propionate ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-4573 | Sodium propionate ( $3-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-3042 | Sodium propionate ( $2,3-{ }^{-13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-1865 | Sodium propionate ( ${ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| CLM-1865-MPT | Sodium propionate ( ${ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| DLM-1601 | Sodium propionate ( $\mathrm{D}_{5}, 98 \%$ ) |


| Catalog No. | Description |
| :---: | :---: |
| CLM-1082 | Sodium pyruvate ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-1082-MPT | Sodium pyruvate ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-1580 | Sodium pyruvate ( $2{ }^{-13} \mathrm{C}, 99 \%$ ) |
| CLM-1575 | Sodium pyruvate ( $3-{ }^{-13} \mathrm{C}, 99 \%$ ) |
| CLM-3507 | Sodium pyruvate ( $2,3-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-2440 | Sodium pyruvate ( ${ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| DLM-6068 | Sodium pyruvate ( $\mathrm{D}_{3}, 97-98 \%$ ) |
| CLM-1084 | Succinic acid (1,4-13 $\left.\mathrm{C}_{2}, 99 \%\right)$ |
| CLM-1199 | Succinic acid (2,3-13 $\left.\mathrm{C}_{2}, 99 \%\right)$ |
| CLM-1571 | Succinic acid ( ${ }^{13} \mathrm{C}_{4}, 99 \%$ ) |
| DLM-584 | Succinic acid ( $\mathrm{D}_{4}, 98 \%$ ) |
| DLM-831 | Succinic acid ( $\mathrm{D}_{6}, 98 \%$ ) |
| ULM-10681 | Succinic acid (unlabeled) |
| CLM-9371 | Succinic acid, disodium salt ( $2,3-{ }^{-13} \mathrm{C}_{2}, 99 \%$ ) |
| DLM-2307 | Succinic acid, disodium salt ( $\mathrm{D}_{4}, 80 \%$ ) CP 95\% |
| ULM-10510 | Trisodium 2-methylcitrate (unlabeled) (racemic mixture of diastereomers) CP 90\% |
| NLM-1697 | Uric acid ( $1,3-{ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |

## Please visit isotope.com for a complete listing of organic acids and conjugate salts.

See pages 30-34 for metabolite mixtures comprising organic acids.

[^3]
## Other Compounds

| Catalog No. | Description |
| :---: | :---: |
| CLM-173 | Acetaldehyde (1,2-13 $\left.\mathrm{C}_{2}, 99 \%\right)$ |
| DLM-112 | Acetaldehyde ( $\mathrm{L}_{4}, 99 \%$ ) |
| CLM-1220 | $N$-Acetylglucosamine ( N -acetyl-1-13 ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-1827 | $N$-Acetylglucosamine ( ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| NLM-8810 | N-Acetylglucosamine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| DLM-9262 | $N, N^{\prime}$-bis(3-Aminopropyl)-1,4-butanediamine• 4 HCl ( $1,1,2,2,3,3,4,4-D_{8^{\prime}}, 97 \%$ ) CP 95\% |
| ULM-10265 | $\mathrm{N}, \mathrm{N}^{\prime}$-bis(3-Aminopropyl)-1,4-butanediamine• 4 HCl (unlabeled) CP 95\% |
| CLM-9435 | $N$-(3-Aminopropyl) butane-1,4-diamine•3HCl (spermidine-3HCI) ( ${ }^{13} \mathrm{C}_{4}, 99 \%$ ) CP 95\% |
| DLM-9261 | N -(3-Aminopropyl) butane-1,4-diamine-3 HCl (1, $1,2,2,3,3,4,4-\mathrm{D}_{8}, 98 \%$ ) CP 95\% |
| ULM-10264 | $N$-(3-Aminopropyl) butane-1,4-diamine (unlabeled) CP 95\% |
| NLM-467 | Ammonium chloride ( ${ }^{15} \mathrm{~N}, 99 \%$ ) |
| NLM-390 | Ammonium nitrate ( ${ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| NLM-390-10 | Ammonium nitrate ( ${ }^{1} \mathrm{~N}_{2}, 10 \%$ ) |
| NLM-390-5 | Ammonium nitrate ( ${ }^{15} \mathrm{~N}_{2}, 5 \%$ ) |
| NLM-711 | Ammonium nitrate (ammonium- ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| NLM-711-10 | Ammonium nitrate (ammonium- ${ }^{15} \mathrm{~N}, 10 \%$ ) |
| NLM-712 | Ammonium nitrate (nitrate- ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| NLM-712-10 | Ammonium nitrate (nitrate- ${ }^{15} \mathrm{~N}, 10 \%$ ) |
| DLM-1100 | Ammonium sulfate ( $\mathrm{D}_{8}, 98 \%$ ) |
| NLM-713 | Ammonium sulfate ( ${ }^{15} \mathrm{~N}_{2}, 99 \%$ ) |
| NLM-713-10 | Ammonium sulfate ( ${ }^{5} \mathrm{~N}_{2}, 10 \%$ ) |
| NLM-713-5 | Ammonium sulfate ( ${ }^{15} \mathrm{~N}_{2}, 5 \%$ ) |
| CLM-8141 | Arsenobetaine bromide (carboxymethyl- ${ }^{13} \mathrm{C}_{2}, 90 \%$ ) |
| CNLM-9695 | 5-Azacytosine (4,6-13 $\mathrm{C}_{2}, 98 \%$; $\left.{ }^{15} \mathrm{~N}_{4}, 98 \%\right)$ |
| DLM-10766 | Aztreonam ( $\mathrm{D}_{6}, 98 \%$ ) CP 95\% |
| DLM-10665 | Bilirubin ( $\mathrm{D}_{4}, \sim 70-80 \%$ ) CP 97\% |
| NLM-499 | Calcium nitrate ( ${ }^{15} \mathrm{~N}_{2}, 98 \%$ ) |
| NLM-499-10 | Calcium nitrate ( ${ }^{15} \mathrm{~N}_{2}, 10 \%$ ) |
| CLM-10642 | P-Coumaric acid (propyl- ${ }^{13} \mathrm{C}_{3}, 99 \%$ ) CP 99\% |
| DLM-9786 | P-Cresol sulfate, potassium salt ( $\mathrm{D}_{7}, 98 \%$ ) CP 95\% |
| DLM-10544 | Desethylamodiaquine (ethyl-D ${ }_{5}, 97 \%$ ) |
| DLM-4 | Deuterium oxide ( $\mathrm{D}, 99.9 \%$ ) |
| DLM-4-99.8 | Deuterium oxide (D, 99.8\%) |
| DLM-4-99 | Deuterium oxide (D, 99\%) |
| CLM-9255 | 1,3-Diaminobenzene $\left({ }^{13} \mathrm{C}_{6}, 99 \%\right)$ CP 95\% |
| CLM-7254 | O, $\mathrm{O}^{\prime}$-Dityrosine (ring- ${ }^{13} \mathrm{C}_{12}, 99 \%$ ) |
| CLM-344 | Ethanol (1-13 $\left.{ }^{13}, 99 \%\right)<6 \% \mathrm{H}_{2} \mathrm{O}$ |
| CLM-130 | Ethanol ( $2-{ }^{13} \mathrm{C}, 99 \%$ ) <6\% $\mathrm{H}_{2} \mathrm{O}$ |
| CLM-551 | Ethanol ( $\left.1,2-{ }^{13} \mathrm{C}_{2}, 99 \%\right)<6 \% \mathrm{H}_{2} \mathrm{O}$ |


| Catalog No. | Description |
| :---: | :---: |
| CLM-2291 | Ethanolamine ( ${ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| DLM-552 | Ethanolamine ( $1,1,2,2-\mathrm{D}_{4}, 98 \%$ ) |
| NLM-8722 | Ethanolamine ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CLM-3911 | Ethanolamine• $\mathrm{HCl}\left(1-1{ }^{13} \mathrm{C}, 99 \%\right)$ |
| CLM-274 | Ethanolamine• $\mathrm{HCl}\left(1,2-{ }^{13} \mathrm{C}_{2}, 99 \%\right)$ |
| CLM-10773 | Ethyl-4-chloroacetoacetate ( $1,2,3,4-{ }^{13} \mathrm{C}_{4}, 99 \%$ ) |
| DLM-10667 | Ethyl hexacosanoate (hexacosanoyl-12,12,13,13-D, $98 \%$ ) |
| NLM-6723 | Guanidine $\mathrm{HBr}\left({ }^{15} \mathrm{~N}_{3}, 98 \%\right)$ |
| DLM-2338 | 1-Hexene ( $\mathrm{D}_{12}, 98 \%$ ) |
| CLM-10368 | Hydrocinnamic acid (1-13 C, 99\%) |
| CLM-9260 | 4-Hydroxy-3-methoxycinnamic acid (ferulic acid) $\left(1^{\prime}, 2^{\prime}, 3^{\prime}-{ }^{13} C_{3}, 99 \%\right)$ |
| CNLM-10399 | DL-3-Hydroxykynurenine <br> ( $1,2,3-{ }^{13} \mathrm{C}_{3}, 98 \% ; \alpha$-amino- ${ }^{15} \mathrm{~N}, 98 \%$ ) CP 95\% |
| CNLM-10539 | Mecamylamine. HCl (tetramethyl- ${ }^{13} \mathrm{C}_{4}, 99 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CLM-359 | Methanol ( ${ }^{13} \mathrm{C}, 99 \%$ ) |
| DLM-1211 | Methanol ( $\mathrm{D}, 98 \%$ ) |
| DLM-1209 | Methanol ( $\mathrm{D}_{2}, 98 \%$ ) |
| CDLM-1035 | Methanol ( ${ }^{13} \mathrm{C}, 99 \%$; $\mathrm{D}_{3}, 98 \%$ ) |
| CLM-10706 | Methylcarbamate ( $1-{ }^{13} \mathrm{C}, 99 \%$ ) |
| DLM-651 | Methyl formate (formyl-D, 99\%) |
| DLM-9039 | Morpholine (3,3,5,5-D ${ }_{4}$, 98\%) |
| CLM-10700 | Pentanoic acid, pentyl ester ( ${ }^{13} \mathrm{C}_{10}, 99 \%$ ) |
| CLM-10410 | Porphobilinogen (propanoic-1, $2-{ }^{-13} \mathrm{C}_{2}, 99 \%$ ) CP 95\% |
| NLM-765 | Potassium nitrate ( ${ }^{15} \mathrm{~N}, 99 \%$ ) |
| NLM-765-10 | Potassium nitrate ( ${ }^{15} \mathrm{~N}, 10 \%$ ) |
| CLM-222 | Potassium thiocyanate ( ${ }^{13} \mathrm{C}, 95-99 \%$ ) CP 95\% |
| CNLM-3952 | Potassium thiocyanate ( ${ }^{13} \mathrm{C}, 99 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| DLM-10542 | Resorufin ( $\mathrm{D}_{6}, 98 \%$ ) CP 96\% |
| DLM-3579 | Serotonin creatinine sulfate complex ( $\alpha, \alpha, \beta, \beta-D_{4}, 98 \%$ ) |
| CLM-441 | Sodium bicarbonate ( ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-441-MPT | Sodium bicarbonate ( ${ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-9676 | Sodium isopropyl carbonate (carbonyl- ${ }^{13} \mathrm{C}, 99 \%$ ) |
| NLM-157 | Sodium nitrate ( ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CLM-3780 | Sodium dichloroacetate ( ${ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-10417 | Toxoflavin (3,4 $\alpha, 5,8 \alpha-{ }^{13} \mathrm{C}_{4}, 98 \%$ ) CP 95\% |
| CLM-10839 | Triacetin (triacetyl ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| CNLM-9258 | 1,2,4-Triazole ( $3,5-{ }^{13} \mathrm{C}_{2}, 99 \% ; 1,2,4-{ }^{15} \mathrm{~N}_{3}, 98 \%$ ) |
| DLM-4779 | Trimethylamine N -oxide ( $\mathrm{D}_{9}, 98 \%$ ) |
| CLM-10543 | cis-Urocanic acid (1,2,3-13 $\left.\mathrm{C}_{3}, 99 \%\right)$ |

Please visit isotope.com for a complete product listing.

MPT: microbiologically and pyrogen tested.
Chemical purity (CP) is 98\% or greater, unless otherwise indicated. For research use only. Not for use in diagnostic procedures.

## Steroids and Hormones

| Catalog No. | Description |
| :---: | :---: |
| DLM-8438* | Aldosterone ( $2,2,4,6,6,17,21,21-\mathrm{D}_{8}$ ) |
| ULM-9134 ${ }^{\text { }}$ | Aldosterone (unlabeled) CP 95\% |
| CLM-10548 | 5 $\alpha$-Androstan-3,17-dione (androstanedione) $\left(2,3,4-{ }^{13} \mathrm{C}_{3}, 98 \%\right)$ |
| ULM-8794* | $5 \alpha$-Androstan-3,17-dione (androstanedione) (unlabeled) |
| DLM-9769* | $5 \alpha-A n d r o s t a n-3 \alpha-o l-17 \beta$-diol (16,16,17-D ${ }_{3}$, 98\%) CP 95\% |
| ULM-9752* | $5 \alpha$-Androstan-3 $\alpha$-ol-17 $\beta$-diol (unlabeled) |
| DLM-10269 | $5 \alpha$-Androstan-3 $\beta$-ol-17-one (epiandrosterone) $\left(2,2,4,4-D_{4}, 98 \%\right)$ |
| ULM-10270 | $5 \alpha$-Androstan-3 $\beta$-ol-17-one (epiandrosterone) (unlabeled) |
| DLM-8750 | $5 \beta$-Androstan-3 $\alpha$-ol-17-one (etiocholanolone) $\left(16,16-D_{2}, 98 \%\right)$ |
| DLM-10008* | $5 \beta$-Androstan-3 $\alpha$-ol-17-one (etiocholanolone) $\left(2,2,3,4,4-D_{5}, 98 \%\right)$ |
| ULM-10009* | $5 \beta$-Androstan-3 $\alpha$-ol-17-one (etiocholanolone) (unlabeled) |
| ULM-10732 | $5 \alpha$-Androstane-3 $3,17 \beta$-diol (unlabeled) |
| DLM-9787 | Androstanediol glucuronide, sodium salt (16,16,17-D ${ }_{3}, 98 \%$ ) CP 97\% |
| DLM-10397 | 4-Androsten-11 $\beta, 17 \beta$-diol-3-one (9,11,12,12-D ${ }_{4}, 98 \%$ ) CP 95\% |
| DLM-10396 | 4-Androsten-11 $\beta$-ol-3,17-dione (9,11,12,12-D ${ }_{4}, 98 \%$ ) |
| DLM-9697 | 4-Androsten-11 $\beta$-ol-3,17-dione (2,2,4,6,6,16,16-D ${ }_{7}, 98 \%$ ) |
| DLM-10401 | 5-Androsten-3ק,17ק-diol (16,16,17-D ${ }_{3}, 98 \%$ ) CP 95\% |
| CLM-9135* | 4-Androstene-3,17-dione ( $2,3,4-{ }^{13} C_{3}, 98 \%$ ) |
| DLM-8330 | 4-Androstene-3,17-dione (2,2,4,6,6-D $\left.{ }_{5}, 98 \%\right)$ |
| DLM-7976 | 4-Androstene-3,17-dione ( $2,2,4,6,6,16,16-\mathrm{D}_{7}, 97 \%$ ) |
| ULM-8472* | 4-Androstene-3,17-dione (unlabeled) |
| DLM-10420 ${ }^{\ddagger}$ | 4-Androstene-6ß,17ß-diol-3-one (16,16,17-D ${ }_{3}$, 98\%) |
| DLM-7937 | Androsterone ( $5 \alpha$-androstan-3 $\alpha$-ol-17-one) $\left(16,16-D_{2}, 98 \%\right)$ |
| DLM-10402 ${ }^{\ddagger}$ | Androsterone ( $5 \alpha$-androstan-3 $\alpha$-ol-17-one) (2,2,4,4-D ${ }_{4}, 98 \%$ ) CP 95\% |
| ULM-10403* | Androsterone ( $5 \alpha$-androstan-3 $\alpha$-ol-17-one) (unlabeled) |
| DLM-9137 | Androsterone glucuronide, sodium salt ( $2,2,4,4-\mathrm{D}_{4}, 98 \%$ ) |
| ULM-9138 | Androsterone glucuronide, sodium salt (unlabeled) |
| DLM-4700 | Cholestane (3,3-D ${ }_{2}, 98 \%$ ) |
| DLM-8276 | Cholestenone (2,2,4,6,6-D $\left.{ }_{5}, 98 \%\right)$ |
| CLM-804 | Cholesterol ( $3,4-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-804-CTM | Cholesterol ( $3,4-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-9139* | Cholesterol ( $2,3,4-{ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| CLM-9587* | Cholesterol ( $23,24,25,26,27-{ }^{13} \mathrm{C}_{5}, 99 \%$ ) |
| DLM-1831 | Cholesterol (3-D, 97\%) |
| DLM-7260 | Cholesterol ( $25,26,26,26-\mathrm{D}_{4}, 98 \%$ ) |
| DLM-2607 ${ }^{\text { }}$ | Cholesterol ( $2,2,3,4,4,6-\mathrm{D}_{6}, 97-98 \%$ ) |
| DLM-3057 | Cholesterol ( $25,26,26,26,27,27,27-\mathrm{D}_{7}, 98 \%$ ) |
| OLM-7695 | Cholesterol ( ${ }^{18} \mathrm{O}, 95 \%$ ) |
| ULM-9140* | Cholesterol (unlabeled) CP 97\% |
| CLM-3361 | Cholesterol-3-octanoate (octanoate-1-13 $\mathrm{C}, 99 \%$ ) |
| DLM-10416 | Cholesterol-3-sulfate, sodium salt (25,26,26,26,27,27,27-D, $98 \%)$ |

CTM: manufactured following ICH Q7, Section XIX
*Compounds available in dry and solution forms.
+Compounds available in solution only.
\#Compounds available in dry and solution forms; chemical purity varies 95-98\%
Chemical purity (CP) is $98 \%$ or greater, unless otherwise indicated.
For research use only. Not for use in diagnostic procedures.

| Catalog No. | Description |
| :---: | :---: |
| DLM-7347 | Corticosterone (2,2,4,6,6,17 ${ }^{\text {, 21, }}$, $11-\mathrm{D}_{8}, 97-98 \%$ ) |
| ULM-9988* | Corticosterone (unlabeled) |
| CLM-10371 ${ }^{+}$ | Cortisol ( $2,3,4-{ }^{13} C_{3}, 99 \%$ ) |
| DLM-2615 | Cortisol (1,2-D ${ }_{2}, 98 \%$ ) |
| DLM-2057 | Cortisol (9,12,12-D $\left.{ }_{3}, 98 \%\right)$ |
| DLM-2218 | Cortisol (9,11,12,12-D $\left.{ }_{4}, 98 \%\right)$ |
| ULM-9141* | Cortisol (unlabeled) |
| CLM-10536 ${ }^{+}$ | Cortisone ( $2,3,4-{ }^{13} \mathrm{C}_{3}, 98 \%$ ) CP 97\% |
| DLM-8863 | Cortisone (1,2-D ${ }_{2}, 98 \%$ ) CP 95\% |
| DLM-9142* | Cortisone ( $\left.2,2,4,6,6,12,12-D_{7}\right)$ |
| DLM-9976 | Cortisone (2,2,4,6,6,9,12,12-D ${ }_{8}, 98 \%$ ) |
| ULM-9202* | Cortisone (unlabeled) |
| CLM-10537 ${ }^{+}$ | Cortisone 21 -sulfate, sodium salt $\left(2,3,4-{ }^{13} C_{3}, 98 \%\right)$ CP 95\% |
| DLM-4216 | 7-Dehydrocholesterol ( $25,26,26,26,27,27,27-\mathrm{D}_{7}, 98 \%$ ) |
| DLM-10748 | 8-Dehydrocholesterol ( $25,26,26,26,27,27,27-D_{7}, 92 \%$ ) CP 95\% |
| CLM-10549* | Dehydroepiandrosterone (DHEA) $\left(2,3,4-{ }^{13} \mathrm{C}_{3}, 99 \%\right)$ |
| DLM-7714 | Dehydroepiandrosterone (DHEA) ( $16,16-\mathrm{D}_{2}, 97 \%$ ) |
| DLM-8049* | Dehydroepiandrosterone (DHEA) (2,2,3,4,4,6-D $6,98 \%$ ) CP 97\% |
| ULM-9143* | Dehydroepiandrosterone (DHEA) (unlabeled) |
| CLM-10784* | Dehydroepiandrosterone sulfate, sodium salt (DHEAS) $\left(2,3,4-{ }^{13} C_{3}, 98 \%\right)$ |
| DLM-8701 | Dehydroepiandrosterone sulfate, sodium salt (DHEAS) $\left(16,16-D_{2}, 97 \%\right)$ |
| DLM-8337* | Dehydroepiandrosterone sulfate, sodium salt (DHEAS) $\left(2,2,3,4,4,6-D_{6}, 95 \%\right)$ |
| ULM-9144* | Dehydroepiandrosterone sulfate, sodium salt (DHEAS) (unlabeled) |
| CLM-10384* | 11-Deoxycortisol (2,3,4-13 $\left.\mathrm{C}_{3}, 99 \%\right)$ CP 97\% |
| DLM-7209 | 11-Deoxycortisol (21,21-D $\left.{ }_{2}, 96 \%\right)$ |
| DLM-8336* | 11-Deoxycortisol ( $2,2,4,6,6-\mathrm{D}_{5}, 98 \%$ ) |
| ULM-9145* | 11-Deoxycortisol (unlabeled) |
| DLM-8305 | 21-Deoxycortisol (2,2,4,6,6,21,21,21-D ${ }_{8}, 97 \%$ ) |
| ULM-9987* | 21-Deoxycortisol (unlabeled) |
| DLM-170* | DiethyIstilbestrol (cis/trans mix) (ring-3,3',5,5'-diethyl-1,1, $\left.1^{\prime}, 1^{\prime}-D_{8}, 98 \%\right)$ |
| CLM-9146* | $5 \alpha$-Dihydrotestosterone ( $2,3,4-{ }^{13} \mathrm{C}_{3}, 99 \%$ ) CP 97\% |
| DLM-9041 | $5 \alpha$-Dihydrotestosterone ( $2,2,4,4-\mathrm{D}_{4}, 98 \%$ ) CP 95\% |
| ULM-8364* | $5 \alpha$-Dihydrotestosterone (unlabeled) |
| DLM-3023 | Dihydrotestosterone (16,16,17-D ${ }_{3}, 98 \%$ ) |
| CLM-9222* | L-3,3'-Diiodothyronine (T2) (phenoxy- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) CP 97\% |
| ULM-9223* | L-3,3'-Diiodothyronine (T2) (unlabeled) |
| CLM-7401 | L-Dopa (1-13C, 99\%) |
| CLM-1007 | L-Dopa (ring- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| CLM-7824 | L-Dopa ( $1-{ }^{13} \mathrm{C}$, ring- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| DLM-2084 | L-Dopa (ring- $\mathrm{D}_{3}, 98 \%$ ) |
| COLM-2232 | L-Dopa ( $2,3-{ }^{13} \mathrm{C}_{2}, 97 \%$; 4-hydroxy- ${ }^{18} \mathrm{O}, 95 \%$ ) |
| CLM-7768 | Epicholesterol ( $3,4-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| DLM-9088 | DL-Epinephrine (ring-D ${ }_{3}, 1,2,2-\mathrm{D}_{3}, 98 \%$ ) |
| CNLM-7889 | DL-Epinephrine ( $1,2-{ }^{13} \mathrm{C}_{2}, 99 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |

Steroids and Hormones (continued)

| Catalog No. | Description |
| :---: | :---: |
| CLM-803* | Estradiol ( $3,4-{ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| DLM-3694 | Estradiol (16,16,17-D ${ }_{3}, 98 \%$ ) CP 95\% |
| DLM-2487 | Estradiol (2,4,16,16-D $\left.{ }_{4}, 95-97 \%\right)$ |
| ULM-7449* | Estradiol (unlabeled) |
| CLM-9147* | Estriol ( $16 \alpha$-hydroxyestradiol) (2,3,4-13 $\mathrm{C}_{3}, 99 \%$ ) CP 97\% |
| DLM-8586 | Estriol ( $2,4,16-\mathrm{D}_{3}, 98 \%$ ) CP 96\% |
| DLM-8343 | Estriol (2,4,17-D ${ }_{3}, 98 \%$ ) CP 96\% |
| CLM-673 ${ }^{\ddagger}$ | Estrone (3,4- ${ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| CLM-9148* | Estrone ( $2,3,4-{ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| DLM-3976 | Estrone (2,4,16,16-D $\left.{ }_{4}, 97 \%\right)$ |
| CLM-8033 | DL-Estrone 3-methyl ether ( $13,14,15,16,17,18-{ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| DLM-4691 | 17 $\alpha$-Ethynylestradiol (2,4,16,16-D ${ }_{4}, 97-98 \%$ ) |
| ULM-10267 | $7 \alpha$-Hydroxycholesterol (unlabeled) |
| DLM-8646 | $7 \beta$-Hydroxycholesterol ( $25,26,26,26,27,27,27-D_{7}, 98 \%$ ) CP 97\% |
| ULM-10268 | $7 \beta$-Hydroxycholesterol (unlabeled) |
| DLM-9150 ${ }^{\text { }}$ | 18-Hydroxycorticosterone (9,11,12,12-D. ${ }_{4}$, 98\%) CP 95\% |
| ULM-9151* | 18-Hydroxycorticosterone (unlabeled) CP 95\% |
| DLM-9149 | $6 \beta$-Hydroxycortisol (9,11,12,12-D ${ }^{\text {) CP }}$ 95\% |
| CLM-8012 | DL-2-Hydroxyestradiol ( $13,14,15,16,17,18-{ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| CLM-8016 | DL-2-Hydroxyestrone-3-methyl ether $\left(13,14,15,16,17,18-{ }^{13} C_{6}, 99 \%\right)$ |
| CLM-9153* | $16 \alpha$-Hydroxyestrone ( $2,3,4-{ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| ULM-9152* | 16 $\alpha$-Hydroxyestrone (unlabeled) |
| CLM-8013 | DL-4-Hydroxyestrone ( $13,14,15,16,17,18-{ }^{13} \mathrm{C}_{6}, 99 \%$ ) CP 97\% |
| CLM-9936* | 5-Hydroxyindole-3-acetic acid ( $3 \alpha, 4,5,6,7,7 \alpha-{ }^{13} \mathrm{C}_{6}, 98 \%$ ) |
| DLM-7206 | $17 \alpha$-Hydroxypregnenolone ( $21,21,21-\mathrm{D}_{3}, 97 \%$ ) |
| CDLM-9154* | 17 $\alpha$-Hydroxypregnenolone <br> (20,21- $\left.{ }^{13} \mathrm{C}_{2}, 98 \% ; 16,16-\mathrm{D}_{2}, 98 \%\right)$ |
| ULM-9155* | 17 $\alpha$-Hydroxypregnenolone (unlabeled) |
| CLM-9157* | $17 \alpha$-Hydroxyprogesterone ( $2,3,4-{ }^{13} \mathrm{C}_{3}, 98 \%$ ) |
| DLM-6598 | 17 $\alpha$-Hydroxyprogesterone ( $2,2,4,6,6,21,21,21-\mathrm{D}_{8}, 98 \%$ ) |
| ULM-9156* | 17 $\alpha$-Hydroxyprogesterone (unlabeled) |
| DLM-8647 | 7-Ketocholesterol (25,26,26,26,27,27,27-D ${ }^{\text {, }}$, 99\%) |
| DLM-10395 | 11-Ketotestosterone (16,16,17-D ${ }_{3}, 98 \%$ ) CP 95\% |
| DLM-7101 | Melatonin (acetyl- ${ }_{3}, 98 \%$ ) |
| CLM-8015 | DL-2-Methoxyestradiol ( $13,14,15,16,17,18-{ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| CLM-8014 | DL-2-Methoxyestrone ( $13,14,15,16,17,18-{ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| CLM-8017 | DL-4-Methoxyestrone ( $13,14,15,16,17,18-{ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| DLM-2646 | 5-Methoxytryptamine $\cdot \mathrm{HCl}\left(\alpha, \alpha, \beta, \beta-\mathrm{D}_{4}, 98 \%\right)$ |
| CLM-2468 | Norethindrone (ethynyl- ${ }^{13} \mathrm{C}_{2}, 99 \%$ ) |
| DLM-3979* | 19-Nortestosterone (16,16,17- $\mathrm{D}_{3}, 98 \%$ ) |
| DLM-3754 | 5 -Pregnan-3 $\alpha$-ol-20-one (17,21,21,21-D CP 95\% 96-98\%) CP 95\% |
| DLM-7492 | 5 $\alpha$-Pregnan-3 $\beta$-ol-20-one ( $17 \alpha, 21,21,21-D_{4}, 97 \%$ ) CP 96\% |
| ULM-8242 | $5 \alpha$-Pregnan-3 $\beta$-ol-20-one (unlabeled) |
| DLM-2294 | $5 \beta$-Pregnan-3 $\alpha$-ol-20-one (17,21,21,21-D ${ }_{4}, 96-98 \%$ ) |
| DLM-8751 | $5 \beta$-Pregnan- $3 \alpha, 11 \beta, 17 \alpha, 21$-tetrol-20-one (9,11 $\alpha, 12-\mathrm{D}_{3}, 95 \%$ ) |


| Catalog No. | Description |
| :---: | :---: |
| DLM-8753 | $5 \beta$-Pregnan-3 $\alpha, 17 \alpha, 20$-triol (20,21,21,21-D $\left.{ }_{4}, 98 \%\right)$ mix of $20 \alpha$ and $20 \beta$ |
| DLM-3910 | $5 \alpha$-Pregnane-3 $\alpha$, 21-diol-20-one (17,21,21- $\mathrm{D}_{3}, 95 \%$ ) |
| DLM-3816 | $5 \alpha$-Pregnane-3,20-dione (1,2,4,5,6,7-D ${ }_{6}, 95 \%$ ) |
| ULM-10385 | $5 \alpha$-Pregnane-3 2,21 -diol-20-one (unlabeled) |
| DLM-9901 | 5 $\beta$-Pregnane-3,20-dione <br> (2,2,4,4,17 $\left., 21,21,21-D_{8,}, 98 \%\right)$ CP 97\% |
| CLM-10411 | $5 \beta$-Pregnane-3 $\alpha, 20 \alpha$-diol $\left(2,3,4,20,21-{ }^{13} \mathrm{C}_{5}, 99 \%\right)$ CP 95\% |
| DLM-10413 | $5 \beta$-Pregnane-3 $\alpha, 20 \alpha$-diol ( $2,2,3,4,4-\mathrm{D}_{5}, 98 \%$ ) |
| CLM-10412 | $5 \beta$-Pregnane- $3 \alpha, 20 \alpha$-diol glucuronide, sodium salt (2,3,4,20,21-13 $\left.C_{5}, 99 \%\right)$ CP 95\% |
| CLM-10010* | 4-Pregnen-21-ol-3,20-dione ( $2,3,4-{ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| DLM-7228 | 4-Pregnen-21-ol-3,20-dione <br> (2,2,4,6,6,17,21,21-D ${ }_{8}, 96 \%$ ) CP 97\% |
| ULM-10011* | 4-Pregnen-21-ol-3,20-dione (unlabeled) |
| CDLM-9158* | Pregnenolone ( $20,21-{ }^{13} \mathrm{C}_{2}, 98 \% ; 16,16-\mathrm{D}_{2}, 98 \%$ ) |
| DLM-6896 | Pregnenolone (17,21,21,21-D ${ }_{4}$, 98\%) |
| ULM-9159* | Pregnenolone (unlabeled) |
| CDLM-9160 | Pregnenolone sulfate, sodium salt (20,21- $\left.{ }^{13} \mathrm{C}_{2}, 99 \% ; 16,16-\mathrm{D}_{2}, 98 \%\right)$ |
| ULM-9161 | Pregnenolone sulfate, sodium salt (unlabeled) |
| CLM-457 | Progesterone ( $3,4-{ }^{13} \mathrm{C}_{2}, 90 \%$ ) |
| CLM-9162* | Progesterone ( $2,3,4-{ }^{-13} \mathrm{C}_{3}, 99 \%$ ) |
| CLM-10414 | Progesterone ( $2,3,4,20,21-{ }^{13} \mathrm{C}_{5}, 99 \%$ ) |
| DLM-7953* | Progesterone ( $2,2,4,6,6,17 \alpha, 21,21,21-\mathrm{D}_{9}, 98 \%$ ) |
| DLM-3627 ${ }^{+}$ | Prostaglandin A2 ( $3,3,4,4-\mathrm{D}_{4}, 98 \%$ ) |
| DLM-3728 ${ }^{+}$ | Prostaglandin E1 (3,3,4,4-D $\left.{ }_{4}, 98 \%\right)$ |
| DLM-3628 ${ }^{+}$ | Prostaglandin E2 (3,3,4,4-D $\left.{ }_{4}, 98 \%\right)$ |
| DLM-3558 ${ }^{+}$ | Prostaglandin-F2 $\alpha$ (3,3,4,4-D ${ }_{4}, 98 \%$ ) |
| DLM-4200 ${ }^{+}$ | $9 \alpha, 11 \alpha$-Prostaglandin F2 (3, $\left.3^{\prime}, 4,4^{\prime}-\mathrm{D}_{4}, 98 \%\right)$ |
| DLM-7457 | Sodium $17 \beta$-estradiol 3 -sulfate ( $2,4,16,16-D_{4}, 98 \%$ ) stabilized with $50 \% \mathrm{w} / \mathrm{w}$ tris |
| DLM-9503 | Stigmastanol ( $2,2,3,4,4-\mathrm{D}_{5}, 98 \%$ ) |
| CLM-159 | Testosterone (3,4-13 $\left.\mathrm{C}_{2}, 99 \%\right)$ |
| CLM-9164* | Testosterone ( $2,3,4-{ }^{13} \mathrm{C}_{3}, 99 \%$ ) |
| DLM-683 | Testosterone (1,2-D ${ }_{2}, 98 \%$ ) |
| DLM-6224* | Testosterone (16,16,17-D ${ }_{3}$, 98\%) |
| DLM-8085* | Testosterone ( $2,2,4,6,6-\mathrm{D}_{5}, 98 \%$ ) |
| DLM-8265 | Testosterone diacetate (testosterone-D ${ }_{4}$, acetate methyl- $\mathrm{D}_{6}, 98 \%$ ) |
| ULM-9163 | $3 \alpha, 5 \beta$-Tetrahydroaldosterone (unlabeled) |
| CLM-6725 | L-Thyroxine (tyrosine-ring- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) CP 90\% |
| CLM-8931 | L-Thyroxine (ring- ${ }^{13} \mathrm{C}_{12}, 99 \%$ ) CP 97\% |
| ULM-8184 | L-Thyroxine (unlabeled) |
| CLM-7185* | 3,3',5-Triiodo-L-thyronine $\cdot \mathrm{HCl}$ (ring- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) $\mathrm{CP}>95 \%$ |
| DLM-6989 | Tryptamine $\cdot \mathrm{HCl}\left(\alpha, \alpha, \beta, \beta-\mathrm{D}_{4}, 97 \%\right)$ |

Please visit isotope.com for a complete listing of steroids and hormones.
*Compounds available in dry and solution forms
† Compounds available in solution only.
\#Compounds available in dry and solution forms; chemical purity varies 95-98\%
Chemical purity (CP) is $98 \%$ or greater, unless otherwise indicated.
For research use only. Not for use in diagnostic procedures.

## Vitamins and Their Metabolites

| Catalog No. | Description |
| :---: | :---: |
| CLM-6126 | $\beta$-Carotene ( $10,10^{\prime}, 11,11^{\prime}-1{ }^{13} \mathrm{C}_{4}, 99 \%$ ) |
| CLM-9641 | $\beta$-Carotene <br> (12,12',13,13', 14, 14', 15, 15',20,20'- ${ }^{13} \mathrm{C}_{10}, 99 \%$ ) $\mathrm{CP}>97 \%$ |
| DLM-3829 | $\beta$-Carotene (19,19,19,19',19',19'-D $\left.6_{6}, 98 \%\right)$ |
| DLM-2439 | $\beta$-Carotene (10, $\left.10^{\prime}, 19,19,19,19^{\prime}, 19^{\prime}, 19^{\prime}-\mathrm{D}_{8}, 97 \%\right)$ |
| DLM-10279 | Coenzyme Q10 (dimethoxy-D ${ }_{6}$, methyl- $\mathrm{D}_{3}, 98 \%$ ) CP 97\% |
| ULM-9106* | 1,25-Dihydroxyvitamin D2 (unlabeled) CP 95\% |
| ULM-9109* | 24,25-Dihydroxyvitamin D2 (unlabeled) |
| DLM-9107* | 1,25-Dihydroxyvitamin D3 (6,19,19-D ${ }_{3}, 97 \%$ ) CP 95\% |
| ULM-9108* | 1,25-Dihydroxyvitamin D3 (unlabeled) CP 95\% |
| DLM-9404* | 24R,25-Dihydroxyvitamin D3 (26,26,26,27,27,27-D $\left.{ }_{6}, 98 \%\right)$ CP 97\% |
| ULM-10610* | 24R, 25-Dihydroxyvitamin D3 (unlabeled) CP 97\% |
| DLM-9481 | 3-epi-25-Hydroxyvitamin D2 (6,19,19-D $\left.{ }_{3}, 98 \%\right)$ |
| ULM-9110* | 3-epi-25-Hydroxyvitamin D2 (unlabeled) |
| CLM-9113 ${ }^{+}$ | $25-H y d r o x y v i t a m i n ~ D 2 ~(~ 25,26,27-13 ~[~ 3, ~ 99 \%) ~ C P ~ 95 \% ~$ |
| DLM-9114* | 25-Hydroxyvitamin D2 (6,19,19-D ${ }_{3}, 97 \%$ ) |
| ULM-9115* | 25-Hydroxyvitamin D2 (unlabeled) |
| DLM-10611 ${ }^{+}$ | 25-Hydroxyvitamin D2 sulfate, sodium salt (6,19,19-D ${ }_{3}$, $97 \%$ ) CP 97\% |
| ULM-10612 ${ }^{+}$ | 25-Hydroxyvitamin D2 sulfate, sodium salt (unlabeled) CP 97\% |
| CLM-10266* | 3-epi-25-Hydroxyvitamin D3 (23,24,25,26,27- $\left.{ }^{13} \mathrm{C}_{5}, 99 \%\right)$ |
| DLM-9111* | 3 -epi-25-Hydroxyvitamin D3 (6,19,19-D ${ }_{3}, 98 \%$ ) |
| DLM-10912 | 3-epi-25-Hydroxyvitamin D3 $\left(26,26,26,27,27,27-D_{6}, 96 \%\right) \text { CP 95\% }$ |
| ULM-9112* | 3-epi-25-Hydroxyvitamin D3 (unlabeled) |
| CLM-10025* | 25 -Hydroxyvitamin D3 ( $23,24,25,26,27-{ }^{13} \mathrm{C}_{5}, 99 \%$ ) CP 95\% |
| DLM-9116* | 25-Hydroxyvitamin D3 (6,19,19-D ${ }_{3}$, 97\%) |
| ULM-9117* | 25-Hydroxyvitamin D3 (unlabeled) |
| DLM-7708* | 25-Hydroxyvitamin D3 monohydrate $\left(26,26,26,27,27,27-D_{6}, 98 \%\right) \text { CP 97\% }$ |
| CLM-7613 | $\begin{aligned} & \text { trans-Lycopene } \\ & \left(8,8^{\prime}, 9,99^{\prime}, 10,10^{\prime}, 11,11^{\prime}, 19,19^{\prime}-{ }^{13} \mathrm{C}_{10}, 99 \%\right) \end{aligned}$ |
| CLM-9548 | 5-Methyltetrahydrofolic acid (glutamic acid- ${ }^{13} \mathrm{C}_{5}, 99 \%$ ) CP 95\% |
| CLM-7321-N | 5-Methyltetrahydrofolic acid, calcium salt (glutamic acid- ${ }^{13} \mathrm{C}_{5}, 98 \%$ ) CP 95\% |
| CLM-7321 | (6S)-5-Methyltetrahydrofolic acid, calcium salt (glutamic acid- ${ }^{-13} \mathrm{C}_{5}, 90 \%$ ) contains $\sim 10 \% \mathrm{H}_{2} \mathrm{O}$ |
| CNLM-9757 | Nicotinamide ( 2,6, carbonyl- ${ }^{13} \mathrm{C}_{3}, 99 \%$; ring-1-15 $\mathrm{N}, 98 \%$ ) |
| DLM-9793-N | Pyridoxal phosphate (mix of 5-,3-isomers) (methyl-D ${ }_{3}, 97 \%$ ) |
| CLM-7563 | Pyridoxine• $\mathrm{HCl}\left(4,5\right.$-bis(hydroxymethyl)-- ${ }^{13} \mathrm{C}_{4}, 99 \%$ ) |
| DLM-8754 | Pyridoxine•HCl (5-hydroxymethyl- ${ }_{2}$, 98\%) |
| CLM-320 | Vitamin A (retinal) ( $10-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-325 | Vitamin A (retinal) (11-13C, 99\%) |
| CLM-326 | Vitamin A (retinal) (14-13C, 99\%) |
| CLM-327 | Vitamin A (retinal) ( $15-{ }^{13} \mathrm{C}, 98 \%$ ) |
| DLM-7719 | Vitamin A (retinal) (19,19, 19,20,20,20-D ${ }_{6}, 96 \%$ ) |


| Catalog No. | Description |
| :---: | :---: |
| CLM-331 | Vitamin A (retinoic acid) (10-13 ${ }^{13}$, 99\%) |
| CLM-328 | Vitamin A (retinoic acid) (11-13 $\mathrm{C}, 98 \%)$ |
| CLM-329 | Vitamin A (retinoic acid) (14-13 $\mathrm{C}, 99 \%)$ |
| CLM-330 | Vitamin A (retinoic acid) ( $15-{ }^{13} \mathrm{C}, 99 \%$ ) |
| CLM-4343 | Vitamin A (retinoic acid) $\left(10,11,14,15-{ }^{13} \mathrm{C}_{4}, 99 \%\right)$ |
| DLM-7720 | Vitamin A (retinoic acid) (19,19, 19,20,20,20-D ${ }_{6}, 96 \%$ ) |
| DLM-9305 | Vitamin A (retinol) (10,19,19,19-D ${ }_{4}, 96 \%$ ) |
| CLM-10259 | Vitamin A (retinol) $\left(12,13,14,20-{ }^{13} \mathrm{C}_{4}, 99 \%\right)$ |
| DLM-8113 | Vitamin A (retinol) (19,19,19,20,20,20-D ${ }_{6}, 97 \%$ ) |
| DLM-9306 | Vitamin A (retinol) (10,14,19,19,19,20,20,20-D $\left.{ }_{8}, 90 \%\right)$ CP 96\% |
| CLM-8870 | Vitamin A acetate (retinal acetate) ( $\left.12,13,14,20-{ }^{13} C_{4}, 99 \%\right)$ |
| CLM-4831 | Vitamin A acetate (retinal acetate) ( $8,9,10,12,13,14,19,20-{ }^{13} \mathrm{C}_{8}, 99 \%$ ) |
| CLM-7277 | Vitamin A acetate (retinal acetate) <br> ( $8,9,10,11,12,13,14,15,19,20-{ }^{13} \mathrm{C}_{10}, 99 \%$ ) |
| DLM-2244 | Vitamin A acetate (retinal acetate) (10,19,19,19-D $\left.{ }_{4}, 96 \%\right) 3-4 \%$ cis |
| DLM-3828 | Vitamin $A$ acetate (retinal acetate) (19,19,19,20,20,20-D ${ }_{6}, 96 \%$ ) 3-4\% cis |
| DLM-4203 | Vitamin A acetate (retinal acetate) (10,14,19,19,19,20,20,20-D ${ }_{8}, 90 \%$ ) 3-4\% cis |
| CLM-10772 | Vitamin A aldehyde (retinal) (12,13,14,20-13 $\left.\mathrm{C}_{4}, 96 \%\right)$ |
| CLM-10838 | Vitamin A palmitate (retinyl palmitate) ( $8,9,10,11,12,13,14,15,19,20-{ }^{13} \mathrm{C}_{10}, 99 \%$ ) (all trans, <4\% cis; butylated hydroxytoluene) |
| DLM-4902 | Vitamin A palmitate (retinyl palmitate) ( $10,19,19,19-D_{4}, 96 \%$ ) all trans, $<4 \%$ cis, 50 ppm butylated hydroxytoluene |
| CLM-7667 | Vitamin $\mathrm{B}_{1}$ hydrochloride (thiamine hydrochloride) (4,5,4-methyl- ${ }^{13} \mathrm{C}_{3}, 99 \%$ ) CP 97\% |
| ULM-10004 | Vitamin B, hydrochloride (thiamine hydrochloride) (unlabeled) |
| DLM-8741 | Vitamin B, pyrophosphate (thiamine pyrophosphate) (pyrimidyl-methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| CNLM-8851 | Vitamin $\mathrm{B}_{2}$ (riboflavin) ( ${ }^{13} \mathrm{C}_{4}, 99 \%$; ${ }^{15} \mathrm{~N}_{2}, 98 \%$ ) CP 97\% |
| ULM-9123 | Vitamin $\mathrm{B}_{2}$ (riboflavin) (unlabeled) CP 97\% |
| CNLM-10744 | Vitamin $\mathrm{B}_{2}$ phosphate (riboflavin phosphate) ( ${ }^{13} \mathrm{C}_{4}, 99 \%$; ${ }^{15} \mathrm{~N}_{2}, 98 \%$ ) CP $>90 \%$ |
| CLM-9925 | Vitamin $\mathrm{B}_{3}$ (nicotinamide ( ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| DLM-6883 | Vitamin $\mathrm{B}_{3}$ (nicotinamide) ( $\mathrm{L}_{4}, 98 \%$ ) |
| CNLM-9757 | Vitamin $B_{3}$ (nicotinamide) <br> ( 2,6, carbonyl- ${ }^{-13} \mathrm{C}_{3}, 99 \%$; ring-1-15 $\mathrm{N}, 98 \%$ ) |
| CLM-9954 | Vitamin $\mathrm{B}_{3}$ (nicotinic acid) ( ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| CNLM-9512 | Vitamin $\mathrm{B}_{3}$ (nicotinic acid) <br> (2,6,carboxyl- ${ }^{-13} \mathrm{C}_{3}, 99 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) CP 97\% |
| CNLM-7694 | Vitamin $\mathrm{B}_{5}$, calcium salt $\cdot \mathrm{H}_{2} \mathrm{O}$ (calcium pantothenate $\cdot \mathrm{H}_{2} \mathrm{O}$ ) ( $\beta$-alanyl- ${ }^{13} \mathrm{C}_{3}, 99 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| ULM-10003 | Vitamin $\mathrm{B}_{5}$, calcium salt $\cdot \mathrm{H}_{2} \mathrm{O}$ (calcium pantothenate $\cdot \mathrm{H}_{2} \mathrm{O}$ ) (unlabeled) |
| DLM-9069 | Vitamin $\mathrm{B}_{6}$ (pyridoxal) (methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| ULM-9118 | Vitamin $\mathrm{B}_{6}$ (pyridoxal-HCI) (unlabeled) |

*Compounds available in dry and solution forms.

+ Compounds available in solution only.
Chemical purity (CP) is $98 \%$ or greater, unless otherwise indicated. For research use only. Not for use in diagnostic procedures.

Vitamins and Their Metabolites (continued)

| Catalog No. | Description |
| :---: | :---: |
| DLM-9119 | Vitamin $\mathrm{B}_{6}$ (pyridoxamine 2 HCl ) (methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| ULM-9120 | Vitamin $\mathrm{B}_{6}$ (pyridoxamine 2 HCl ) (unlabeled) |
| CLM-7563 | Vitamin $\mathrm{B}_{6}$ (pyridoxine- HCl ) <br> (4,5-bis(hydroxymethyl)- ${ }^{13} \mathrm{C}_{4}, 99 \%$ ) |
| DLM-8754 | Vitamin $\mathrm{B}_{6}$ (pyridoxine• HCl ) (5-hydroxymethyl-D ${ }_{2}, 98 \%$ ) |
| DLM-9121 | Vitamin $\mathrm{B}_{6}$ (pyridoxine• HCl ) (methyl- $\mathrm{D}_{3}, 98 \%$ ) CP 96\% |
| ULM-9122 | Vitamin $\mathrm{B}_{6}$ (pyridoxine•HCI) (unlabeled) CP 96\% |
| DLM-8806 | Vitamin $\mathrm{B}_{7}$ (biotin) (ring-6,6-D ${ }_{2}$, 98\%) CP 97\% |
| DLM-9751 | Vitamin $\mathrm{B}_{7}$ (biotin) (3', $3^{\prime}, 4^{\prime}, 4^{\prime}-\mathrm{D}_{4}, 98 \%$ ) CP 95\% |
| ULM-9129 | Vitamin $\mathrm{B}_{7}$ (biotin) (unlabeled) |
| CLM-7861 | Vitamin $\mathrm{B}_{9}$ (folic acid) (glutamic acid- ${ }^{13} \mathrm{C}_{5}, 95 \%$ ) contains ~10\% $\mathrm{H}_{2} \mathrm{O}$ |
| CLM-7861-N | Vitamin $\mathrm{B}_{9}$ (folic acid) (glutamic acid- ${ }^{13} \mathrm{C}_{5}, 99 \%$ ) CP 95\% |
| CNLM-9564 | Vitamin $\mathrm{B}_{9}$ (folic acid) (glutamic acid- ${ }^{13} \mathrm{C}_{5}, 99 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) CP 95\% |
| CLM-9770 ${ }^{+}$ | Vitamin $\mathrm{B}_{12}$ (cyanocobalamin) ( ${ }^{13} \mathrm{C}_{7}, 99 \%$ ) CP 95\% |
| ULM-10005 ${ }^{+}$ | Vitamin $\mathrm{B}_{12}$ (cyanocobalamin) (unlabeled) |
| CLM-3085 | Vitamin C (L-ascorbic acid) (1-13C, 99\%) |
| CLM-7283 | Vitamin C (L-ascorbic acid) ( ${\left.\mathrm{U}-{ }^{13} \mathrm{C}_{6}, 98 \%\right) ~}_{\text {, }}$ |
| DLM-8985* | Vitamin $\mathrm{D}_{2}$ (ergocalciferol) $\left(6,19,19-\mathrm{D}_{3}, 97 \%\right)$ |
| ULM-9124* | Vitamin $\mathrm{D}_{2}$ (ergocalciferol) (unlabeled) |
| DLM-10478 ${ }^{+}$ | Vitamin $D_{2}$ sulfate, sodium salt (6,19,19- $D_{3}, 98 \%$ ) CP 97\% |
| ULM-10477 ${ }^{+}$ | Vitamin $\mathrm{D}_{2}$ sulfate, sodium salt (unlabeled) CP 97\% |
| CLM-7850 | Vitamin $\mathrm{D}_{3}$ (cholecalciferol) $\left(23,24-{ }^{13} \mathrm{C}_{2}, 99 \%\right) \mathrm{CP} 90 \%$ |
| CLM-10470 ${ }^{+}$ | Vitamin $D_{3}$ (cholecalciferol) $\left(23,24,25,26,26-{ }^{13} C_{5}, 98 \%\right)$ CP 97\% |
| DLM-8853 ${ }^{+}$ | Vitamin $\mathrm{D}_{3}$ (cholecalciferol) (6,19,19-D $\left.{ }_{3}, 97 \%\right)$ CP 97\% |
| DLM-10749 ${ }^{+}$ | Vitamin $D_{3}$ (cholecalciferol) $\left(26,26,26,27,27,27-D_{6}, 98 \%\right)$ CP 95\% |
| ULM-9125* | Vitamin $\mathrm{D}_{3}$ (cholecalciferol) (unlabeled) |
| DLM-10476 ${ }^{+}$ | Vitamin $D_{3}$ sulfate, sodium salt (26,26,26, 27,27,27-D ${ }_{6}, 98 \%$ ) CP 97\% |
| DLM-10475 ${ }^{+}$ | Vitamin $D_{3}$ sulfate, sodium salt (6,19,19-D ${ }_{3}, 98 \%$ ) CP 97\% |
| $\underline{\text { ULM-10474 }}$ | Vitamin $\mathrm{D}_{3}$ sulfate, sodium salt (unlabeled) CP 97\% |


| Catalog No. | Description |
| :---: | :---: |
| CLM-10274 | Vitamin E (DL-rac-2-tocopherol) (trimethyl- ${ }^{13} \mathrm{C}_{3}, 99 \%$ ) CP $96 \%$ |
| CLM-10273 | Vitamin E ( $\alpha$-tocopherol) (trimethylphenyl- ${ }^{13} \mathrm{C}_{3}$, 99\%) CP 96\% |
| CLM-10275 | Vitamin E ( $\alpha$-tocopherol) (phenyl- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) CP 96\% |
| CLM-10276 | Vitamin E ( $\alpha$-tocopherol) (trimethylphenyl- ${ }^{13} \mathrm{C}_{9}, 99 \%$ ) CP 96\% |
| DLM-9126 | Vitamin E ( $\alpha$-tocopherol) <br> (5-methyl-D ${ }_{3}, 7-$ methyl- $\mathrm{D}_{3}, 98 \%$ ) |
| ULM-9127 | Vitamin E ( $\alpha$-tocopherol) (unlabeled) CP 96\% |
| DLM-8847 | Vitamin E acetate (tocopherol acetate) (acetyl-D ${ }_{3}, 98 \%$ ) |
| CLM-9566 | Vitamin $\mathrm{K}_{1}$ (phylloquinone) ( $4 \alpha, 5,6,7,8,8 \alpha-{ }^{13} \mathrm{C}_{6}, 99 \%$ ) |
| DLM-7702 | Vitamin $K_{1}$ (phylloquinone) (ring- $\mathrm{D}_{4}, 98 \%$ ) |
| DLM-9130 | Vitamin $\mathrm{K}_{1}$ (phylloquinone) ( $\mathrm{D}_{7}, 99 \%$ ) CP 97\% |
| ULM-9131 | Vitamin $\mathrm{K}_{1}$ (phylloquinone) (unlabeled) CP 97\% |
| CLM-10376 | Vitamin $\mathrm{K}_{2}$ (menaquinone MK-4) ( 4 ', 5, 6, $7,8,8^{\prime}-{ }^{13} \mathrm{C}_{6}, 99 \%$ ) CP 95\% |
| DLM-10379 | $\begin{aligned} & \text { Vitamin } \mathrm{K}_{2} \text { (menaquinone MK-4) } \\ & \left(5,6,7,8-\mathrm{D}_{4}, 2 \text {-methyl- } \mathrm{D}_{3}, 98 \%\right) \text { CP } 95 \% \end{aligned}$ |
| CLM-10377 | Vitamin $\mathrm{K}_{2}$ (menaquinone MK-7) ( 4 ', 5, 6, 7, $8,8{ }^{\prime}-{ }^{13} C_{6}$, 99\%) CP 95\% |
| DLM-10380 | Vitamin $\mathrm{K}_{2}$ (menaquinone MK-7) (5,6,7,8-D ${ }_{4}, 2$-methyl-D ${ }_{3}, 98 \%$ ) CP 95\% |
| CLM-10378 | $\begin{aligned} & \text { Vitamin } \mathrm{K}_{2} \text { (menaquinone MK-9) } \\ & \left(4^{\prime}, 5,6,7,8,8^{\prime}-{ }^{13} \mathrm{C}_{6}, 99 \%\right) \text { CP } 95 \% \end{aligned}$ |
| DLM-10381 | Vitamin $\mathrm{K}_{2}$ (menaquinone MK-9) (5,6,7,8-D ${ }_{4}, 2$-methyl-D ${ }_{3}, 98 \%$ ) CP 95\% |
| DLM-10382 | Vitamin $\mathrm{K}_{2}$ 2,3-epoxide (menaquinone-4 2,3-epoxide) (5,6,7,8-D ${ }_{4}, 2$-methyl-D ${ }_{3}, 98 \%$ ) CP 95\% |
| ULM-10383 | Vitamin $\mathrm{K}_{2}$ 2,3-epoxide (menaquinone-4 2,3-epoxide) (unlabeled) CP 95\% |
| DLM-9132 | Vitamin $\mathrm{K}_{3}$ (menadione) ( $\mathrm{D}_{8}, 98 \%$ ) CP 97\% |
| ULM-9133 | Vitamin $\mathrm{K}_{3}$ (menadione) (unlabeled) CP 97\% |

## Please visit isotope.com for a complete listing of vitamins and their metabolites.

*Compounds available in dry and solution forms.

+ Compounds available in solution only.
Chemical purity (CP) is 98\% or greater, unless otherwise indicated. For research use only. Not for use in diagnostic procedures.


## Urea and Water

| Catalog No. | Description |
| :--- | :--- |
| DLM-6 | Deuterium oxide "100\%" (D, 99.96\%) |
| DLM-11 | Deuterium oxide (D, 99.9\%) low paramagnetic |
| DLM-4 | Deuterium oxide (D, 99.9\%) |
| DLM-4-99.8 | Deuterium oxide (D, 99.8\%) |
| DLM-4-99 | Deuterium oxide (D, 99\%) |
| DLM-4-70 | Deuterium oxide (D, 70\%) |
| CLM-311 | Urea $\left({ }^{13} \mathrm{C}, 99 \%\right)$ |
| CLM-311-GMP | Urea $\left({ }^{13} \mathrm{C}, 99 \%\right)$ |
| CLM-311-MPT | Urea $\left({ }^{13} \mathrm{C}, 99 \%\right)$ |
| DLM-1269 | Urea $\left(\mathrm{D}_{4}, 98 \%\right)$ |
| NLM-233 | Urea $\left({ }^{15} \mathrm{~N}_{2}, 98 \%\right)$ |
| NLM-233-MPT | Urea $\left({ }^{15} \mathrm{~N}_{2}, 98 \%\right)$ |
| NLM-233-10 | Urea $\left({ }^{15} \mathrm{~N}_{2}, 10 \%\right)$ |
| NLM-233-5 | Urea $\left({ }^{15} \mathrm{~N}_{2}, 5 \%\right)$ |
| OLM-655 | Urea $\left({ }^{18} \mathrm{O}, 95 \%\right)$ |
| CNLM-234 | Urea $\left({ }^{13} \mathrm{C}, 99 \% ;{ }^{15} \mathrm{~N}_{2}, 98 \%\right)$ |
| COLM-4861 | Urea $\left({ }^{13} \mathrm{C}, 99 \% ;{ }^{18} \mathrm{O}, 98 \%\right)$ |
| CNOLM-8871 | Urea $\left({ }^{13} \mathrm{C}, 99 \% ;{ }^{15} \mathrm{~N}_{2}, 99 \% ;{ }^{18} \mathrm{O}, 99 \%\right)$ |


| Catalog No. | Description |
| :--- | :--- |
| DOLM-242 | Water $\left(\mathrm{D}_{2}, 98 \% ;{ }^{18} \mathrm{O}, 97 \%\right)$ |
| OLM-240-99 | Water $\left({ }^{18} \mathrm{O}, 99 \%\right)$ |
| OLM-240-97 | Water $\left({ }^{18} \mathrm{O}, 97 \%\right)$ |
| OLM-240-10 | Water $\left({ }^{18} \mathrm{O}, 10 \%\right)$ |
| OLM-782-90 | Water $\left({ }^{17} \mathrm{O}, 90 \%\right)$ |
| OLM-782-70 | Water $\left({ }^{17} \mathrm{O}, 70 \%\right)$ |
| OLM-782-40 | Water $\left({ }^{17} \mathrm{O}, 35-40 \%\right)$ |
| OLM-782-20 | Water $\left({ }^{17} \mathrm{O}, 20 \%\right)$ |
| OLM-782-10 | Water $\left({ }^{17} \mathrm{O}, 10 \%\right)$ |

[^4]MPT: microbiologically and pyrogen tested.
*Compounds available in dry and solution forms.

+ Compounds available in solution only.
Chemical purity (CP) is $98 \%$ or greater, unless otherwise indicated. For research use only. Not for use in diagnostic procedures.


## Sets, Mixtures, and Kits <br> Sets

Table 1. Standard products for MS/MS screening or tuning.

| Catalog No. | Description |
| :--- | :--- |
| NSK-A | Labeled Amino Acid Standards Set A |
| NSK-A1 | Labeled Amino Acid Standards Set A1 |
| NSK-A-US | Unlabeled Amino Acid Standards Set A |
| NSK-B | Labeled Carnitine Standards Set B |
| NSK-B-US | Unlabeled Carnitine Standards Set B |
| NSK-B-G1 | Labeled Carnitine Standards Supplement to NSK-B |
| NSK-B-G1-US | Unlabeled Carnitine Standards Supplement to NSK-B |
| NSK-AB | Labeled Standards Sets A \& B |
| NSK-S-CAH | Labeled Steroid CAH Set S |
| NSK-T | Labeled Succinylacetone Standard Set T |
| NSK-T-US | Unlabeled Succinylacetone Standard Set T |
| NSK-A-TS | Labeled Amino Acid Tuning Standards Set A |
| NSK-PO-1 | Lysosomal $\alpha-$-Glucosidase Substrate and Internal Standard |
| NSK-FA-1 | $\alpha-$-Galactosidase Substrate and Internal Standard |
| NSK-GA-1 | Glucocerebrosidase Substrate and Internal Standard |
| NSK-KR-1 | Galactocerebrosidase Substrate and Internal Standard |
| NSK-MP-1 | $\alpha-$--Iduronidase Substrate and Internal Standard |
| NSK-NI-1 | Acid Spingomyelinase Substrate and Internal Standard |

Table 2. Composition details of NSK-A, -B, and -B-G1. Please refer to isotope.com for additional information for other mixes.

| NSK-A |  |
| :---: | :---: |
| Components | Conc. ( $\mu \mathrm{M}$ ) |
| L-Alanine ( $2,3,3,3-\mathrm{D}_{4}, 98 \%$ ) | 500 |
| L-Arginine. $\mathrm{HCl}\left(5-{ }^{13} \mathrm{C}, 99 \% ; 4,4,5,5-\mathrm{D}_{4}, 95 \%\right)$ | 500 |
| L-Aspartatic acid (2,3,3-D ${ }_{3}, 98 \%$ ) | 500 |
| L-Citruline (5,5-D ${ }_{2}$, 98\%) | 500 |
| DL-Glutamatic acid (2,4,4-D ${ }_{3}, 98 \%$ ) | 500 |
| Glycine ( $2-{ }^{13} \mathrm{C}, 99 \%$; ${ }^{15} \mathrm{~N}, 98 \%$ ) | 2500 |
| L-Leucine (5,5,5-D ${ }_{3}, 99 \%$ ) | 500 |
| L-Methionine (methyl-D ${ }_{3}$, 98\%) | 500 |
| L-Ornithine. $\mathrm{HCl}\left(5,5-\mathrm{D}_{2}, 98 \%\right)$ | 500 |
| L-Phenylalanine (ring- ${ }^{13} \mathrm{C}_{6}, 99 \%$ ) | 500 |
| L-Tyrosine (ring- ${ }^{13} \mathrm{C}_{6}{ }^{\prime}$, 99\%) | 500 |
| L-Valine ( $\mathrm{D}_{8}, 98 \%$ ) | 500 |
| NSK-B |  |
| Components | Conc. ( $\mu \mathrm{M}$ ) |
| L-Carnitine (trimethyl- $\mathrm{D}_{9}$, 98\%) | 152 |
| O-Acetyl-L-carnitine $\cdot \mathrm{HCl}$ ( N -methyl- $\mathrm{D}_{3}, 98 \%$ ) | 38 |
| O-Butyryl-L-carnitine•HCI ( N -methyl-D ${ }_{3}, 98 \%$ ) CP 97\% | 7.6 |
| O-Isovaleryl-L-carnitine•HCI ( $\mathrm{N}, \mathrm{N}, \mathrm{N}$-trimethyl- $\mathrm{D}_{9}, 98 \%$ ) | 7.6 |
| O-Myristoyl-L-carnitine•HCI ( $\mathrm{N}, \mathrm{N}, \mathrm{N}$-trimethyl-D ${ }_{9}, 98 \%$ ) | 7.6 |
| O-Octanoyl-L-carnitine $\cdot \mathrm{HCl}$ ( N -methyl- $\mathrm{D}_{3}, 98 \%$ ) | 7.6 |
| O-Palmitoyl-L-carnitine $\cdot \mathrm{HCl}$ ( N -methyl- $\mathrm{D}_{3}, 98 \%$ ) | 15.2 |
| O-Propionyl-L-carnitine•HCl ( N -methyl-D ${ }_{3}, 98 \%$ ) | 7.6 |

NSK-B-G1

| Components | Conc. ( $\mu \mathrm{M}$ ) |
| :---: | :---: |
| O-Dodecanoyl-L-carnitine•HCl ( $\mathrm{N}, \mathrm{N}, \mathrm{N}$-trimethyl-D ${ }_{9}$, 98\%) | 7.6 |
| O-Glutaryl-L-carnitine $\cdot \mathrm{CLO}_{4}$ ( N -methyl- $\mathrm{D}_{3}, 98 \%$ ) CP 97\% | 152 |
| 3-Hydroxyisovaleryl-L-carnitine. $\mathrm{CLO}_{4}\left(\mathrm{~N}\right.$-methyl- $\left.\mathrm{D}_{3}, 98 \%\right)$ | 7.6 |
| O-3-DL-Hydroxypalmitoyl-L-carnitine•CLO ( N -methyl- $\mathrm{D}_{3}, 98 \%$ ) | 15.2 |
| O-Octadecanoyl-L-carnitine. HCl ( N -methyl- $\mathrm{D}_{3}, 98 \%$ ) | 15.2 |

Note: The concentration tolerances are $\pm 20 \%$ (exception: O-Glutaryl-Lcarnitine $\cdot \mathrm{CLO}_{4}$ at $\pm 40 \%$ ). Also, NSK-A1 is equivalent in composition to NSK-A, with the exception of the Orn labeling (i.e., $3,3,4,4,5,5,-D_{6}$ in NSK-A1 vs. $5,5-D_{2}$ in NSK-A.

## > Custom mixes can be formulated according to user specifications. Please inquire for details.

## Example References

Rodríguez-Colman, M.J.; Schewe, M.; Meerlo, M.; et al. 2017. Interplay between metabolic identities in the intestinal crypt supports stem cell function. Nature, 543(7645), 424-427.

Huang, T.; Cao, Y.; Zeng, J.; et al. 2016. Tandem mass spectrometry-based newborn screening strategy could be used to facilitate rapid and sensitive lung cancer diagnosis. Onco Targets Ther, 9, 2479-2487
Wang, Q.; Sun, T.; Cao, Y. 2016. A dried blood spot mass spectrometry metabolomic approach for rapid breast cancer detection. Onco Targets Ther, 9, 1389-1398.

Table 3. Sets of uniformly labeled dNTPs and rNTPs.

| Catalog No. | Description | Conc. ( $\mu \mathrm{M}$ ) |
| :---: | :---: | :---: |
| NLM-7512-SL | Set of 4 2'-deoxyribonucleoside <br> 5'-triphosphates (U- $\left.{ }^{15} \mathrm{~N}, 98 \%\right)$ <br> (Li salts/in soln) CP >90\% | 55 for dATP, dCTP, and TTP; 50 for dGTP |
| DLM-7511-SL | Set of 4 2'-deoxyribonucleoside 5'-triphosphates (U-D, 98\%) (Li salts/in soln) CP >90\% | 50 for dATP, 60 for dCTP, 58 for dGTP, and 66 for TTP |
| CNLM-7513-SL | Set of 4 2'-deoxyribonucleoside 5'-triphosphates ( $\mathrm{U}-{ }^{13} \mathrm{C}, 98 \%$; U- ${ }^{15} \mathrm{~N}$, 98\%) (Li salts/in soln) CP $>90 \%$ | 100 for dATP, dCTP, dGTP, and TTP |
| NLM-7519-CA | Set of 4 2'-ribonucleoside 5'-triphosphates (U- ${ }^{15} \mathrm{~N}$; 98\%) ( $\mathrm{NH}_{4}$ salts/in soln) $\mathrm{CP}>90 \%$ | 100 for ATP, CTP, GTP, and UTP |
| CNLM-7503-CA | Set of 4 2'-ribonucleoside <br> $5^{\prime}$-triphosphates ( $\mathrm{U}-{ }^{-13} \mathrm{C}, \mathrm{U}-{ }^{15} \mathrm{~N}$; <br> 98-99\%) ( $\mathrm{NH}_{4}$ salts/in soln) $\mathrm{CP}>90 \%$ | 100 for ATP, CTP, GTP, and UTP |
| DLM-7518-CA | Set of 4 ribonucleoside 5'-triphosphates (U-D, 98\%) ( $\mathrm{NH}_{4}$ salts/in soln) $\mathrm{CP}>90 \%$ | 100 for ATP, CTP. GTP, and UTP |

## Example Reference

Song, Y.; Marmion, R.A.; Park, J.O.; et al. 2017. Dynamic control of dNTP synthesis in early embryos. Dev Cell, 42(3), 301-308

## Mixtures

Table 4. Algae-derived amino acid mixtures and whole cells.

| Catalog No. | Description |
| :---: | :---: |
| CLM-1548 | Algal amino acid mixture (U- ${ }^{13} \mathrm{C}, 97-99 \%$ ) |
| NLM-2161 | Algal amino acid mixture (U-15 ${ }^{15}$, 98\%) |
| DLM-2082 | Algal amino acid mixture (U-D, 98\%) |
| CNLM-452 | Algal amino acid mixture (U- ${ }^{13} \mathrm{C}, 97-99 \%$; U-15 ${ }^{15}, 97-99 \%$ ) |
| DNLM-819 | Algal amino acid mixture (U-D, 98\%; U- ${ }^{15} \mathrm{~N}, 98 \%$ ) |
| CDNLM-2496 | Algal amino acid mixture <br> (U- ${ }^{13} \mathrm{C}, 97-99 \% ;$ U-D, $97-99 \% ;$ U- ${ }^{15} \mathrm{~N}, 97-99 \%$ ) |
| ULM-2314 | Algal amino acid mixture (unlabeled) |
| CLM-2065 | Algal lyophilized cells (U- ${ }^{13} \mathrm{C}, 98 \%$ ) |
| NLM-2162 | Algal lyophilized cells (U-15 ${ }^{15}, 96-99 \%$ ) |
| DLM-2066 | Algal lyophilized cells (U-D, 98\%) |
| CNLM-455 | Algal lyophilized cells (U- ${ }^{13} \mathrm{C}, 98 \%$; U-15N, 96-99\%) |
| CDLM-3441 | Algal lyophilized cells (U-13 ${ }^{13}$, 98\%; U-D, 98\%) |
| DNLM-839 | Algal lyophilized cells (U-D, 98\%; U-15N, 96-99\%) |
| CDNLM-3677 | Algal lyophilized cells <br> (U- ${ }^{13} \mathrm{C}, 98 \%$; U-D, $98 \%$; U- ${ }^{15} \mathrm{~N}, 96-99 \%$ ) |
| ULM-2177 | Algal lyophilized cells (unlabeled) |

Note: The algal strain is Agmenelum quadriplicatum. Also, the pH of the mixture may require adjustment after dissolution before its intended research use.

## Example References

Wei, X.; Lorkiewicz, P.K.; Shi, B.; et al. 2017. Analysis of stable isotope assisted metabolomics data acquired by high resolution mass spectrometry. Anal Methods, 9(15), 2275-2283.
Wei, X.; Shi, B.; Koo, I.; et al. 2017. Analysis of stable isotope assisted metabolomics data acquired by GC-MS. Anal Chim Acta, 980, 25-32.
Millard, P.; Cahoreau, E.; Heuillet, M.; et al. 2017. ${ }^{15} \mathrm{~N}$-NMR-based approach for amino acids-based ${ }^{13} \mathrm{C}$-metabolic flux analysis of metabolism. Anal Chem, 89(3), 2101-2106.
Qiu, J.; Chan, P.K.; Bondarenko, P.V. 2016. Monitoring utilizations of amino acids and vitamins in culture media and Chinese hamster ovary cells by liquid chromatography tandem mass spectrometry. J Pharm Biomed Anal, 117, 163-172.

Table 5. Uniform stable-isotope-labeled fatty acid mixtures.

| Catalog No. | Description |
| :--- | :--- |
| CLM-8455 | Mixed fatty acids (U- $\left.{ }^{13} \mathrm{C}, 98 \%\right)$ |
| DLM-8572 | Mixed fatty acids (U-D, 96-98\%) |
| CDLM-8376 | Mixed fatty acids (U- ${ }^{13} \mathrm{C}, 98 \% ;$ U-D, 97\%) |
| CLM-8381 | Mixed fatty acid methyl esters (U- $\left.{ }^{13} \mathrm{C}, 98 \%\right)$ <br> (terminal ester unlabeled) CP 95\% |
| DLM-2497 | Mixed fatty acid methyl esters (U-D, 96-98\%) |

## > Please inquire for composition of mixed fatty acids.

## Example References

Schoors, S.; Bruning, U.; Missiaen, R.; et al. 2015. Fatty acid carbon is essential for dNTP synthesis in endothelial cells. Nature, 520(7546), 192-197.
Sharma, S.C.; Klinman, J.P. 2015. Kinetic detection of orthogonal protein and chemical coordinates in enzyme catalysis: double mutants of soybean lipoxygenase. Biochem, 54(35), 5447-5456.

Table 6. Stable isotope-labeled canonical amino acid mix composition (MSK-CAA-1). Reconstituting in 1 mL solvent results in concentrations of 2.5 mM (exception L-cystine: 1.25 mM ).

| Compound | Abbrev. | Label and Enrichment |
| :---: | :---: | :---: |
| L-Alanine | Ala | ${ }^{13} \mathrm{C}_{3}, 99 \% ;{ }^{15} \mathrm{~N}, 99 \%$ |
| L-Arginine. HCl | Arg | ${ }^{13} \mathrm{C}_{6}, 99 \% ;{ }^{15} \mathrm{~N}_{4}, 99 \%$ |
| L-Asparagine $\cdot \mathrm{H}_{2} \mathrm{O}$ * | Asn | ${ }^{13} \mathrm{C}_{4}, 99 \% ;{ }^{15} \mathrm{~N}_{2}, 99 \%$ |
| L-Aspartic Acid | Asp | ${ }^{13} \mathrm{C}_{4}, 99 \% ;{ }^{15} \mathrm{~N}, 99 \%$ |
| L-Cystine | Cys-Cys | ${ }^{13} \mathrm{C}_{6}, 99 \% ;{ }^{15} \mathrm{~N}_{2}, 99 \%$ |
| L-Glutamic Acid | Glu | ${ }^{13} \mathrm{C}_{5}, 99 \% ;{ }^{15} \mathrm{~N}, 99 \%$ |
| L-Glutamine* | Gln | ${ }^{13} \mathrm{C}_{5}, 99 \% ;{ }^{15} \mathrm{~N}_{2}, 99 \%$ |
| Glycine | Gly | ${ }^{13} \mathrm{C}_{2}, 99 \% ;{ }^{15} \mathrm{~N}, 99 \%$ |
| L-Histidine• $\mathrm{HCl} \cdot \mathrm{H}_{2} \mathrm{O}$ | His | ${ }^{13} \mathrm{C}_{6}, 97-99 \% ;{ }^{15} \mathrm{~N}_{3}, 97-99 \%$ |
| L-Isoleucine | Iso | ${ }^{13} \mathrm{C}_{6}, 99 \% ;{ }^{15} \mathrm{~N}, 99 \%$ |
| L-Leucine | Leu | ${ }^{13} \mathrm{C}_{6}, 99 \% ;{ }^{15} \mathrm{~N}, 99 \%$ |
| L-Lysine 2 HCl | Lys | ${ }^{13} \mathrm{C}_{6}, 99 \% ;{ }^{15} \mathrm{~N}_{2}, 99 \%$ |
| L-Methionine | Met | ${ }^{13} \mathrm{C}_{5}, 99 \% ;{ }^{15} \mathrm{~N}, 99 \%$ |
| L-Phenylalanine | Phe | ${ }^{13} \mathrm{C}, 9,99 \% ;{ }^{15} \mathrm{~N}, 99 \%$ |
| L-Proline | Pro | ${ }^{13} \mathrm{C}_{5}, 99 \% ;{ }^{15} \mathrm{~N}, 99 \%$ |
| L-Serine | Ser | ${ }^{13} \mathrm{C}_{3}, 99 \% ;{ }^{15} \mathrm{~N}, 99 \%$ |
| L-Threonine | Thr | ${ }^{13} \mathrm{C}_{4}, 97-99 \% ;{ }^{15} \mathrm{~N}, 97-99 \%$ |
| L-Tryptophan* | Trp | ${ }^{13} \mathrm{C}_{11}, 99 \% ;{ }^{15} \mathrm{~N}_{2}, 99 \%$ |
| L-Tyrosine | Tyr | ${ }^{13} \mathrm{C} 9,99 \% ;{ }^{15} \mathrm{~N}, 99 \%$ |
| L-Valine | Val | ${ }^{13} \mathrm{C}_{5}, 99 \% ;{ }^{15} \mathrm{~N}, 99 \%$ |

*Compounds absent in the MSK-A2-1.2 mix, which comprises 17
compounds and is supplied as a 1.2 mL solution (in 0.1 M HCl ).

## Example References

Chen, W.W.; Freinkman, E.; Sabatini, D.M. 2017. Rapid immunopurification of mitochondria for metabolite profiling and absolute quantification of matrix metabolites. Nat Protoc, 12(10), 2215-2231.

Havelund, J.F.; Andersen, A.D.; Binzer, M.; et al. 2017. Changes in kynurenine pathway metabolism in Parkinson patients with L-DOPA-induced dyskinesia. $J$ Neurochem, 142(5), 756-766.

Mayers, J.R.; Torrence, M.E.; Danai, L.V.; et al. 2016. Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers. Science, 353(6304), 1161-1165.

Table 7. Stable isotope-labeled noncanonical amino acid mix composition (MSK-NCAA-1). Reconstituting in 1 mL solvent results in concentrations of 2.5 mM .

| Compound | Abbrev. | Label and Enrichment |
| :--- | :---: | :--- |
| $\beta$-Alanine | $\beta$-Ala | ${ }^{13} \mathrm{C}_{3}, 98 \% ;{ }^{15} \mathrm{~N}, 96-99 \%$ |
| L-Azidohomoalanine $\cdot \mathrm{HCl}$ | hAHA | $1,2,3,4-{ }^{13} \mathrm{C}_{4}, 99 \% ; 2,4-{ }^{-15} \mathrm{~N}_{2}, 98 \%$ |
| L-Citrulline | Cit | $1,2,3,4,5-{ }^{13} \mathrm{C}_{5}, 98 \%$ |
| L-Dihydroxyphenylalanine | DOPA | $1-{ }^{13} \mathrm{C}$, ring- $-13 \mathrm{C}_{6}, 99 \%$ |
| L-Homoarginine $\cdot \mathrm{HCl}$ | Harg | ${ }^{13} \mathrm{C}_{7}, 98 \% ;{ }^{15} \mathrm{~N}_{4}, 98 \%$ |
| L-Ornithine $\cdot \mathrm{HCl}$ | Orn | ${ }^{13} \mathrm{C}_{5}, 98 \%$ |
| Sarcosine $\cdot \mathrm{HCl}$ | Sar | ${ }^{13} \mathrm{C}_{3}, 99 \% ;{ }^{15} \mathrm{~N}, 98 \%$ |

## Kits

The kits described below are all accompanied by user manuals that outline general procedures and processing examples for user reference. Additionally provided are troubleshooting notes and alternate method suggestions, as well as instructions and guides for data analysis.

## Metabolomics QC Kit

Quality control (QC) of methods and processes is an essential factor toward the generation of reliable LC-MS data that can be reproduced by independent laboratories using untargeted or targeted MS technologies. Toward that, CIL offers a metabolomics QC kit (MSK-QC-KIT) for performance assessment of analytical workflows.

Table 8. Analyte composition of MSK-QC-KIT. Rehydrating each mix in 1 mL of solvent (e.g., $0.1 \%$ FA/5\% ACN in water) yields the concentrations noted.

| Components | Conc. $(\mu \mathrm{g} / \mathrm{mL})$ | Vial |
| :--- | :---: | :---: |
| L-Alanine $\left({ }^{13} \mathrm{C}_{3}, 99 \%\right)$ | 4 | 1 |
| L-Leucine $\left({ }^{13} \mathrm{C}_{6}, 99 \%\right)$ | 4 | 1 |
| L-Phenylalanine (ring- $\left.{ }^{13} \mathrm{C}_{6}, 99 \%\right)$ | 4 | 1 |
| L-Tryptophan $\left({ }^{13} \mathrm{C}_{11}, 99 \%\right)$ | 40 | 1 |
| L-Tyrosine (ring- $\left.{ }^{13} \mathrm{C}_{6}, 99 \%\right)$ | 4 | 1 |
| D-Glucose $\left(\mathrm{U}-{ }^{13} \mathrm{C}_{6}, 99 \%\right)$ | 4 | 2 |
| D-Sucrose (glucose- $\left.{ }^{13} \mathrm{C}_{6}, 98 \%\right)$ | 4 | 2 |
| Caffeine (trimethyl- $\left.{ }^{13} \mathrm{C}_{3}, 99 \%\right)$ | 4 | 2 |
| Stearic acid, sodium salt $\left(\mathrm{U}-{ }^{13} \mathrm{C}_{18}, 98 \%\right) \mathrm{CP} 97 \%$ | 0.4 | 2 |
| Sodium octanoate $\left({ }^{13} \mathrm{C}_{8}, 99 \%\right)$ | 4 | 2 |
| Sodium propionate $\left({ }^{13} \mathrm{C}_{3}, 99 \%\right)$ | 4 | 2 |
| Sodium benzoate (ring- $\left.{ }^{13} \mathrm{C}_{6}, 99 \%\right)$ | 4 | 2 |
| Sodium citrate $\left(1,5,6-\mathrm{carboxy-}{ }^{13} \mathrm{C}_{3}, 99 \%\right)$ | 4 | 2 |
| Succinic acid, disodium salt $\left({ }^{13} \mathrm{C}_{4}, 99 \%\right)$ | 4 | 2 |

## Custom mixes can be formulated according to user specifications. Please inquire for details.



Figure 2. Representative XICs of a subset of kit metabolites vial 1 in a) and vial 2 in b) - measured in human plasma by RP-LC-MS (negative ESI, Q Exactive). Procedurally, aliquots of the reconstituted vials were mixed then prepared/processed according to the user manual. Note that all isotopically labeled metabolites in the mixes co-eluted with their endogenous analytes in the plasma analyses and their $m / z$ were predominantly $[\mathrm{M}-\mathrm{H}]$.

## Metabolite Yeast Extract

In partnership with ISOtopic Solutions, CIL is pleased to offer an unlabeled and ${ }^{13} \mathrm{C}$-labeled metabolite yeast extract for use as an internal or external standard in LC-/GC-MS studies. The unlabeled extract is designed for QC assessment and the isotopically enriched extract for quantitation of 100s of metabolites in a variety of samples (e.g., plasma, cells).

Catalog No. Description

| ISO1 | Metabolite Yeast Extract (U- ${ }^{13} \mathrm{C}, 98 \%$ ) |
| :--- | :--- |
| ISO1-UNL | Metabolite Yeast Extract (unlabeled) |

Dry extract of $\sim 2 \times 10^{9}$ Pichia pastoris cells ( $\sim 15 \mathrm{mg}$ dry cell weight).

## GISOtopic

Table 9. Examples of reproducibly measured metabolites in ISO1 and ISO1-UNL (see CoA for specifics). Other metabolites have been identified with alternate methods and analysis techniques.

| Amino Acids and Derivatives (L enantiomer where applicable) |  |  |
| :--- | :--- | :--- |
| S-Adenosyl-homocysteine | Glutamate | Methionine |
| Alanine | Glutamine | (+/-)-3-Methyl-2-oxovalerate |
| $\alpha$-Aminoadipate | Glycine | Ornithine |
| Arginine | Guanidineacetate | Phenylalanine |
| Argininosuccinate | Histidine | Proline |
| Asparagine | Homoserine | Sarcosine |
| Aspartate | Isoleucine | Serine |
| Betaine | $\alpha$-Ketoisovalerate | Threonine |
| Citrulline | Kynurenine | Tryptophan |
| Cystathionine | Leucine | Tyrosine |
| Dihydroxyisovalerate | Lysine | Valine |
| Organic Acids | DL-2-Hydroxyglutarate | Malate |
| cis-Aconitate | Isocitrate | Pyruvate |
| Citrate | Lactate | Succinate |
| Fumerate | $\alpha$-Ketoglutarate |  |
| Gluconate | Cytidine triphosphate |  |
| Nucleobases, Nucleosides, and Nucleotides | Inosine monophosphate |  |
| Adenine | Deoxyadenosine monophosphate | 5 --Deoxy-5'-methylthioadenosine |
| Adenosine | Guanine | 5-Methyluridine |
| Adenosine diphosphate | Guanosine | Pseudouridine |
| Adenosine monophosphate | Guanosine diphosphate | Uridine |
| Adenosine triphosphate | Guanosine monophosphate | Uridine diphosphate |
| Cyclic adenosine monophosphate | Guanosine triphosphate | Uridine monophosphate |
| Cyclic guanosine monophosphate | Inosine |  |
| Cytidine monophosphate | Ribose |  |
| Sugar and Sugar Phosphates (D enantiomer where applicable) | Ribose-5-phosphate |  |
| Dihydroxyacetone phosphate | Glucose-6-phosphate | Sedoheptulose-7-phosphate |
| Erythritol | Mannitol |  |
| Fructose | Mannose |  |
| Fructose-1,6-bisphosphate | Mase |  |
| Fructose-6-phosphate | 6 -Phosphogluconate |  |
| Galactose | 2 -Phosphoglycerate |  |
| Vitamins and Coenzymes | Nicotinamide adenine dinucleotide, oxidized | Nicotinamide adenine dinucleotide phosphate, oxidized |
| Choline | Nicotinamide adenine dinucleotide, reduced |  |
| Othetinamide | Glutamylcysteine |  |
| Glutathione, oxidized |  |  |
| Glutathione, reduced |  |  |

Kits (continued)


Figure 3. Mixed extract of ISO1 and ISO1-UNL measured by LC-MS on a Q Exactive HF. Procedurally, both ISO1 and ISO1-UNL were reconstituted in 2 mL of water before aliquot addition ( $100 \mu \mathrm{~L}$ each) to solvent ( $500 \mu \mathrm{~L}$ ACN and $300 \mu \mathrm{~L}$ water) and HILIC-MS measurement. Shown here is the MS1 spectrum of $\mathrm{NAD}^{+}\left(\mathrm{C}_{21} \mathrm{H}_{27} \mathrm{~N}_{7} \mathrm{O}_{14} \mathrm{P}_{2} ; \mathrm{m} / \mathrm{z} 664.1164\right.$ for unlabeled and 685.1869 for $\left.\mathrm{U}-{ }^{13} \mathrm{C}\right)$, with its matching chromatogram in inset.

## Example References

Rusz, M.; Rampler, E.; Keppler, B.K.; et al. 2019. Single spheroid metabolomics: optimizing sample preparation of three-dimensional multicellular tumor spheroids. Metabolites, 9(12). pii: E304.
Zhang, Y.; Vera, J.M.; Xie, D.; et al. 2019. Multiomic fermentation using chemically defined synthetic hydrolyzates revealed multiple effects of lignocellulose-derived inhibitors on cell physiology and xylose utilization in Zymomonas mobilis. Front Microbiol, 10, 2596.

Galvez, L.; Rusz, M.; Schwaiger-Haber, M.; et al. 2019. Preclinical studies on metal based anticancer drugs as enabled by integrated metallomics and metabolomics. Metallomics, 11(10), 1716-1728.

Demarest, T.G.; Truong, G.T.D.; Lovett, J.; et al. 2019. Assessment of NAD ${ }^{+}$metabolism in human cell cultures, erythrocytes, cerebrospinal fluid and primate skeletal muscle. Anal Biochem, 572, 1-8.
Hermann, G.; Schwaiger, M.; Volejnik, P.; et al. 2018. ${ }^{13}$ C-labelled yeast as internal standard for LC-MS/MS and LC high resolution MS based amino acid quantification in human plasma. J Pharm Biomed Anal, 155, 329-334

Guijas, C.; Montenegro-Burke, J.R.; Domingo-Almenara, X.; et al. 2018. METLIN: a technology platform for identifying knowns and unknowns. Anal Chem, 90(5), 3156-3164.

Si-Hung, L.; Causon, T.J.; Hann, S. 2017. Comparison of fully wettable RPLC stationary phases for LC-MS-based cellular metabolomics. Electrophoresis, 38(18), 2287-2295.
Schwaiger, M.; Rampler, E.; Hermann, G.; et al. 2017. Anion-exchange chromatography coupled to high-resolution mass spectrometry: a powerful tool for merging targeted and non-targeted metabolomics. Anal Chem, 89(14), 7667-7674

Ortmayr, K.; Hann, S.; Koellensperger, G. 2015. Complementing reversed-phase selectivity with porous graphitized carbon to increase the metabolome coverage in an on-line two-dimensional LC-MS setup for metabolomics. Analyst, 140(10), 3465-3473.

Neubauer, S.; Chu, D.B.; Marx, H.; et al. 2015. LC-MS/MS-based analysis of coenzyme A and short-chain acyl-coenzyme A thioesters. Anal Bioanal Chem, 407(22), 6681-6688.

## Credentialed E. coli Cell Extract Kits

An exceeding challenge in optimizing metabolomic methods toward improved metabolome coverage has been the difficulty in comparing the number of metabolites profiled in each. This evaluation is challenged by artifactual (i.e., noncredentialed) features arising from sample contamination during metabolite extraction, background noise, and/or misannotation of data during bioinformatic processing. To help streamline method optimization/ evaluation in untargeted metabolomics, Dr. Gary Patti and colleagues developed a credentialed platform that utilizes a simple software algorithm for interrogating $E$. coli extracts (see references below). To aid broad utility, CIL is proud to offer E. coli cell extract kits that can be applied for performance comparisons of 100 s of
metabolites across different metabolomic workflows and instrument platforms. The figure below illustrates a credentialed metabolite measured in the E. coli extract.

| Catalog No. | Description |
| :--- | :--- |
| MSK-CRED-KIT | Credentialed E. coli Cell Extract Kit (solution) |
| MSK-CRED-DD-KIT | Credentialed E. coli Cell Extract Kit (dried down) |

Note: Each kit contains two vials of E. coli cell extracts (K12 strain MG1655), with one grown in ${ }^{13} \mathrm{C}$ D-glucose $\left(\mathrm{U}-{ }^{13} \mathrm{C}_{6}, 99 \%\right)$ and the other in natural abundance D-glucose. Procedurally, these are to be mixed (at defined ratios) prior to LC-MS analysis and bioinformatic processing


Figure 4. Credentialed extract measured by LC-MS on a Q Exactive Plus. Shown are the measured parameters and observed spectra for reduced glutathione $\left(\mathrm{C}_{10} \mathrm{H}_{17} \mathrm{~N}_{3} \mathrm{O}_{6} \mathrm{~S}\right.$; unlabeled CAS 70-18-8). The $\mathrm{M}+0$ in the MS survey scan is at $\mathrm{m} / \mathrm{z} 308.0914$, while the $\mathrm{M}+\mathrm{U}$ is at 318.1249 .

## Example References

Wang, L.; Naser, F.J.; Spalding, J.L.; et al. 2019. A protocol to compare methods for untargeted metabolomics. Methods Mol Biol, 1862, 1-15.
Naser, F.J.; Mahieu, N.G.; Wang, L.; et al. 2018. Two complementary reversed-phase separations for comprehensive coverage of the semipolar and nonpolar metabolome. Anal Bioanal Chem, 410(4), 1287-1297.
Mahieu, N.G.; Patti, G.J. 2017. Systems-level annotation of a metabolomics data set reduces 25,000 features to fewer than 1000 unique metabolites. Anal Chem, 89(19), 10397-10406.

Benton, H.P.; Ivanisevic, J.; Mahieu, N.G.; et al. 2015. Autonomous metabolomics for rapid metabolite identification in global profiling. Anal Chem, 87(2), 884-891.
Mahieu, N.G.; Huang, X.; Chen, Y.; et al. 2014. Credentialing features: a platform to benchmark and optimize untargeted metabolomic methods. Anal Chem, 86(19), 9583-9589.

## Kits (continued)

## IROA ${ }^{\oplus}$ Biochemical Quantitation Kits

By using specific isotopic balances (e.g., $95 \%{ }^{13} \mathrm{C}$ and $5 \%{ }^{13} \mathrm{C}$ D-glucose in the basic protocol for control and experimental groups), IROA's quantitative assay kits can be used to study biomarkers, systems biology, and flux in a wide variety of cell populations and biological samples (see references below for general background and application examples). The reduced enrichment enables isotopic distributions to be detected by MS in a predictable and distinguishable manner. These distributions can then be used to: (i) differentiate biological signals from artifacts, (ii) calculate accurate molecular formulae, and (iii) determine relative concentrations of the metabolites of biological origin.

| Catalog No. | Description | Protocol |
| :--- | :--- | :--- |
| IROA-100-50 | IROA 100 for Yeast/Fungi <br> Metabolic Profiling | Basic |
| IROA-200-50 | IROA 200 for Bacterial <br> Metabolic Profiling | Basic |
| IROA-300-250 | IROA 300 for Mammalian <br> Metabolic Profiling | Basic |
| IROA-PHENO-95-300 | IROA 300 for Phenotypic <br> Metabolic Profiling | Phenotypic |
| IROA-FLUX-05 | IROA 300 for Fluxomic <br> Metabolic Profiling | Flux |

Note: Unlabeled bacterial (IROA-200-UL) and mammalian (IROA-300-UL) media are also available for cell-growth testing and adaptation.

IROA is a registered trademark of IROA Technologies

## Basic Protocol



Phenotypic Protocol


Flux Protocol


Figure 5. MS spectra for L-arginine $\left(\mathrm{C}_{6} \mathrm{H}_{14} \mathrm{~N}_{4} \mathrm{O}_{2}\right)$ measured by LC-MS under three types of IROA protocols. Briefly, the cell populations are grown with istopically labeled D-glucose for control and experimental samples in the basic protocol, control samples only in phenotypic, and experimental samples only in fluxomic (tracers added after harvest at $99 \%{ }^{13} \mathrm{C}$ ). Note: the control signals (at $95 \%{ }^{13} \mathrm{C}$ ) are illustrated in blue across all protocols and the experimental (at $5 \%{ }^{13} \mathrm{C}$ in the basic and flux protocols or natural abundance in the phenotypic) in green (for the basic and flux protocols) or black (for the phenotypic protocol). IROA's ClusterFinder software is used for data analysis and the statistical interpretation.

## Example References

Rahman, M.A.; Akond, M.; Babar, M.A.; et al. 2017. LC-HRMS based non-targeted metabolomic profiling of wheat (Triticum aestivum L.) under post-anthesis drought stress. Am J Plant Sci, 8, 3024-3061.
Viant, M.R.; Kurland, I.J.; Jones, M.R.; et al. 2017. How close are we to complete annotation of metabolomes? Curr Opin Chem Biol, 36, 64-69.
Clendinen, C.S.; Stupp, G.S.; Ajredini, R.; et al. 2015. An overview of methods using (13)C for improved compound identification in metabolomics and natural products. Front Plant Sci, 6, 611.3.

Edison, A.S.; Clendinen, C.S.; Ajredini, R.; et al. 2015. Metabolomics and natural-products strategies to study chemical ecology in nematodes. Integr Comp Biol, 55(3), 478-485.

Stupp, G.S.; Clendinen, C.S.; Ajredini, R.; et al. 2013. Isotopic ratio outlier analysis global metabolomics of Caenorhabditis elegans. Anal Chem, 17, 11858-11865. de Jong, F.A.; Beecher, C. 2012. Addressing the current bottlenecks of metabolomics: Isotopic Ratio Outlier Analysis ${ }^{\text {™ }}$, an isotopic-labeling technique for accurate biochemical profiling. Bioanalysis, 4, 2303-2314.

Chemical purity (CP) is 98\% or greater, unless otherwise indicated.
For research use only. Not for use in diagnostic procedures.

## Additional Information Research Use of Products

CIL manufactures highly pure research biochemicals that are produced for research applications. As a service to our customers, some of these materials have been tested for the presence of S. aureus, P. aeruginosa, E. coli, Salmonella sp., aerobic bacteria, yeast, and mold, as well as the presence of endotoxin in the bulk material by taking a random sample of the bulk product. Subsequent aliquots are not retested. Presence of endotoxin is assessed by determining endotoxin content following established protocols and standardized limulus amebocyte lysate (LAL) reagents. Any materials listed in our catalog or website that are designated as "MPT" in the item product number (e.g., DLM-349-MPT) contain these tests as part of release specifications.

If a product does not have an "MPT" designation, CIL may be able to provide microbiological testing on the product. Depending on the compound and the quantity ordered, an additional fee may apply for the testing. Please note that microbiological-tested products are not guaranteed to be sterile and pyrogen-free when received by the customer, and microbiological testing does not imply suitability for any desired use. If the product must be sterile and pyrogen-free for a desired application, CIL recommends that the product be packaged or formulated into its ultimate dose form by the customer or appropriate local facility. The product should always be tested by a qualified pharmacy/facility prior to actual use.

CIL research products are labeled "For research use only. Not for use in diagnostic procedures." Persons intending to use CIL products in applications involving humans are responsible for complying with all applicable laws and regulations including but not limited to the US FDA, other local regulatory authorities and institutional review boards concerning their specific application or desired use.

It may be necessary to obtain approval for using these research products in humans from the US FDA or the comparable governmental agency in the country of use. CIL will provide supporting information, such as lot-specific analytical data and test method protocols, to assist medical research groups in obtaining approval for the desired use. An Enhanced Data Package (EDP) is also available (see next page for an overview of the technical package contents).

CIL will allocate a specific lot of a product to customers who are starting long-term projects requiring large amounts of material. Benefits from this type of arrangement include experimental consistency arising from use of only one lot, no delay in shipments, and guaranteed stock. Please note that some CIL products have a specific shelf life and cannot be held indefinitely. If interested, please contact your sales manager for further details.

Because of increasing regulatory requirements, CIL manufactures different grades of materials to help researchers with those requirements. Listed below are the grades of materials that CIL currently manufactures:

| Catalog No. | Description |
| :--- | :--- |
| CLM-XXX-PK | Research grade |
| CLM-XXX-MPT-PK | Microbiologically and Pyrogen Tested |
| CLM-XXX-CTM | Manufactured following ICH Q7, Section XIX |
| CLM-XXX-GMP | Good Manufacturing Practices grade |

[^5]

Image is for illustrative purposes only and may not be representative of actual product(s).

## Enhanced Data Package (EDP)

CIL offers the option of an Enhanced Data Package (EDP). This technical data package is available for most MPT products. It includes all of the data currently included with the MPT products, as well as the additional information listed below. You have the option of purchasing this package at the time of order or at a later date.

Please note that if you choose to purchase at a later date, some of the information listed below may not be available. Also, the EDP may not be available for all lots. In some cases, only a partial EDP may be available. Please confirm availability and content prior to order.

## EDP Contents

- Product description: structural formula, stereochemical description, molecular formula.
- Product physical properties: melting point, pH, optical rotation (mix of literature or measured values).
- Outline of the synthesis route (including details of solvents used).
- Data used to confirm structure and chemical purity.
- Additional testing data: products with an EDP have been tested to the specifications/monograph similar to those detailed in the USP or EP, but not using compendia methods.
- Impurities: available data on impurities detected and identified together with the method of detection and the cutoff applied.
- Residual solvents: measured residual solvents from the final synthetic step and purification.
- Certificates of Analysis of raw materials, where appropriate.
- Informal stability data: estimated and measured.
- This will be either actual shelf life data, if it can be obtained from CIL history or by analysis of in-stock batches, or
- If no data is available, CIL will commit to assaying the batch provided after six months and one year. Data will be provided after one year, unless the batch fails assay after six months. This option will not be available if the Enhanced Data Package is ordered at a later date.


## cGMP Production Capabilities

With increasing requirements from institutional review boards (IRBs) and governmental agencies, partnering with CIL for your next stable isotope cGMP (current good manufacturing practices) project can help ensure your regulatory compliance. With the world's largest ${ }^{13} \mathrm{C}$ and ${ }^{18} \mathrm{O}$ isotope-separation plants, CIL is able to provide the raw materials necessary for your project. Your compound of interest most likely already appears in CIL's extensive list of research compounds - if not, CIL's team of PhD chemists can determine the best method of synthesis for incorporating ${ }^{13} \mathrm{C},{ }^{15} \mathrm{~N}, \mathrm{D},{ }^{17} \mathrm{O}$, and/or ${ }^{18} \mathrm{O}$ into your compound.

CIL has manufactured bulk active pharmaceutical ingredients (APIs) since 1994. It recently added a 15,000-square-foot, state-of-the-art cGMP facility to complement its existing cGMP facilities. An additional team of experts - specializing in synthetic chemistry, customer support, quality control, and quality assurance - serves to provide technical guidance from beginning to end of your project. Partner with CIL to help you meet your increasing regulatory compliance requirements.

## Products of Interest

| Catalog No. | Description |
| :--- | :--- |
| CLM-804-CTM | Cholesterol $\left(3,4-{ }^{13} C_{2}\right)$ |
| DLM-349-CTM | D-Glucose $\left(6,6-\mathrm{D}_{2}\right)$ |
| CLM-2262-CTM | L-Leucine $\left({ }^{13} \mathrm{C}_{6}\right)$ |
| DLM-1259-CTM | L-Leucine $\left(5,5,5-\mathrm{D}_{3}\right)$ |
| CLM-762-CTM | L-Phenylalanine $\left(1-{ }^{13} \mathrm{C}\right)$ |
| CLM-8077-CTM | Pyruvic acid $\left(1-{ }^{13} \mathrm{C}\right)$ |
| CLM-156-CTM | Sodium acetate $\left(1-{ }^{13} \mathrm{C}\right)$ |
| CLM-440-CTM | Sodium acetate $\left(1,2-{ }^{13} \mathrm{C}_{2}\right)$ |
| CLM-311-GMP | Urea $\left({ }^{13} \mathrm{C}\right)$ |

## Other products may be available as CTM/cGMP. Please inquire for details.

## Manufacturing Capabilities

- Dedicated development facility
- Five production and two isolation suites
- Dedicated packaging room
- Production scale from milligrams to multikilograms
- Clinical trials to bulk API
- Customizable projects to meet your needs


## Analytical Services

- Fully equipped, cGMP-dedicated analytical facility
- Method development and validation
- Raw material and final product testing
- Wet chemistry and compendial methods
- Stability studies and chambers
- Analytical instrumentation:
- High-field NMR ( ${ }^{1} \mathrm{H}, \mathrm{D},{ }^{13} \mathrm{C},{ }^{15} \mathrm{~N}$, multinuclear)
- HPLC with UV, RI, ELSD, DA, Pickering, and MS detection
- GC with FID, ECD, and MS detection
- KF
- FT-IR
- Polarimetry
- TOC


## Quality and Compliance

- Drug master files
- FDA-audited facility
- QA release of API product
- Follows FDA and ICH guidances
- CMC sections for NDA or IND


CTM: manufactured following ICH Q7, Section XIX
GMP: good manufacturing practices grade
Chemical purity (CP) is 98\% or greater, unless otherwise indicated. For research use only. Not for use in diagnostic procedures.

## Application Note Examples

## Application Note 47

## Organic Acid Quantitation in Mouse Muscle by Ion Chromatography-Mass Spectrometry with

 Isotopically Labeled Standards

Organic acids (OAs) are important metabolites that play an essential role in an array of energy metabolism pathways (e.g., glycolysis and tricarboxylic acid cycle). ${ }^{1,2}$ In addition, short chained OAs are emerging as important regulators of host immune responses and transcriptional regulation. ${ }^{3,4}$ Their significance to cellular metabolism is heightened by their association with diseases, such as cancer and diabetes. ${ }^{5-7}$ As a result, research has been focused on quantifying OAs in various biological samples (e.g., urine, ${ }^{8}$ plasma, ${ }^{9}$ serum ${ }^{10}$ ). In these studies, measurements of OAs were accomplished by liquid chromatography (LC) or capillary electrophoresis (CE) coupled to mass spectrometry (MS). ${ }^{11,12}$ The commonly utilized modes of chromatography include reversed-
phase (with $\mathrm{C}_{18}$ bonded silica), ion pair, and hydrophilic interactions. Despite that, the efficiency of separating polar OAs with these techniques can be challenging. An attractive complementary technique for untargeted metabolomics of polar metabolites is ion chromatography (IC)-MS. ${ }^{13}$ In this note, a targeted IC-MS method using stable isotope-labeled standards (SIS) was used to quantify a panel of polar OAs in mouse muscle. ${ }^{14}$ The SIS OAs served as internal standards for enhanced precision and accuracy of OA measurements. Statistically significant quantitative differences were observed for four OAs in the quadricep muscle of sedentary and fatigued mice. Overall, this study demonstrated the ability of IC-MS with stable isotope-labeled OAs to separate and quantify a collection of low molecular weight polar metabolites that are difficult to analyze by other techniques. Read more at isotope.com.

## Application Note 43

Analysis of Whole-Body Branched-Chain Amino Acid Metabolism in Mice Utilizing 20\% Leucine ${ }^{13} \mathrm{C}_{6}$ and $20 \%$ Valine ${ }^{13} \mathrm{C}_{5}$ Mouse Feed


Cancer cells have altered metabolism relative to normal cells. To date, most cancer metabolism research has focused on understanding the mechanisms of cell autonomous metabolic alterations such as the influence of different oncogenic signals on nutrient utilization and the effects of altered regulation of specific enzymes on metabolic fluxes through different pathways (Cairns, et al., 2011). While these studies have provided insight into metabolic needs of proliferating cancer cells (Vander Heiden, et al., 2009), they do not address potential interactions between tumor and normal tissues. Research on whole-body metabolic alterations
associated with type 2 diabetes (T2DM) provides insight into how altered metabolite sensing can affect the metabolism of specific tissues. Intriguingly, there are clear epidemiological connections between diabetes and several types of cancer, especially pancreatic adenocarcinoma (PDAC) (Everhart and Wright, 1995; Wang, et al., 2003). Indeed, epidemiologic evidence indicates that pancreatic cancer can be both a consequence of longstanding diabetes (Ben, et al., 2011) and cause of new-onset cases (Huxley, et al., 2005). Methods to study metabolism across tissues are needed to understand how whole-body metabolic alterations influence tumor metabolism, and to understand the systemic changes associated with metabolic disease. Read more at isotope.com.

## Application Note 31

## Tracing Lipid Disposition in vivo Using Stable Isotope-Labeled Fatty Acids and Mass Spectrometry



Lipids are ubiquitous molecules which serve a variety of important biological functions, including energy storage (triglycerides), modulation of cellular membrane structure and function (phospholipids and cholesterol), intracellular signaling and hormonal regulation. Dysfunctions of lipid metabolism contribute to a variety of diseases including, among others, atherosclerosis, hypertriglyceridemia and type 2 diabetes. As such, understanding
the synthesis, regulation and transport of lipids in the body is important to developing new and improved therapies for these diseases. Stable isotopes have been used to study several aspects of lipid metabolism including the synthesis and disposition of cholesterol, phospholipids and VLDL triglycerides. In this application note, we highlight some of the advantages and experimental considerations for using stable isotope-labeled fatty acids as substrates to study lipid metabolism in vivo in mice.
Read more at isotope.com.


For research use only. Not for use in diagnostic procedures.


For research use only. Not for use in diagnostic procedures.


[^0]:    MPT: microbiologically and pyrogen tested
    Chemical purity (CP) is $98 \%$ or greater, unless otherwise indicated. For research use only. Not for use in diagnostic procedures.

[^1]:    Chemical purity (CP) is 98\% or greater, unless otherwise indicated.
    For research use only. Not for use in diagnostic procedures.

[^2]:    Chemical purity (CP) is $98 \%$ or greater, unless otherwise indicated.

[^3]:    CTM: manufactured following ICH Q7, Section XIX MPT: microbiologically and pyrogen tested.

    Chemical purity (CP) is $98 \%$ or greater, unless otherwise indicated. For research use only. Not for use in diagnostic procedures.

[^4]:    GMP: good manufacturing practices grade

[^5]:    $>$ For more information on controls in manufacturing and testing of the different grades, go to: Search $\rightarrow$ Literature $\rightarrow$ Product Quality Designations from the isotope.com home page.

